compounds

Selective TrkB PAMs address the limitations of current TrkB-targeting therapies by enhancing neuroplasticity selectively and safely, overcoming pharmacokinetic and psychotropic challenges, thus expanding therapeutic applicability.

WO2026234272A1PCT designated stage Publication Date: 2026-11-12KASVU THERAPEUTICS OY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2026/063497
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-08
Filing Date
2026-05-08
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current therapeutic strategies targeting tropomyosin receptor kinase B (TrkB) for neuroplasticity modulation face challenges such as poor pharmacokinetics, non-selective activation of TrkB receptors, and psychotropic liabilities associated with direct TrkB activation, limiting their clinical applicability and safety.

Method used

Development of selective TrkB PAMs that enhance TrkB responsiveness to endogenous BDNF without activating the receptor independently, thereby avoiding serotonin 2A receptor engagement and hallucinogenic effects, ensuring physiologically relevant neuroplasticity modulation.

Benefits of technology

Selective TrkB PAMs provide enhanced safety and efficacy by promoting neuroplasticity in a controlled manner, applicable across a broader range of patient populations, including those with comorbidities or serotonin-related adverse effects, while minimizing risks of maladaptive synaptic plasticity and hallucinations.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure EP2026063497_12112026_PF_FP_ABST
    Figure EP2026063497_12112026_PF_FP_ABST
Patent Text Reader

Abstract

Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: (I) wherein Ring A, Ring B, Ring C, R1, L, X1, B1, B2, B3, and B4 are as defined herein. The compounds can induce neuronal plasticity processes through modulation of the tropomyosin receptor kinase B (TrkB or NTRK2). Compounds of the invention can induce neuronal plasticity processes without mediating the serotonin 2A (5-HT2A) receptor, which is known to cause undesirable hallucinations. Also disclosed are pharmaceutical compositions comprising the compounds and the compounds for use in the treatment of a disease or medical disorder associated with dysregulation of tropomyosin receptor kinase B (TrkB).
Need to check novelty before this filing date? Find Prior Art

Description

COMPOUNDS

[0001] The present disclosure is directed to compounds which can induce neuronal plasticity, compositions comprising such compounds, methods for inducing neuroplasticity and compounds for use in such methods. Compounds of the invention can induce neuronal plasticity processes through modulation of the tropomyosin receptor kinase B (TrkB or NTRK2). Compounds of the invention can induce neuronal plasticity processes without mediating the serotonin 2A (5-HT2A) receptor, which is known to cause undesirable hallucinations.BACKGROUND

[0002] Tropomyosin receptor kinase B (TrkB) is a high-affinity receptor for brain-derived neurotrophic factor (BDNF), a key neurotrophin involved in synaptic plasticity, neuronal survival, learning, memory and cognitive function. TrkB-mediated signaling plays a central role in neurodevelopment and neuroplasticity (Park& Poo, 2013; Lu et al., 2013).

[0003] TrkB activation through BDNF binding initiates neurotrophic downstream signaling cascades including the MAPK / ERK, PI3K / Akt, and PLCy pathways, all of which regulate synaptic strength, dendritic spine morphology, and long-term potentiation (LTP), crucial processes underlying learning and memory (Yamada & Nabeshima, 2003; Minichiello, 2009). Disruptions in TrkB signaling impair experience-dependent plasticity, which is essential during both development and adulthood (Lu et al., 2005).

[0004] Alterations in BDNF-TrkB signaling have been observed in major depressive disorder, anxiety disorders, and bipolar disorder. Reduced BDNF levels and impaired TrkB activity correlate with depressive symptoms and treatment resistance (Duman & Monteggia, 2006). Antidepressants such as SSRIs and ketamine exert therapeutic effects through the upregulation of BDNF and activation of TrkB (Autry & Monteggia, 2012; Castren & Antila, 2017).

[0005] Neurodevelopmental conditions such as autism spectrum disorders (ASD) and intellectual disabilities exhibit aberrant TrkB-related pathways. Genetic and epigenetic alterations in the BDNF-TrkB axis can lead to disrupted cortical development and synaptogenesis, contributing to behavioral and cognitive impairments (Numakawa et al., 2017).

[0006] Impaired TrkB function has been noted in developmental syndromes such as Rett syndrome, where BDNF deficits contribute to cognitive and motor impairments (Chang et al., 2006; Zoghbi, 2003).

[0007] Following traumatic brain injury (TBI), TrkB expression is dynamically regulated. Upregulation of BDNF-TrkB is associated with both adaptive plasticity and maladaptive hyperexcitability, depending on timing and context (Binder et al., 2001; McNamara & Scharfman, 2012).

[0008] Recent advances building on the role of TrkB in neuroplasticity have revealed a common mechanism underlying the therapeutic effects of antidepressants and psychedelics. Traditionally, the efficacy of antidepressants was attributed to their modulation of monoaminergic systems, with the TrkB-mediated neuroplastic effects being considered downstream consequences. However, Casarotto et al. have demonstrated that a wide range of antidepressants — including SSRIs, tricyclics, and ketamine — directly bind to the transmembrane domain of the TrkB receptor, functioning as positive allosteric modulators (PAMs) (Casarotto et al., 2021; Moliner et al., 2023).

[0009] This direct interaction with TrkB facilitates its surface localization and enhances its activation by BDNF, thereby promoting synaptic plasticity independently of serotonin transporter or NMDA receptor modulation (Casarotto et al., 2021). Molecular dynamics simulations and structural biology studies have shown that antidepressants stabilize the TrkB transmembrane domain (TMD) dimer in a conformation favorable for BDNF signaling, suggesting that TrkB is not merely a downstream effector but a primary target for antidepressant action (Casarotto et al., 2021; Moliner et al., 2023; Enkavi et al., 2023; Kot et al., 2024).

[0010] Expanding on this paradigm, another landmark study revealed that psychedelics such as lysergic acid diethylamide (LSD) and psilocin also bind directly to the TMD of TrkB with exceptionally high affinity — up to 1,000 times greater than typical antidepressants (Moliner et al., 2023). These compounds act as TrkB PAMs by stabilizing the TMD dimer in a conformation that enhances responsiveness to endogenous BDNF, thus promoting robust and sustained neuroplastic changes.

[0011] Crucially, the antidepressant and plasticity-promoting effects of psychedelics are mediated through TrkB and are mechanistically dissociable from their hallucinogenic properties, which are driven by serotonin 2A (5-HT2A) receptor activation. Indeed, while psychedelics like LSD induce behavioral and neuronal plasticity via TrkB activation, their hallucinogenic effects are entirely dependent on 5-HT2A signaling and independent of TrkB (Moliner et al., 2023). A recent case report with a depression patient treated with psilocybin in a clinical trial that was also being treated with a 5-HT2A receptor antagonist illustrates that this might also be the case in humans, as the patient displayed a fast and long-lastingantidepressant response without experiencing the hallucinations that characterize psychedelics (Rosenblat et al., 2023).

[0012] This understanding sets the stage for a new class of TrkB PAM neurotherapeutics. By targeting the transmembrane allosteric site on TrkB, it is now possible to pursue the development of compounds that retain the rapid and durable therapeutic benefits observed with psychedelics but are devoid of their psychotropic liabilities — thereby overcoming a major obstacle to the widespread clinical adoption of psychedelic-based treatments (Enkavi et al., 2023; Moliner et al., 2023). As such, promotion of neuroplasticity through TrkB allosteric modulation represents a unifying mechanism across pharmacologically diverse therapeutics and a promising frontier for precision drug development in any disorders that involve BDNF and TrkB neurotrophic signaling dysregulation.

[0013] While BDNF mimetics and direct TrkB agonists have long been explored as therapeutic strategies, their clinical development has faced substantial obstacles. BDNF itself, as a large and unstable peptide, has poor pharmacokinetics and bioavailability, making systemic delivery challenging. Moreover, due to its broad activity profile, exogenous BDNF or small molecule BDNF mimetics can indiscriminately activate all TrkB receptors, which are widely expressed in the brain, potentially interfering with normal receptor function and offsetting the necessary activity-dependent fine-tuning of synapses and neuronal networks (Enkavi et al., 2023). Similarly, engineered TrkB agonist antibodies, though promising in neurodegenerative contexts, typically act with high potency and low selectivity in terms of spatial and temporal resolution, risking receptor desensitization or non-physiological activation that could disrupt synaptic homeostasis (Enkavi et al., 2023).

[0014] In contrast, selective TrkB PAMs offer several pharmacological advantages. Unlike orthosteric agonists, PAMs do not activate the receptor independently; instead, they enhance the receptor's responsiveness to endogenous BDNF in an activity-dependent manner. This preserves the natural spatial and temporal dynamics of TrkB signaling, which is tightly regulated by neuronal activity and synaptic localization. Such modulation ensures plasticity is enhanced only when and where it is needed, minimizing risks of maladaptive synaptic plasticity and neuronal network remodeling (Enkavi et al., 2023; Moliner et al., 2023; Casarotto et al., 2021).

[0015] Furthermore, a highly selective TrkB PAM lacking 5-HT2A and other off-target activities avoids the major limitations associated with psychedelic compounds. By eliminating 5-HT2A receptor engagement, these compounds can bypass hallucinogenic effects, risks of developing irreversible psychosis or hallucinogen persisting perception disorder (HPPD), andthe need for intensive clinical monitoring that currently restricts the use of psychedelics in mental health care (Moliner et al., 2023). This pharmacological precision not only enhances safety and efficacy but also expands the therapeutic applicability of TrkB-targeting drugs across broader patient populations, including those with comorbidities or vulnerability to serotonin-related adverse effects. In this light, the design of selective TrkB PAMs represents a rational and promising therapeutic direction, balancing efficacy, safety, and physiologically relevant modulation of neuroplasticity.ReferencesAutry AE, Monteggia LM. Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol Rev. 2012 Apr;64(2):238-58. doi: 10.1124 / pr.111.005108. Epub 2012 Mar 8. PMID: 22407616; PMCID: PMC3310485.Binder DK, Croll SD, Gall CM, Scharfman HE. BDNF and epilepsy: too much of a good thing? Trends Neurosci. 2001 Jan;24(1):47-53. doi: 10.1016 / s0166-2236(00)01682-9. PMID: 11163887.Casarotto PC, Girych M, Fred SM, Kovaleva V, Moliner R, Enkavi G, Biojone C, Cannarozzo C, Sahu MP, Kaurinkoski K, Brunello CA, Steinzeig A, Winkel F, Patil S, Vestring S, Serchov T, Diniz CRAF, Laukkanen L, Cardon I, Antila H, Rog T, Piepponen TP, Bramham CR, Normann C, Lauri SE, Saarma M, Vattulainen I, Castren E. Antidepressant drugs act by directly binding to TRKB neurotrophin receptors. Cell. 2021 Mar 4;184(5):1299-1313.e19. doi: 10.1016 / j. cell.2021.01.034. Epub 2021 Feb 18. PMID: 33606976; PMCID: PMC7938888.Castren E, Antila H. Neuronal plasticity and neurotrophic factors in drug responses. Mol Psychiatry. 2017 Aug;22(8):1085-1095. doi: 10.1038 / mp.2017.61. Epub 2017 Apr 11. PMID: 28397840; PMCID: PMC5510719.Chang Q, Khare G, Dani V, Nelson S, Jaenisch R. The disease progression of Mecp2 mutant mice is affected by the level of BDNF expression. Neuron. 2006 Feb 2;49(3):341-8. doi: 10.1016 / j. neuron.2005.12.027. PMID: 16446138.Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry. 2006 Jun 15;59(12):1116-27. doi: 10.1016 / j. biopsych.2006.02.013. Epub 2006 Apr 21. PMID: 16631126.Enkavi G, Girych M, Moliner R, Vattulainen I, Castren E. TrkB transmembrane domain: bridging structural understanding with therapeutic strategy. Trends Biochem Sci. 2024 May;49(5):445-456. doi: 10.1016 / j.tibs.2024.02.001. Epub 2024 Mar 2. PMID: 38433044.Kot EF, Goncharuk SA, Franco ML, McKenzie DM, Arseniev AS, Benito-Martínez A, Costa M, Cattaneo A, Hristova K, Vilar M, Mineev KS. Structural basis for the transmembrane signaling and antidepressant-induced activation of the receptor tyrosine kinase TrkB. Nat Commun.2024 Oct 29;15(1):9316. doi: 10.1038 / S41467-024-53710-7. PMID: 39472452; PMCID: PMC11522581.Lu B, Nagappan G, Guan X, Nathan PJ, Wren P. BDNF-based synaptic repair as a diseasemodifying strategy for neurodegenerative diseases. Nat Rev Neurosci. 2013 Jun;14(6):401-16. doi: 10.1038 / nrn3505. Epub 2013 May 15. PMID: 23674053.Lu B, Pang PT, Woo NH. The yin and yang of neurotrophin action. Nat Rev Neurosci. 2005 Aug;6(8):603-14. doi: 10.1038 / nrn1726. PMID: 16062169.McNamara JO, Scharfman HE. Temporal Lobe Epilepsy and the BDNF Receptor, TrkB. In: Noebels JL, Avoli M, Rogawski MA, Olsen RW, Delgado-Escueta AV, editors. Jasper's Basic Mechanisms of the Epilepsies [Internet]. 4th ed. Bethesda (MD): National Center for Biotechnology Information (US); 2012. PMID: 22787630.Minichiello L. TrkB signalling pathways in LTP and learning. Nat Rev Neurosci. 2009 Dec;10(12):850-60. doi: 10.1038 / nrn2738. PMID: 19927149.Moliner R, Girych M, Brunello CA, Kovaleva V, Biojone C, Enkavi G, Antenucci L, Kot EF, Goncharuk SA, Kaurinkoski K, Kuutti M, Fred SM, Elsila LV, Sakson S, Cannarozzo C, Diniz CRAF, Seiffert N, Rubiolo A, Haapaniemi H, Meshi E, Nagaeva E, Ohman T, Rog T, Kankuri E, Vilar M, Varjosalo M, Korpi ER, Permi P, Mineev KS, Saarma M, Vattulainen I, Casarotto PC, Castren E. Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. Nat Neurosci. 2023 Jun;26(6):1032-1041. doi: 10.1038 / s41593-023-01316-5. Epub 2023 Jun 5. PMID: 37280397; PMCID: PMC10244169.Numakawa T, Odaka H, Adachi N. Actions of Brain-Derived Neurotrophic Factor and Glucocorticoid Stress in Neurogenesis. Int J Mol Sci. 2017 Nov 2;18(11):2312. doi: 10.3390 / ijms18112312. PMID: 29099059; PMCID: PMC5713281.Park H, Poo MM. Neurotrophin regulation of neural circuit development and function. Nat Rev Neurosci. 2013 Jan;14(1):7-23. doi: 10.1038 / nrn3379. PMID: 23254191.Rosenblat JD, Leon-Carlyle M, Ali S, Husain Ml, McIntyre RS. Antidepressant Effects of Psilocybin in the Absence of Psychedelic Effects. Am J Psychiatry. 2023 May 1;180(5):395-396. doi: 10.1176 / appi.ajp.20220835. Epub 2023 Mar 22. PMID: 36945824.Yamada K, Nabeshima T. Brain-derived neurotrophic factor / TrkB signaling in memory processes. J Pharmacol Sci. 2003 Apr;91(4):267-70. doi: 10.1254 / jphs.91.267. PMID: 12719654.Zoghbi HY. Postnatal neurodevelopmental disorders: meeting at the synapse? Science. 2003 Oct31;302(5646):826-30. doi: 10.1126 / science.1089071. PMID: 14593168.BRIEF SUMMARY OF THE DISCLOSURE

[0016] In accordance with the present invention there is provided a compound of formula (I), or a pharmaceutically acceptable salt and / or solvate thereof:wherein:R1is selected from:-membered heteroaryl, and -C(O)NR1aR1b;whereinR1aand R1bare each independently selected from: H, Ci-6alkyl, and Ci-6haloalkyl; Z1and Z4are each nitrogen, andZ2, Z3, Z5, and Z6are independently selected from: a bond, carbon, nitrogen, and oxygen;and wherein said-membered heteroaryl are optionally substituted by one or more R2;R2is selected from: deuterium, halo, -CN, -NO2, -NR2aR2b, -OR2a, =O, Ci_6alkyl, Ci_6haloalkyl, C2-6 alkenyl, C2.6alkynyl, C3-6 cycloalkyl, 4- to 6-membered heterocycloalkyl, -S(O)xR2a, -C(O)R2a, -OC(O)R2a, and -C(O)OR2a;L is selected from: Ci.3alkylene and -C(O)-;wherein said C1.3 alkylene is optionally substituted by one or more R3;R3is selected from: deuterium, halo, -CN, -NO2, -NR3aR3b, -OR3a, =O, Ci_6alkyl, Ci_6haloalkyl, C2-6 alkenyl, C2.6alkynyl, C3-6 cycloalkyl, 4- to 6-membered heterocycloalkyl, -S(O)xR3a, -C(O)R3a, -OC(O)R3a, -C(O)OR3a;X1is selected from: -O-, and -S(O)X-;Ring A is selected from:wherein A1, A2, and A3are each independently selected from the group consisting of: carbon, nitrogen, oxygen, and sulphur, optionally wherein Ring A is substituted by one or more R4;, wherein A4, A5, A6, and A7are each independently selected from the group consisting of: carbon and nitrogen, optionally wherein Ring A is substituted by one or more R5; provided that Ring A is not a substituted or unsubstitutediii), wherein A8, A9, and A10are each independently selected from the group consisting of: carbon, nitrogen, oxygen, and sulphur, optionally wherein Ring A is substituted by one or more R4;R4is selected from: deuterium, halo, -CN, -NO2, -NR4aR4b, -OR4a, =O, Ci_6alkyl, Ci_6haloalkyl, C2-6alkenyl, C2.6alkynyl, C3-6 cycloalkyl, 4- to 6-membered heterocycloalkyl, -S(O)xR4a, -C(O)R4a, -OC(O)R4a, and -C(O)OR4a;R5is selected from: deuterium, halo, -CN, -NO2, -NR5aR5b, -OR5a, Ci_6alkyl, Ci_6haloalkyl, C2.6alkenyl, C2.6alkynyl, C3-6 cycloalkyl, 4- to 6-membered heterocycloalkyl, -S(O)xR5a, -C(O)R5a, -OC(O)R5a, and -C(O)OR5a;Ring B is 5- or 6-membered heteroaryl, wherein:one of B1and B3is selected from: a bond, -CH=, -CR61=, -N=, and -NR62-, and the other of B1and B3is selected from: -CH=, -CR61=, -N=, and -NR62-,B2is selected from: -C= and -N-, andB4is selected from: -N= and -NR62-,provided that B3is -CH= or -CR61= when B1is a bond and B2is -C=, and that B2is -C= when B1is -CH= or-CR61= and B3is a bond;R61is selected from: deuterium, halo, -CN, -NO2, -NR6aR6b, -OR6a, Ci_6alkyl, Ci_6haloalkyl, C2.6alkenyl, C2.6alkynyl, C3-6 cycloalkyl, 4- to 6-membered heterocycloalkyl, -S(O)xR6a, -C(O)R6a, -OC(O)R6a, and -C(O)OR6a;R62is selected from: Ci_6alkyl, Ci_6haloalkyl, C2.6alkenyl, C2.6alkynyl, C3-6 cycloalkyl, 4- to 6-membered heterocycloalkyl, -S(O)xR6a, -C(O)R6a, and -C(O)OR6a;Ring C is selected from: 4- to 7-membered cycloalkyl, 5- to 7-membered cycloalkenyl, 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, phenyl, and 5- or 6-membered heteroaryl,wherein said 4- to 7-membered heterocycloalkyl, 4- to 7-membered cycloalkyl, 5- to 7-membered cycloalkenyl, and 5- to 7-membered heterocycloalkenyl are optionally substituted by one or more R7, and said phenyl and 5- or 6-membered heteroaryl are optionally substituted by one or more R8;R7is selected from: halo, -CN, -NO2, -NR7aR7b, -OR7a, =O, Ci_6alkyl, Ci_6haloalkyl, C2.6alkenyl, C2-6alkynyl, C3.6cycloalkyl, 4- to 6-membered heterocycloalkyl, -S(O)xR7a, -C(O)R7a, -OC(O)R7a, and -C(O)OR7a;R8is selected from: halo, -CN, -NO2, -NR8aR8b, -OR8a, Ci_6alkyl, Ci_6haloalkyl, C2.6alkenyl, C2.6alkynyl, C3.6cycloalkyl, 4- to 6-membered heterocycloalkyl, -S(O)xR8a, -C(O)R8a, -OC(O)R8a, and -C(O)OR8a;R2a, R3a, R4a, R5a, R6a, R7a, and R8aare each independently selected from: H, deuterium, C1-6alkyl, C1-6haloalkyl, C3-6cycloalkyl, and 4- to 6-membered heterocycloalkyl;R2b, R3b, R4b, R5b, R6b, R7b, and R8bare each independently selected from: H, deuterium, C1-6alkyl, C1-6haloalkyl, C3-6cycloalkyl, 4- to 6-membered heterocycloalkyl, and -C(O)-Ci-6alkyl;or wherein, at each occurrence, R2aand R2b, R3aand R3b, R4aand R4b, R5aand R5b, R6aand R6b, R7aand R7b, or R8aand R8b, together with the nitrogen atom to which they are attached, may form a 4-6-membered heterocycloalkyl ring;each x is independently 0, 1, or 2;wherein any of the aforementioned alkyl, alkylene, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, phenyl, or heteroaryl groups is optionally substituted, where chemically possible, by one or more substituents independently at each occurrence selected from the group consisting of: Ci-6alkyl, Ci_6alkyl-ORa, deuterium, oxo, halo, nitro, cyano, NRaRb, ORa, SRa, CO2Ra, C(O)Ra, CONRaRa, S(O)Ra, and S(O)2Ra; wherein Rais independently at eachoccurrence selected from H, and Ci-4alkyl; and Rbis independently at each occurrence selected from H, Ci-4alkyl, C(O)-Ci-4alkyl and S(O)2-Ci-4alkyl; andwherein the compound of formula (I) is not:ii) a compound selected from List A:List A:

[0017] Also provided is a pharmaceutical composition comprising a compound of the invention, except that the compounds of List A are not excluded, or a pharmaceutically acceptable salt and / or solvate thereof, and a pharmaceutically acceptable excipient. In an embodiment, there is provided a pharmaceutical composition comprising a compound of the invention, or a pharmaceutically acceptable salt and / or solvate thereof, and a pharmaceutically acceptable excipient.

[0018] Also provided is a compound of the invention, except that the compounds of List A a re not excluded, or a pharmaceutically acceptable salt and / or solvate thereof, for use as a medicament. In an embodiment, there is provided a compound of the invention, or a pharmaceutically acceptable salt and / or solvate thereof, for use as a medicament.

[0019] Also provided is a compound of the invention, except that the compounds of disclaimer i) and ii) in paragraph

[0016] are not excluded, ora pharmaceutically acceptable salt and / or solvate thereof, for use in the treatment of a disease or medical disorder associated with dysregulation of tropomyosin receptor kinase B (TrkB or NTRK2). In an embodiment, there is provided a compound of the invention, or a pharmaceutically acceptable salt and / or solvate thereof, for use in the treatment of a disease or medical disorder associated with dysregulation of tropomyosin receptor kinase B (TrkB or NTRK2).

[0020] Also provided is a method of treating a disease or medical disorder associated with dysregulation of tropomyosin receptor kinase B (TrkB or NTRK2) in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of the invention, except that the compounds of disclaimer i) and ii) in paragraph

[0016] are not excluded, or a pharmaceutically acceptable salt and / or solvate thereof. In an embodiment, there is provided a method of treating a disease or medical disorder associated with dysregulation of tropomyosin receptor kinase B (TrkB or NTRK2) in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of the invention, or a pharmaceutically acceptable salt and / or solvate thereof.

[0021] Also provided is a compound of the invention, except that the compounds of disclaimer i) and ii) in paragraph

[0016] are not excluded, ora pharmaceutically acceptable salt and / or solvate thereof, for use in the treatment of a disease or medical disorder selected from: autism spectrum disorder (ASD), intellectual disability, Rett Syndrome, Down’s Syndrome (DS), Major Depressive Disorder (MDD), Bipolar Disorder (BD), Post-Traumatic Stress Disorder (PTSD), Generalized Anxiety Disorder (GAD), NeuroAIDS (HIV-associated neurocognitive disorder), Fetal Alcohol Spectrum Disorder (FASD), Hypoxia-Ischemic Encephalopathy (HIE), and Traumatic Brain Injury (TBI). In an embodiment, there is provided a compound of the invention, or a pharmaceutically acceptable salt and / or solvate thereof, for use in treating autism spectrum disorder (ASD), intellectual disability, Rett Syndrome, Down’s Syndrome (DS), Major Depressive Disorder (MDD), Bipolar Disorder (BD), Post-Traumatic Stress Disorder (PTSD), Generalized Anxiety Disorder (GAD), NeuroAIDS (HIV-associated neurocognitive disorder), Fetal Alcohol Spectrum Disorder (FASD), Hypoxia-Ischemic Encephalopathy (HIE), and Traumatic Brain Injury (TBI).

[0022] Also provided is a method of treating a disease or medical disorder selected from: autism spectrum disorder (ASD), intellectual disability, Rett Syndrome, Down’s Syndrome (DS), Major Depressive Disorder (MDD), Bipolar Disorder (BD), Post-Traumatic Stress Disorder (PTSD), Generalized Anxiety Disorder (GAD), NeuroAIDS (HIV-associated neurocognitive disorder), Fetal Alcohol Spectrum Disorder (FASD), Hypoxia-Ischemic Encephalopathy (HIE), and Traumatic Brain Injury (TBI), the method comprising administering to a subject in need thereof, an effective amount of a compound of the invention, except that the compounds of disclaimer i) and ii) in paragraph

[0016] are not excluded, ora pharmaceutically acceptable salt and / or solvate thereof. In an embodiment is a method of treating a disease or medical disorder selected from: autism spectrum disorder (ASD), intellectual disability, Rett Syndrome, Down’s Syndrome (DS), Major Depressive Disorder (MDD), Bipolar Disorder (BD), Post-Traumatic Stress Disorder (PTSD), Generalized Anxiety Disorder (GAD), NeuroAIDS (HIV-associated neurocognitive disorder), Fetal Alcohol Spectrum Disorder (FASD), Hypoxia-Ischemic Encephalopathy (HIE), and Traumatic Brain Injury (TBI), the method comprising administering to a subject in need thereof, an effective amount of a compound of the invention, or a pharmaceutically acceptable salt and / or solvate thereof.DETAILED DESCRIPTION

[0023] Unless otherwise stated, the following terms used in the specification and claims have the following meanings set out below.

[0024] Reference herein to a “compound of the invention” is a reference to any of the compounds disclosed herein including compounds of any of formulae (I), (II), (III), or (IV), a compound selected from List A, or a compound described in any of the Examples, or a pharmaceutically acceptable salt and / or solvate thereof.

[0025] The terms “treating”, or “treatment” refer to any beneficial effect in the treatment or amelioration of an injury, disease, pathology or condition, including any objective or subjective parameter such as abatement; remission; diminishing of symptoms or making the injury, pathology or condition more tolerable to the patient; slowing in the rate of degeneration or decline; modifying the progression of a disease or condition, making the final point of degeneration less debilitating; improving a patient’s physical or mental well-being. The treatment or amelioration of symptoms can be based on objective or subjective parameters; including the results of a physical examination, neuropsychiatric examinations, and / or a psychiatric evaluation. The term "treating" and conjugations thereof, includes prevention of an injury, pathology, condition, or disease (i.e., prophylaxis or prevention). For example, the term "treating" and conjugations thereof, include prevention of a pathology, condition, or disease associated with dysregulation of tropomyosin receptor kinase B (TrkB or NTRK2) (e.g., reducing or preventing symptoms or effects of the disease or condition or preventing or inhibiting progression of the disease or condition.

[0026] The term “associated” or “associated with”, “involving” or “mediated by” in the context of TrkB or NTRK2 means that the disease is caused by (in whole or in part), ora symptom of the disease is caused by (in whole or in part) dysregulation of TrkB or NTRK2. A disease or medical disorder associated with dysregulation of TrkB or NTRK2, may be treated with a compound of the invention effective forstabilizingtheTrkB transmembrane domain dimer in a conformation favorable for BDNF signaling.

[0027] An “effective amount” is an amount sufficient to accomplish a stated purpose. For example an amount sufficient to achieve the effect for which it is administered, treat a disease, reduce enzyme activity, increase enzyme activity, reduce receptor signalling, increase receptor signalling, reduce one or more symptoms of a disease or condition, or to provide a disease modifying effect (i.e. alter the underlying pathophysiology of the disease). An example of an “effective amount” is an amount sufficient to contribute to the treatment, prevention, or reduction of a symptom or symptoms of a disease, or modify the progression of a disease, which could also be referred to as a “therapeutically effective amount.” A “reduction” of a symptom or symptoms means decreasing of the severity or frequency of the symptom(s), or elimination of the symptom(s). A “prophylactically effective amount” of a drug is an amount ofa drug that, when administered to a subject, will have the intended prophylactic effect, e.g., preventing or delaying the onset (or reoccurrence) of an injury, disease, pathology, or condition, or reducing the likelihood of the onset (or reoccurrence) of an injury, disease, pathology, or condition, or their symptoms. The full prophylactic effect does not necessarily occur by administration of one dose and may occur only after administration of a series of doses. Thus, a prophylactically effective amount may be administered in one or more administrations. The exact amounts will depend on the purpose of the treatment and will be ascertainable by one skilled in the art using known techniques (see, e.g., Lieberman, Pharmaceutical Dosage Forms (vols. 1-3, 1992); Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999); Pickar, Dosage Calculations (1999); and Remington: The Science and Practice of Pharmacy, 20th Edition, 2003, Gennaro, Ed., Lippincott, Williams & Wilkins).

[0028] The therapeutically effective amount of a compound of the invention can be initially estimated from the assays described herein. Target concentrations will be those concentrations of active compound(s) that are capable of achieving the therapeutic effect described herein, as measured using the methods described herein or known in the art.

[0029] Therapeutically effective amounts for use in humans can also be determined from animal models using known methods. For example, a dose for humans can be formulated to achieve a concentration that has been found to be effective in animals. The dosage in humans can be adjusted by monitoring compound effectiveness and adjusting the dosage upwards or downwards, as described above. Adjusting the dose to achieve maximal efficacy in humans based on the methods described above and other methods is well within the capabilities of the ordinarily skilled artisan.

[0030] Dosages may be varied depending upon the requirements of the patient and the compound being employed. The dose administered to a patient, in the context of the present invention should be sufficient to effect a beneficial therapeutic response in the patient over time. The size of the dose also will be determined by the existence, nature, and extent of any adverse side-effects. Determination of the proper dosage for a particular situation is within the skill of the practitioner. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under circumstances is reached.

[0031] Dosage amounts and intervals can be adjusted individually to provide levels of the administered compound effective for the particular clinical indication being treated, or in response to a biomarker or other correlate or surrogate end-point of the disease. This willprovide a therapeutic regimen that is commensurate with the severity of the individual's disease state.

[0032] A prophylactic or therapeutic treatment regimen is suitably one that does not cause substantial toxicity and yet is effective to treat the clinical symptoms demonstrated by the particular patient. This determination of a dosage regimen is generally based upon an assessment of the active compound by considering factors such as compound potency, relative bioavailability, patient body weight, presence and severity of adverse side effects, preferred mode of administration and the toxicity profile of the selected agent.

[0033] The term “halo” or “halogen” refers to one of the halogens, group 7 of the periodic table. In particular the term refers to fluorine, chlorine, bromine and iodine. Preferably, the term refers to fluorine or chlorine.

[0034] The term Cm-nrefers to a group with m to n carbon atoms.

[0035] The term “Ci.6alky refers to a linear or branched hydrocarbon chain containing 1, 2, 3, 4, 5 or 6 carbon atoms, for example methyl, ethyl, n-propyl, / so-propyl, n-butyl, / so-butyl, secbutyl, tert-butyl, n-pentyl and n-hexyl. “Ci-4alkyl” similarly refers to such groups containing up to 4 carbon atoms. Alkylene groups are divalent alkyl groups and may likewise be linear or branched and have two points of attachment to the remainder of the molecule. Furthermore, an alkylene group may, for example, correspond to one of those alkyl groups listed in this paragraph. For example, Ci_6alkylene may be -CH2-, -CH2CH2-, -CH2CH(CH3)-, -CH2CH2CH2-or -CH2CH(CH3)CH2-. The alkyl and alkylene groups may be unsubstituted or substituted by one or more substituents. Possible substituents are described herein. For example, substituents for an alkyl or alkylene group may be halogen, e.g. fluorine, chlorine, bromine and iodine, OH, Ci-C4alkoxy, -NR’R” amino, wherein R’ and R” are independently H or alkyl. Other substituents for the alkyl group may alternatively be used.

[0036] The term “Ci.6haloalkyl”, e.g., “Ci-4haloalkyl”, refers to a hydrocarbon chain substituted with at least one halogen atom independently chosen at each occurrence, for example fluorine, chlorine, bromine, and iodine. The halogen atom may be present at any position on the hydrocarbon chain. For example, Ci.6haloalkyl may refer to chloromethyl, fluoromethyl, trifluoromethyl, chloroethyl e.g., 1 -chloromethyl and 2-chloroethyl, trichloroethyl e.g., 1,2,2-trichloroethyl, 2,2,2-trichloroethyl, fluoroethyl e.g., 1 -fluoromethyl and 2-fluoroethyl, trifluoroethyl e.g., 1,2,2-trifluoroethyl and 2,2,2-trifluoroethyl, chloropropyl, trichloropropyl, fluoropropyl, trifluoropropyl. A haloalkyl group may be, for example, -CX3, -CHX2, -CH2CX3, -CH2CHX2or -CX(CH3)CH3wherein X is a halo (e.g., F, Cl, Br, orI). A fluoroalkyl group, i.e., a hydrocarbon chain substituted with at least one fluorine atom (e.g., -CF3, -CHF2, -CH2CF3or -CH2CHF2).

[0037] The term “heteroalkyl,” refers to a stable linear or branched chain alkyl, including at least one carbon atom and at least one heteroatom (e.g., O, N, P, Si, and S), and wherein the nitrogen and sulfur atoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized. The heteroatom(s) (e.g., N, S, Si, or P) may be placed at any interior position of the heteroalkyl group. The heteroalkyl is a non-cyclic group. “2 to 8 membered heteroalkyl” refers to a heteroalkyl in which there are a total of 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms and heteroatoms (e.g., O, N, P, Si, and S) in the heteroalkyl group. Examples include, but are not limited to: -CH2-O-CH3,-CH2-CH2-O-CH3, -CH2-NH-CH3,-CH2-CH2-NH-CH3, -CH2-N(CH3)-CH3, -CH2-CH2-N(CH3)-CH3, -CH2-S-CH2-CH3, -CH2-S(O)-CH3, -CH2-S(O)2-CH3, -CH2-CH2-S-CH3, -CH2-CH2-S(O)-CH3, -CH2-CH2-S(O)2-CH3, -CH2-CH=N-OCH3, Up to two or three heteroatoms may be consecutive, such as, for example, -CH2-NH-OCH3and -CH2-O-Si(CH3)3. A heteroalkyl moiety may include one heteroatom (e.g., O, N, S, Si, or P). A heteroalkyl moiety may include two optionally different heteroatoms (e.g., O, N, S, Si, or P). A heteroalkyl moiety may include three optionally different heteroatoms (e.g., O, N, S, Si, or P). A heteroalkyl moiety may include four optionally different heteroatoms (e.g., O, N, S, Si, or P).

[0038] The term “C2.6alkenyl” includes a branched or linear hydrocarbon chain containing at least one double bond and having 2, 3, 4, 5 or 6 carbon atoms. The double bond(s) may be present as the E or Z isomer. The double bond may be at any possible position of the hydrocarbon chain. For example, the “C2.6alkenyl” may be ethenyl, propenyl, butenyl, butadienyl, pentenyl, pentadienyl, hexenyl and hexadienyl. Alkenylene groups are divalent alkenyl groups and may likewise be linear or branched and have two points of attachment to the remainder of the molecule. Furthermore, an alkenylene group may, for example, correspond to one of those alkenyl groups listed in this paragraph. For example, alkenylene may be -CH=CH-, -CH2CH=CH-, -CH(CH3)CH=CH- or -CH2CH=CH-. Alkenyl and alkenylene groups may unsubstituted or substituted by one or more substituents. Possible substituents are described herein. Forexample, substituents may be those described above as substituents for alkyl groups.

[0039] The term “C2.6alkynyl” includes a branched or linear hydrocarbon chain containing at least one triple bond and having 2, 3, 4, 5 or 6 carbon atoms. The triple bond may be at any possible position of the hydrocarbon chain. For example, the “C2.6alkynyl” may be ethynyl, propynyl, butynyl, pentynyl and hexynyl. Alkynylene groups are divalent alkynyl groups and may likewise be linear or branched and have two points of attachment to the remainder of themolecule. Furthermore, an alkynylene group may, for example, correspond to one of those alkynyl groups listed in this paragraph. For example alkynylene may be -C=C-, -CH2C=C-, -CH2C=CCH2-, -CH(CH3)CH=C- or -CH2C=CCH3. Alkynyl and alkynylene groups may unsubstituted or substituted by one or more substituents. Possible substituents are described herein. For example, substituents may be those described above as substituents for alkyl groups.

[0040] The term “C3.6cycloalkyl” includes a saturated hydrocarbon ring system containing 3, 4, 5 or 6 carbon atoms. For example, the “C3-C6cycloalkyl” may be cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[2.1.1]hexane or bicyclo[1.1.1]pentane. Suitably the “C3-C6cycloalkyl” may be cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.

[0041] The term “heterocyclyl”, “heterocyclic” or “heterocycle” includes a non-aromatic saturated or partially saturated monocyclic orfused, bridged, orspiro bicyclic heterocyclic ring system. Monocyclic heterocyclic rings may contain from about 3 to 12 (suitably from 3 to 7) ring atoms, with from 1 to 5 (suitably 1, 2 or 3) heteroatoms selected from nitrogen, oxygen or sulfur in the ring. Bicyclic heterocycles may contain from 7 to 12-member atoms in the ring. Bicyclic heterocyclic(s) rings may be fused, spiro, or bridged ring systems. The heterocyclyl group may be a 3-12, for example, a 3- to 9- (e.g. a 3- to 7-) membered non-aromatic monocyclic or bicyclic saturated or partially saturated group comprising 1, 2 or 3 heteroatoms independently selected from O, S and N in the ring system (in other words 1, 2 or 3 of the atoms forming the ring system are selected from O, S and N). By partially saturated it is meant that the ring may comprise one or two double bonds. This applies particularly to monocyclic rings with from 5 to 7 members. The double bond will typically be between two carbon atoms but may be between a carbon atom and a nitrogen atom. Bicyclic systems may be spiro-fused, i.e. where the rings are linked to each other through a single carbon atom; vicinally fused, i.e. where the rings are linked to each other through two adjacent carbon and / or nitrogen atoms; or they may be share a bridgehead, i.e. the rings are linked to each other through two non-adjacent carbon or nitrogen atoms (a bridged ring system). Examples of heterocyclic groups include cyclic ethers such as oxiranyl, oxetanyl, tetrahydrofuranyl, dioxanyl, and substituted cyclic ethers. Heterocycles comprising at least one nitrogen in a ring position include, for example, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, tetrahydrotriazinyl, tetra hydropyrazolyl, tetrahydropyridinyl, homopiperidinyl, homopiperazinyl, 2,5-diaza-bicyclo[2.2.1]heptanyl and the like. Typical sulfur containing heterocycles include tetrahydrothienyl, dihydro-1,3-dithiol, tetrahydro-2H-thiopyran, and hexahydrothiepine. Other heterocycles include dihydro oxathiolyl, tetrahydro oxazolyl,tetrahydro-oxadiazolyl, tetrahydrodioxazolyl, tetrahydrooxathiazolyl, hexahydrotriazinyl, tetrahydro oxazinyl, tetrahydropyrimidinyl, dioxolinyl, octa hydro benzofuranyl, octahydrobenzimidazolyl, and octahydrobenzothiazolyl. For heterocycles containing sulfur, the oxidized sulfur heterocycles containing SO or SO2groups are also included. Examples include the sulfoxide and sulfone forms of tetrahydrothienyl and thiomorpholinyl such as tetra hydrothiene 1,1 -dioxide and thiomorpholinyl 1,1 -dioxide. A suitable value for a heterocyclyl group which bears 1 or 2 oxo (=O), for example, 2 oxopyrrolidinyl, 2-oxoimidazolidinyl, 2-oxopiperidinyl, 2,5-dioxopyrrolidinyl, 2,5-dioxoimidazolidinyl or 2,6-dioxopiperidinyl. Particular heterocyclyl groups are saturated monocyclic 3 to 7 membered heterocyclyls containing 1, 2 or 3 heteroatoms selected from nitrogen, oxygen or sulfur, for example azetidinyl, tetrahydrofuranyl, tetra hydropyranyl, pyrrolidinyl, morpholinyl, tetra hydrothienyl, tetrahydrothienyl 1,1 -dioxide, thiomorpholinyl, thiomorpholinyl 1,1 -dioxide, piperidinyl, homopiperidinyl, piperazinyl or homopiperazinyl. As the skilled person will appreciate, any heterocycle may be linked to another group via any suitable atom, such as via a carbon or nitrogen atom. For example, the term “piperidino” or “morpholino” refers to a piperidin-1-ylor morpholin-4-yl ring that is linked via the ring nitrogen.

[0042] The term “heterocyclyl”, “heterocyclic” or “heterocycle” may also include oxosubstituted partially saturated heterocyclic rings which contain a substituted ring nitrogen, such as N-alkyl pyridones. For example, the term “heterocyclyl”, “heterocyclic” or“heterocycle” may include groups such

[0043] The term “bridged ring systems” includes ring systems in which two rings share more than two atoms, see for example Advanced Organic Chemistry, by Jerry March, 4th Edition, Wiley Interscience, pages 131-133, 1992. Suitably the bridge is formed between two non-adjacent carbon or nitrogen atoms in the ring system. The bridge connecting the bridgehead atoms may be a bond or comprise one or more atoms. Examples of bridged heterocyclyl ring systems include, aza-bicyclo[2.2.1]heptane, 2-oxa-5-azabicyclo[2.2.1]heptane, aza-bicyclo[2.2.2]octane, aza-bicyclo[3.2.1]octane, and quinuclidine.

[0044] The term “spiro bi-cyclic ring systems” includes ring systems in which two ring systems share one common spiro carbon atom, i.e., the heterocyclic ring is linked to a further carbocyclic or heterocyclic ring through a single common spiro carbon atom. Examples of spiro ring systems include 3,8-diaza-bicyclo[3.2.1 ]octane, 2,5-diaza-bicyclo[2.2.1 ]heptane, 6-azaspiro[3.4]octane, 2-oxa-6-azaspiro[3.4]octane, 2-azaspiro[3.3]heptane, 2-oxa-6-azaspiro[3.3]heptane, 6-oxa-2-azaspiro[3.4]octane, 2,7-diaza-spiro[4.4]nonane, 2-azaspiro[3.5]nonane, 2-oxa-7-azaspiro[3.5]nonane and 2-oxa-6-azaspiro[3.5]nonane.

[0045] The term “aromatic” when applied to a substituent as a whole includes a single ring or polycyclic ring system with 4n + 2 electrons in a conjugated n system within the ring or ring system where all atoms contributing to the conjugated n system are in the same plane.

[0046] The term “aryl” includes an aromatic hydrocarbon ring system. The ring system has 4n +2 electrons in a conjugated n system within a ring where all atoms contributing to the conjugated n system are in the same plane. An aryl may be a single ring or multiple rings (preferably from 1 to 3 rings) that are fused together (i.e., a fused ring aryl) or linked covalently. A fused ring aryl refers to multiple rings fused together wherein at least one of the fused rings is an aryl ring. For example, the “aryl” may be a C6-12 aryl, suitably phenyl or naphthyl. The aryl system itself may be substituted with other groups. The term “aryl” also covers partially aromatic bi- or polycyclic ring systems wherein at least one ring is an aromatic ring and one or more of the other ring(s) is a non-aromatic, saturated or partially saturated ring.

[0047] The term “heteroaryl” includes an aromatic mono- or bicyclic ring incorporating one or more (for example 1-4, particularly 1, 2 or 3) heteroatoms selected from nitrogen, oxygen or sulfur. The ring or ring system has 4n + 2 electrons in a conjugated n system where all atoms contributing to the conjugated n system are in the same plane.

[0048] Examples of heteroaryl groups are monocyclic and bicyclic groups containing from five to twelve ring members, and more usually from five to ten ring members. The heteroaryl group can be, for example, a 5- or 6-membered monocyclic ring or a 9- or 10-membered bicyclic ring, for example a bicyclic structure formed from fused five and six membered rings or two fused six membered rings, also referred to as a “fused bicyclic heteroaryl”. Bicyclic heteroaryl groups can be vicinally fused, i.e., where the rings are linked to each other through two adjacent carbon and / or nitrogen atoms. Each ring may contain up to about four heteroatoms typically selected from nitrogen, sulfur and oxygen. Typically, the heteroaryl ring will contain up to 4, for example up to 3 heteroatoms, more usually up to 2, for example a single heteroatom. In one embodiment, the heteroaryl ring contains at least one ring nitrogen atom. The nitrogen atoms in the heteroaryl rings can be basic, as in the case of an imidazole or pyridine, or essentially non-basic as in the case of an indole or pyrrole nitrogen. In general, the number of basic nitrogen atoms present in the heteroaryl group, including any amino group substituents of the ring, will be less than five.

[0049] Examples of heteroaryl include furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazenyl, benzofuranyl, indolyl, isoindolyl, benzothienyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, benzothiazolyl, indazolyl, purinyl, benzofurazanyl, quinolyl, isoquinolyl, quinazolinyl, quinoxalinyl, cinnolinyl, pteridinyl, naphthyridinyl, carbazolyl, phenazinyl, benzisoquinolinyl, pyridopyrazinyl, thieno[2,3-b]furanyl, 2H-furo[3,2-b]-pyranyl, 1 H-pyrazolo[4,3-d]-oxazolyl, 4H-imidazo[4,5-d]thiazolyl, pyrazino[2,3-d]pyridazinyl, imidazo[2,1 -b]thiazolyl, imidazo[1,2-b][1,2,4]triazinyl, imidazo[1,2-a]pyridine, imidazo[1,2-a]pyrazine, imidazo[1,2-a]pyrimidine, imidazo[1,2-b]pyridazine, triazolo[1,5-a]pyridine, [1,2,3]triazolo[1,5-a]pyridine,. Examples of heteroaryl groups comprising at least one nitrogen in a ring position include pyrrolyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazenyl, indolyl, isoindolyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, benzothiazolyl, indazolyl, purinyl, benzofurazanyl, quinolyl, isoquinolyl, quinazolinyl, quinoxalinyl, cinnolinyl and pteridinyl.

[0050] Examples of five-membered heteroaryl groups include but are not limited to pyrrolyl, furanyl, thienyl, imidazolyl, furazanyl, oxazolyl, oxadiazolyl, oxatriazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, triazolyl and tetrazolyl groups.

[0051] Examples of six-membered heteroaryl groups include but are not limited to pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl and triazinyl.

[0052] The term “heteroaryl” may also include groups that are tautomers of hydroxy substituted heteroaryl groups, such as pyridones. For example, the term “heteroaryl” mayinclude groups such

[0053] The term “oxo,” or “=O” as used herein, means an oxygen that is double bonded to a carbon atom.

[0054] The term "optionally substituted" includes either groups, structures, or molecules that are substituted and those that are not substituted.

[0055] Where optional substituents are chosen from “one or more” groups it is to be understood that this definition includes all substituents being chosen from one of the specifiedgroups or the substituents being chosen from two or more of the specified groups, which may be the same or different. For example, “one or more optional substituents” may refer to 1 or 2 or 3 substituents (e.g. 1 substituent or 2 substituents).

[0056] Where a moiety is substituted, it may be substituted at any point on the moiety where chemically possible and consistent with atomic valency requirements. The moiety may be substituted by one or more substituents, e.g., 1, 2, 3 or 4 substituents; optionally there are 1 or 2 substituents on a group. Where there are two or more substituents, the substituents may be the same or different.

[0057] Substituents are only present at positions where they are chemically possible, the person skilled in the art being able to decide (either experimentally or theoretically) without undue effort which substitutions are chemically possible and which are not.

[0058] Ortho, meta and para substitution arewell understood terms in the art. Forthe absence of doubt, “ortho” substitution is a substitution pattern where adjacent carbons possess a substituent, whether a simple group, for example the fluoro group in the example below, or other portions of the molecule, as indicated by the bond ending in “

[0059] “Meta” substitution is a substitution pattern where two substituents are on carbons one carbon removed from each other, i.e., with a single carbon atom between the substituted carbons. In other words, there is a substituent on the second atom away from the atom with another substituent. For example, the groups below are meta substituted:

[0060] “Para” substitution is a substitution pattern where two substituents are on carbons two carbons removed from each other, i.e., with two carbon atoms between the substituted carbons. In other words, there is a substituent on the third atom away from the atom with another substituent. For example, the groups below are para substituted:

[0061] Where Z1, Z2, Z3, Z4, Z5, orZ6, are nitrogen, said nitrogen may be substituted by R2to give NR2. Similarly, where Z1, Z2, Z3, Z4, Z5, orZ6, are nitrogen, said nitrogen may be the pointatwhich

[0062] Where Z1, Z2, Z3, Z4, Z5, or Z6, are carbon, said carbon may be substituted by R2to give -CHR2- or =CR2- at any position other than the pointatwhich thegroup is attached to the remainder of the compound. Similarly, where Z1, Z2, Z3, Z4, Z5, orZ6, arecarbon, said carbon may be the point at which thegroup is attached to the remainder of the compound, e.g.:

[0063] The term “nitrogen”, when used in relation to Z1, Z2, Z3, Z4, Z5, Z6, A1, A2, A3, A4, A5, A6, A7, A8, A9, and A10, refers to nitrogen in it’s standard valency, unless otherwise stated. For example, “nitrogen” may refer to -N=, -NH-, or -NR-, e.g. -NR2- or -NR5-.

[0064] The term “carbon”, when used in relation to Z2, Z3, Z5, Z6, A1, A2, A3, A4, A5, A6, A7, A8, A9, and A10, refers to carbon in it’s standard valency, unless otherwise stated. For example, “carbon” may refer to -CH=, -CH2-, -CR=, -C(H)R-, or -CR2-, e.g. -CR5=, or -C(R4)2-.

[0065] Reference to a -NRR’ group forming a 4 to 6 membered heterocycloalkyl refers to R and R’ together with the nitrogen atom to which they are attached forming a 4 to 6 membered heterocycloalkyl group. For example, a -NR2aR2b, -NR3aR3b, -NR4aR4b, -NR5aR5b, -NR6aR6b, - NR7aR7b, and -NR8aR8bgroup may form:

[0066] A bond terminating in a “,.., represents that the bond is connected to another atom that is not shown in the structure. A bond terminating inside a cyclic structure and not terminating at an atom of the ring structure represents that the bond may be connected to any of the atoms in the ring structure where allowed by valency, unless stated otherwise herein.

[0067] The various functional groups and substituents making up the compounds of the present invention are typically chosen such that the molecular weight of the compound does not exceed 1000. More usually, the molecular weight of the compound will be less than 750, for example less than 700, or less than 650, or less than 600, or less than 550.

[0068] Suitable or preferred features of any compounds of the present invention may also be suitable features of any other aspect.

[0069] The invention contemplates pharmaceutically acceptable salts of the compounds of the invention. These may include the acid addition and base salts of the compounds. These may be acid addition and base salts of the compounds.

[0070] Suitable acid addition salts are formed from acids which form non-toxic salts. Examples include the acetate, aspartate, benzoate, besylate, bicarbonate / carbonate, bisulfate / sulfate, borate, camsylate, citrate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hibenzate, hydrochloride / chloride, hydrobromide / bromide, hydroiodide / iodide, isethionate, lactate, malate, maleate, malonate, mesylate, methylsulfate, naphthylate, 1,5-naphthalenedisulfonate, 2-napsylate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate / hydrogen phosphate / dihydrogen phosphate, saccharate, stearate, succinate, tartrate, tosylate and trifluoroacetate salts.

[0071] Suitable base salts are formed from bases which form non-toxic salts. Examples include the aluminium, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, tromethamine and zinc salts. Hemisalts of acids and bases may also be formed, for example, hemisulfate and hemicalcium salts. For a review on suitable salts, see " Handbook of Pharmaceutical Salts: Properties, Selection, and Use" by Stahl and Wermuth (Wiley-VCH, Weinheim, Germany, 2002).

[0072] Pharmaceutically acceptable salts of compounds of the invention may be prepared by for example, one or more of the following methods:(i) by reacting the compound of the invention with the desired acid or base;(ii) by removing an acid- or base-labile protecting group from a suitable precursor of the compound of the invention or by ring-opening a suitable cyclic precursor, for example, a lactone or lactam, using the desired acid or base; or(iii) by converting one salt of the compound of the invention to another by reaction with an appropriate acid or base or by means of a suitable ion exchange column.

[0073] These methods are typically carried out in solution. The resulting salt may precipitate out and be collected by filtration or may be recovered by evaporation of the solvent. The degree of ionisation in the resulting salt may vary from completely ionised to almost non-ionised.

[0074] Compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are termed “isomers”. Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers”. Stereoisomers that are not mirror images of one another are termed “diastereomers” and those that are non-superimposable mirror images of each other are termed “enantiomers”. When a compound has an asymmetric centre, for example, it is bonded to four different groups, a pair of enantiomers is possible. An enantiomer can be characterised by the absolute configuration of its asymmetric centre and is described by the R- and S-sequencing rules of Cahn and Prelog, or by the manner in which the molecule rotates the plane of polarized light and designated as dextro rotatory or levorotatory (i.e., as (+)or (-)-isomers respectively). Achiral compound can exist as either individual enantiomer or as a mixture thereof. A mixture containing equal proportions of the enantiomers is called a “racemic mixture”. Where a compound of the invention has two or more stereo centres any combination of (R) and (S) stereoisomers is contemplated. The combination of (R) and (S) stereoisomers may result in a diastereomeric mixture or a single diastereoisomer. The compounds of the invention may be present as a single stereoisomer or may be mixtures of stereoisomers, for example racemic mixtures and other enantiomeric mixtures, and diasteroemeric mixtures. Where the mixture is a mixture of enantiomers the enantiomeric excess may be any of those disclosed above. Where the compound is a single stereoisomer, the compounds may still contain other diasteroisomers or enantiomers as impurities. Hence a single stereoisomer does not necessarily have an enantiomeric excess (e.e.) or diastereomeric excess (d.e.) of 100% but could have an e.e. or d.e. of about at least 85%, for example at least 90%, at least 95%, at least 99%, or at least 99.9%.

[0075] The compounds of this invention may possess one or more asymmetric centres; such compounds can therefore be produced as individual (R) or (S)stereoisomers or as mixtures thereof. Unless indicated otherwise, the description or namingof a particular compound in the specification and claims is intended to include both individual enantiomers and mixtures, racemic or otherwise, thereof. The methods for the determination of stereochemistry and the separation of stereoisomers are well known in the art (see discussion in Chapter 4 of “Advanced Organic Chemistry”, 4th edition J. March, John Wiley and Sons, New York, 2001), for example by synthesis from optically active starting materials or by resolution of a racemic form. Some of the compounds of the invention may have geometric isomeric centres (E and Z isomers). It is to be understood that the present invention encompasses all optical, diastereoisomers and geometric isomers and mixtures thereof

[0076] Z / E (e.g., cis / trans) isomers may be separated by conventional techniques well known to those skilled in the art, for example, chromatography and fractional crystallisation.

[0077] Conventional techniques for the preparation / isolation of individual enantiomers when necessary include chiral synthesis from a suitable optically pure precursor or resolution of the racemate (or the racemate of a salt or derivative) using, for example, chiral high-pressure liquid chromatography (HPLC). Thus, chiral compounds of the invention (and chiral precursors thereof) may be obtained in enantiomerically-enriched form using chromatography, typically HPLC, on an asymmetric resin with a mobile phase consisting of a hydrocarbon, typically heptane or hexane, containing from 0 to 50% by volume of isopropanol, typically from 2% to 20%, and for specific examples, 0 to 5% by volume of an alkylamine e.g., 0.1% diethylamine. Concentration of the eluate affords the enriched mixture.

[0078] Alternatively, the racemate (or a racemic precursor) may be reacted with a suitable optically active compound, for example, an alcohol, or, in the case where the compound of the invention contains an acidic or basic moiety, a base or acid such as 1 -phenylethylamine or tartaric acid. The resulting diastereomeric mixture may be separated by chromatography and / or fractional crystallization and one or both of the diastereoisomers converted to the corresponding pure enantiomer(s) by means well known to a skilled person.

[0079] When any racemate crystallises, crystals of two different types are possible. The first type is the racemic compound (true racemate) referred to above wherein one homogeneous form of crystal is produced containing both enantiomers in equimolar amounts. The second type is the racemic mixture or conglomerate wherein two forms of crystal are produced in equimolar amounts each comprising a single enantiomer.

[0080] While both of the crystal forms present in a racemic mixture have identical physical properties, they may have different physical properties compared to the true racemate. Racemic mixtures may be separated by conventional techniques known to those skilled in the art - see, for example, “Stereochemistry of Organic Compounds” by E. L. Eliel and S. H. Wilen (Wiley, 1994).

[0081] Compounds and salts described in this specification may be isotopically-labelled (or “radio-labelled”). Accordingly, one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number typically found in nature. Examples of radionuclides that may be incorporated include2H (also written as “D” for deuterium),3H (also written as “T” for tritium),11C,13C,14C,15O,17O,18O,13N,15N,18F,36Cl,123I,125I,32P,35S and the like. The radionuclide that is used will depend on the specific application of that radio-labelled derivative. For example, for in vitro competition assays,3H or14C are often useful. For radio-imaging applications,11C or18F are often useful. In some embodiments, the radionuclide is3H. In some embodiments, the radionuclide is14C. In some embodiments, the radionuclide is11C. And in some embodiments, the radionuclide is18F.

[0082] Isotopically-labelled compounds can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described using an appropriate isotopically-labelled reagent in place of the non-labelled reagent previously employed.

[0083] The selective replacement of hydrogen with deuterium in a compound may modulate the metabolism of the compound, the PK / PD properties of the compound and / or the toxicity of the compound. For example, deuteration may increase the half-life or reduce the clearance of the compound in vivo. Deuteration may also inhibit the formation of toxic metabolites, thereby improving safety and tolerability. It is to be understood that the invention encompasses deuterated derivatives of compounds of formula (I). As used herein, the term deuterated derivative refers to compounds of the invention where in a particular position at least one hydrogen atom is replaced by deuterium. Accordingly, in a compound of the invention one or more hydrogen atom is optionally replaced by deuterium. For example, one or more hydrogen atoms in a Ci.4-alkyl group may be replaced by deuterium to form a deuterated Ci.4-alkyl group. By way of example, if any of R1a, R1b, Raor Rbis H, the invention also encompasses R1a, R1b, Raor RbbeingD. By way of further example, if anyof R1a, R1b, R2, R3, R4, R5, R61, R62, R7, R8, R2a, R3a, R4a, R5a, R6a, R7a, R8aR2b, R3b, R4b, R5b, R6b, R7b, and R8bare methyl, the invention also encompasses -CD3, -CHD2and -CH2D.

[0084] Certain compounds of the invention may exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be understood that the invention encompasses all such solvated forms.

[0085] It is also to be understood that certain compounds of the invention may exhibit polymorphism, and that the invention encompasses all such forms.

[0086] Compounds of the invention may exist in a number of different tautomeric forms and references to compounds of the invention include all such forms. For the avoidance of doubt, where a compound can exist in one of several tautomeric forms, and only one is specifically described or shown, all others are nevertheless embraced by compounds of the invention. Examples of tautomeric forms include keto-, enol-, and enolate-forms, as in, for example, the followingtautomeric pairs: keto / enol (illustrated below), imine / enamine, amide / imino alcohol, amidine / amidine, nitroso / oxime, thioketone / enethiol, and nitro / aci-nitro.keto enol enolate

[0087] The / n vivo effects of a compound of the invention may be exerted in part by one or more metabolites that are formed within the human or animal body after administration of a compound of the invention.

[0088] It is further to be understood that a suitable pharmaceutically-acceptable pro-drug of a compound of the formula (I) also forms an aspect of the present invention. Accordingly, the compounds of the invention encompass pro-drug forms of the compounds and the compounds of the invention may be administered in the form of a pro-drug (i.e., a compound that is broken down in the human or animal body to release a compound of the invention). A pro-drug may be used to alter the physical properties and / or the pharmacokinetic properties of a compound of the invention. A pro-drug can beformed when the compound of the invention contains a suitable group or substituent to which a property-modifying group can be attached. Examples of pro-drugs include in v / vo-cleavable ester derivatives that may be formed at a carboxy group or a hydroxy group in a compound of the invention and in v / vo-cleavable amide derivatives that may be formed at a carboxy group or an amino group in a compound of the invention.

[0089] Accordingly, the present invention includes those compounds of the invention as defined herein when made available by organic synthesis and when made available within thehuman or animal body by way of cleavage of a pro-drug thereof. Accordingly, the present invention includes those compounds of the formula (I) that are produced by organic synthetic means and also such compounds that are produced in the human or animal body by way of metabolism of a precursor compound, that is a compound of the formula (I) may be a synthetically-produced compound ora metabolically-produced compound.

[0090] A suitable pharmaceutically-acceptable pro-drug of a compound of the invention is one that is based on reasonable medical judgement as being suitable for administration to the human or animal body without undesirable pharmacological activities and without undue toxicity.

[0091] Various forms of pro-drug have been described, for example in the following documents:- a) Methods in Enzymology, Vol. 42, p. 309-396, edited by K. Widder, et al. (Academic Press, 1985);b) Design of Pro-drugs, edited by H. Bundgaard, (Elsevier, 1985);c) ATextbook of Drug Design and Development, edited by Krogsgaard-Larsen and H. Bundgaard, Chapter 5 “Design and Application of Pro-drugs”, by H. Bundgaard p. 113-191 (1991);d) H. Bundgaard, Advanced Drug Delivery Reviews, 8, 1-38 (1992);e) H. Bundgaard, etal., Journal of Pharmaceutical Sciences, 77, 285 (1988); f) N. Kakeya, etal., Chem. Pharm. Bull., 32, 692 (1984);g) T. Higuchi and V. Stella, “Pro-Drugs as Novel Delivery Systems”, A. C. S. Symposium Series, Volume 14; andh) E. Roche (editor), “Bioreversible Carriers in Drug Design”, Pergamon Press, 1987.

[0092] A suitable pharmaceutically-acceptable pro-drug of a compound of the formula (I) that possesses a carboxy group is, for example, an in v / vo-cleavable ester thereof. An in vivo-cleavable ester of a compound of the invention containing a carboxy group is, for example, a pharmaceutically-acceptable esterwhich is cleaved in the human oranimal body to produce the parent acid. Suitable pharmaceutically-acceptable esters for carboxy include Ci_6alkyl esters such as methyl, ethyl and tert-butyl, Ci_6alkoxymethyl esters such as methoxymethyl esters, Ci.6alkanoyloxymethyl esters such as pivaloyloxymethyl esters, 3- p hthalidyl esters, C3. s cycloalkylcarbonyloxy- Ci_6alkyl esters such ascyclopentylcarbonyloxymethyl and 1 -cyclohexylcarbonyloxyethyl esters, 2-oxo-1,3-dioxolenylmethyl esters such as 5-methyl-2-oxo-1,3-dioxolen-4-ylmethyl esters and Ci-6alkoxycarbonyloxy- Ci_6alkyl esters such as methoxycarbo nyloxymethyl and 1 -methoxycarbonyloxyethyl esters.

[0093] A suitable pharmaceutically-acceptable pro-drug of a compound of the invention that possesses a hydroxy group is, for example, an in v / vo-cleavable ester or ether thereof. An in v / vo-cleavable ester or ether of a compound of the invention containing a hydroxy group is, for example, a pharmaceutically-acceptable ester or ether which is cleaved in the human or animal bodyto produce the parent hydroxy compound. Suitable pharmaceutically-acceptable ester forming groups for a hydroxy group include inorganic esters such as phosphate esters (including phosphoramidic cyclic esters). Further suitable pharmaceutically-acceptable ester forming groups for a hydroxy group include CMO alkanoyl groups such as acetyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl groups, CMO alkoxycarbonyl groups such as ethoxycarbonyl, A / , A / -(Ci.6alkyl)2carbamoyl, 2-dialkylaminoacetyl and 2-carboxyacetyl groups. Examples of ring substituents on the phenylacetyl and benzoyl groups include aminomethyl, A / -alkylaminomethyl, A / , A / -dialkylaminomethyl, morpholinomethyl, piperazin-1 -ylmethyl and 4-(Ci.4alkyl)piperazin-1-ylmethyl. Suitable pharmaceutically-acceptable ether forming groups for a hydroxy group include 0-acyloxyalkyl groups such as acetoxymethyl and pivaloyloxymethyl groups.

[0094] A suitable pharmaceutically-acceptable pro-drug of a compound of the invention that possesses a carboxy group is, for example, an in v / vo-cleavable amide thereof, for example an amide formed with an amine such as ammonia, a Ci.4alkylamine such as methylamine, a (Ci.4alkyl)2amine such as dimethylamine, A / -ethyl-A / -methylamine or diethylamine, a Ci.4alkoxy- C2.4alkylamine such as 2-methoxyethylamine, a phenyl-Ci.4alkylamine such as benzylamine and amino acids such as glycine oran esterthereof.

[0095] A suitable pharmaceutically-acceptable pro-drug of a compound of the invention that possesses an amino group is, for example, an in v / vo-cleavable amide or carbamate derivative thereof. Suitable pharmaceutically-acceptable amides from an amino group include, for example an amide formed with C O alkanoyl groups such as an acetyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl groups. Examples of ring substituents on the phenylacetyl and benzoyl groups include aminomethyl, A / -alkylaminomethyl, N, N-dialkylaminomethyl, morpholinomethyl, piperazin-1 -ylmethyl and 4-(Ci.4alkyl)piperazin-1 -ylmethyl. Suitable pharmaceutically-acceptable carbamates from an amino group include, for example acyloxyalkoxycarbonyl and benzyloxycarbonyl groups.

[0096] Throughout the description and claims of this specification, the words “comprise” and “contain” and variations of them mean “including but not limited to”, and they are not intended to (and do not) exclude other moieties, additives, components, integers or steps. Throughout the description and claims of this specification, the singular encompasses the plural unless the context otherwise requires. In particular, where the indefinite article is used, the specification is to be understood as contemplating plurality as well as singularity, unless the context requires otherwise.

[0097] Features, integers, characteristics, compounds, chemical moieties or groups described in conjunction with a particular aspect, embodiment or example of the invention are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith. All of the features disclosed in this specification (including any accompanying claims, abstract and drawings), and / or all of the steps of any method or process so disclosed, may be combined in any combination, except combinations where at least some of such features and / or steps are mutually exclusive. The invention is not restricted to the details of any foregoing embodiments. The invention extends to any novel one, or any novel combination, of the features disclosed in this specification (including any accompanying claims, abstract and drawings), orto any novel one, or any novel combination, of the steps of any method or process so disclosed.

[0098] The reader's attention is directed to all papers and documents which are filed concurrently with or previous to this specification in connection with this application and which are open to public inspection with this specification, and the contents of all such papers and documents are incorporated herein by reference.COMPOUNDS

[0099] According to the first aspect, there is provided a compound of formula (I), as described herein.

[0100] In an embodiment, the compound of formula (I) is a compound of formula (II), or a pharmaceutically acceptable salt and / or solvate thereof:whereinR1is selected from:-membered heteroaryl, optionally substituted by one or more R2; andR2, A4, A5, A6, A7, B1, B2, B3, B4, Z1, Z2, Z3, Ring B, and Ring C are as defined for formula (I).

[0101] In an embodiment, the compound of formula (I) is a compound of formula (III), or a pharmaceutically acceptable salt and / or solvate thereof:whereinthegroup is optionally substituted by one or more R2; andR2, A4, A5, A6, A7, B1, B2, B3, B4, Z1, Z2, Z3, Ring B, and RingC are as defined for formula (I).

[0102] In an embodiment, the compound of formula (I) is a compound of formula (IV), or a pharmaceutically acceptable salt and / or solvate thereof:whereinthegroup is optionally substituted by one or more R2; andR2, B1, B2, B3, B4, Ring B, and Ring C are as defined for formula (I).

[0103] In certain embodiments compounds of the invention include, for example, compounds of formulae (I) to (IV), or a pharmaceutically acceptable salt and / or solvate thereof, wherein, unless otherwise stated, each group or variable has any of the meanings defined hereinbefore or in any of the following embodiments. These statements are independent and interchangeable. In other words, any of the features described in anyone of the following embodiments may (where chemically allowable) be combined with the features described in one or more other embodiments below. In particular, where a compound is exemplified or illustrated in this specification, any two or more of the statements below which describe a feature of that compound, expressed at any level of generality, may be combined so as to represent subject matter which is contemplated as forming part of the disclosure of this invention in this specification.

[0104] In an embodiment,, optionally substituted by one or more R2.

[0105] In an embodiment, Z1is NH or NR2.

[0106] In an embodiment, Z2is a bond. In an embodiment, Z2is a carbon. In an embodiment, Z2is a nitrogen. In an embodiment, Z2is an oxygen. In an embodiment, Z3is a bond. In an embodiment, Z3is a carbon. In an embodiment, Z3is a nitrogen. In an embodiment, Z3is an oxygen.

[0107] In an embodiment, Z2and Z3are independently selected from: carbon, nitrogen, and oxygen. In an embodiment, Z2and Z3are independently selected from: a bond, nitrogen, and oxygen. In an embodiment, Z2and Z3are independently selected from: a bond, carbon, and oxygen. In an embodiment, Z2and Z3are independently selected from: a bond, carbon and nitrogen. In an embodiment, Z2and Z3are independently selected from: a bond and carbon. In an embodiment, Z2and Z3are independently selected from: nitrogen, and oxygen. In an embodiment, Z2and Z3are independently selected from: a bond and oxygen. In an embodiment, Z2and Z3are independently selected from: carbon and oxygen. In an embodiment, Z2and Z3are independently selected from: a bond and nitrogen. In an embodiment, Z2and Z3are independently selected from: carbon and nitrogen. In an embodiment, Z2and Z3is carbon. In an embodiment, Z2and Z3is nitrogen.

[0108] In an embodiment, Z1is nitrogen, Z2is a bond and Z3is a bond. In an embodiment, Z1is nitrogen, Z2is a bond and Z3is carbon. In an embodiment, Z1is nitrogen, Z2is a bond and Z3is nitrogen. In an embodiment, Z1is nitrogen, Z2is a bond and Z3is oxygen.

[0109] In an embodiment, Z1is nitrogen, Z2is carbon and Z3is a bond. In an embodiment, Z1is nitrogen, Z2is carbon and Z3is carbon. In an embodiment, Z1is nitrogen, Z2is carbon and Z3is nitrogen. In an embodiment, Z1is nitrogen, Z2is carbon and Z3is oxygen.

[0110] In an embodiment, Z1is nitrogen, Z2is nitrogen and Z3is a bond. In an embodiment, Z1is nitrogen, Z2is nitrogen and Z3is carbon. In an embodiment, Z1is nitrogen, Z2is nitrogen and Z3is nitrogen. In an embodiment, Z1is nitrogen, Z2is nitrogen and Z3is oxygen.

[0111] In an embodiment, Z1is nitrogen, Z2is oxygen and Z3is a bond. In an embodiment, Z1is nitrogen, Z2is oxygen and Z3is carbon. In an embodiment, Z1is nitrogen, Z2is oxygen and Z3is nitrogen. In an embodiment, Z1is nitrogen, Z2is oxygen and Z3is oxygen.

[0112] In an embodiment, Z1is NH. In an embodiment, Z1is N. In an embodiment, Z1is NR2.

[0113] In an embodiment, Z2is bonded to L, such that

[0114] In an embodiment, Z3is bonded to L, such that R1-L- is

[0115] In an embodiment, R1is bonded to L, such that R1-L is

[0116] In an embodiment, R1is bonded to L, such that

[0117] In an embodiment, Z1is bonded to L, such that

[0118] In an embodiment,, optionally substituted by one or more R2.

[0119] In an embodiment, Z4is NH or NR2.

[0120] In an embodiment, Z5is a bond. In an embodiment, Z5is a carbon. In an embodiment, Z5is a nitrogen. In an embodiment, Z5is an oxygen. In an embodiment, Z6is a bond. In an embodiment, Z6is a carbon. In an embodiment, Z6is a nitrogen. In an embodiment, Z6is an oxygen.

[0121] In an embodiment, Z5and Z6are independently selected from: carbon, nitrogen, and oxygen. In an embodiment, Z5and Z6are independently selected from: a bond, nitrogen, and oxygen. In an embodiment, Z5and Z6are independently selected from: a bond, carbon, and oxygen. In an embodiment, Z5and Z6are independently selected from: a bond, carbon and nitrogen. In an embodiment, Z5and Z6are independently selected from: a bond and carbon. In an embodiment, Z5and Z6are independently selected from: nitrogen, and oxygen. In an embodiment, Z5and Z6are independently selected from: a bond and oxygen. In an embodiment, Z5and Z6are independently selected from: carbon and oxygen. In an embodiment, Z5and Z6are independently selected from: a bond and nitrogen. In an embodiment, Z5and Z6are independently selected from: carbon and nitrogen. In an embodiment, Z5and Z6is a carbon. In an embodiment, Z5and Z6is a nitrogen.

[0122] In an embodiment, Z4is nitrogen, Z5is a bond and Z6is a bond. In an embodiment, Z4is nitrogen, Z5is a bond and Z6is carbon. In an embodiment, Z4is nitrogen, Z5is a bond and Z6is nitrogen. In an embodiment, Z4is nitrogen, Z5is a bond and Z6is oxygen.

[0123] In an embodiment, Z4is nitrogen, Z5is carbon and Z6is a bond. In an embodiment, Z4is nitrogen, Z5is carbon and Z6is carbon. In an embodiment, Z4is nitrogen, Z5is carbon and Z6is nitrogen. In an embodiment, Z4is nitrogen, Z5is carbon and Z6is oxygen.

[0124] In an embodiment, Z4is nitrogen, Z5is nitrogen and Z6is a bond. In an embodiment, Z4is nitrogen, Z5is nitrogen and Z6is carbon. In an embodiment, Z4is nitrogen, Z5is nitrogen and Z6is nitrogen. In an embodiment, Z4is nitrogen, Z5is nitrogen and Z6is oxygen.

[0125] In an embodiment, Z4is nitrogen, Z5is oxygen and Z6is a bond. In an embodiment, Z4is nitrogen, Z5is oxygen and Z6is carbon. In an embodiment, Z4is nitrogen, Z5is oxygen and Z6is nitrogen. In an embodiment, Z4is nitrogen, Z5is oxygen and Z6is oxygen.

[0126] In an embodiment, Z4is NH. In an embodiment, Z4is N. In an embodiment, Z4is NR2.

[0127] In an embodiment, Z5is bonded to L, such that

[0128] In an embodiment, Z6is bonded to L, such that

[0129] In an embodiment, R1is bonded to L, such that

[0130] In an embodiment, R1is bonded to L, such that

[0131] In an embodiment, Z4is bonded to L, such that R1-L- is

[0132] In an embodiment, R1is selected from, wherein said R1is optionally substituted with one or more R2.

[0133] In an embodiment, R1is selected fromoptionally substituted with one or more R2.

[0134] In an embodiment, R1is selected fromoptionally substituted with one or more R2.R1is optionally substituted with one or more R2.

[0136] In an embodiment,wherein said R1is optionally substituted with one or more R2.

[0137] In an embodiment, R1is selected fromwherein said R1is optionally substituted with one or more R2.

[0138] In an embodiment, R1is selected from, wherein said R1is optionally substituted with one or more R2., wherein said R1is optionally substituted with one or more R2.

[0141] In an embodiment, R1is, wherein said R1is optionally substituted with one or more R2.

[0147] In an embodiment,

[0148] In an embodiment, R1is a 5 to 6-membered heteroaryl. In an embodiment, R1is a 5-membered heteroaryl. In an embodiment, R1is a 6-membered heteroaryl. Said R1is optionally substituted with one or more R2.

[0149] In an embodiment, R1is a 5- or 6-membered heteroaryl selected from: furan, thiophene, pyrrole, pyrazole, imidazole, oxazole, isoxazole, thiazole, isothiazole, triazole (e.g.1.2.4-triazole or 1,2,3-triazole), pyridine, pyridazine, pyrimidine, pyrazine and triazine (e.g.1.2.4-triazine or 1,3,5-triazine), wherein said R1is optionally substituted with one or more R2.

[0150] In an embodiment, R1is a 5- or 6-membered heteroaryl selected from:substituted with one or more R2.

[0151] In an embodiment, R1is a 5-membered heteroaryl selected from: furan, thiophene, pyrrole, pyrazole, imidazole, oxazole, isoxazole, thiazole, isothiazole and triazole (e.g. 1,2,4-triazole or 1,2,3-triazole) wherein said R1is optionally substituted with one or more R2.

[0152] In an embodiment, R1is a 5-membered heteroaryl selected from:HN-N, wherein said R1is optionally substituted with one or more R2.

[0153] In an embodiment, R1is a 6-membered heteroaryl selected from: pyridine, pyridazine, pyrimidine, pyrazine and triazine (e.g. 1,2,4-triazine or 1,3,5-triazine), wherein said R1is optionally substituted with one or more R2.

[0154] In an embodiment, R1is a 6-membered heteroaryl selected from:wherein said R1is optionally substituted with one or more R2.

[0155] In an embodiment, R1is a 5- or 6-membered heteroaryl selected from:, wherein said R1is optionally substituted with one or more R2.

[0156] In an embodiment, R1is a 5-membered heteroaryl selected from:substituted with one or more R2.

[0157] In an embodiment, R1, wherein said R1is optionally substituted with one or more R2.

[0158] In an embodiment, R1is a 5-membered heteroaryl selected from:R2,

[0161] In an embodiment, R1is a 6-membered heteroaryl with the formula

[0162] In an embodiment, R1is a 5- or 6-membered heteroaryl selected from: pyrazole, imidazole, isoxazole, 1,2,4-triazole, pyridine, pyridazine and pyrazine, wherein said R1is optionally substituted with one or more R2.

[0163] In an embodiment, R1is a 5- or 6-membered heteroaryl selected from:, wherein said R1is optionally substituted with one or more R2.

[0164] In an embodiment, R1is a 5-membered heteroaryl selected from: pyrazole, imidazole, isoxazole and 1,2,4-triazole, wherein said R1is optionally substituted with one or more R2.H

[0165] In an embodiment, R1is a 5-membered heteroaryl selected from:O-N HN-N; wherein said R1is optionally substituted with one or more R2.

[0166] In an embodiment, R1is a 6-membered heteroaryl selected from: pyridine, pyridazine and pyrazine, wherein said R1is optionally substituted with one or more R2.

[0167] In an embodiment, R1is a 6-membered heteroaryl selected from:, wherein said R1is optionally substituted with one or more R2.

[0168] In an embodiment, R1is selected frommembered heteroaryl selected from: pyrazole, imidazole, isoxazole, 1,2,4-triazole, pyridine, pyridazine and pyrazine, wherein said R1is optionally substituted with one or more R2.

[0169] In an embodiment, R1is selected from, wherein said R1is optionally substituted with one or more R2.

[0170] In an embodiment, R1is selected frommembered heteroaryl selected from: pyrazole, imidazole, isoxazole and 1, 2, 4-triazole wherein said R1is optionally substituted with one or more R2.

[0171] In an embodiment, R1is selected fromis optionally substituted with one or more R2.membered heteroaryl selected from: pyridine, pyridazine and pyrazine, wherein said R1is optionally substituted with one or more R2.

[0173] In an embodiment, R1is selected frommembered heteroaryl selected from:, wherein said R1is optionally substituted with one or more R2.said R1is optionally substituted with one or more R2.optionally substituted with one or more R2.

[0176] In an embodiment, R1is, wherein said R1is optionally substituted with one or more R2., wherein said R1is optionally substituted with one or more R2.

[0178] In an embodiment, R1is substituted by one R2group.

[0179] In an embodiment, R1is substituted by two independently selected R2groups.

[0180] In an embodiment, R1is substituted by three independently selected R2groups.

[0181] In an embodiment, R2is selected from: deuterium, halo, -CN, -NO2, -NR2aR2b, -OR2a, =O, C1-6alkyl, C1-6haloalkyl, C2-6alkenyl, C2.6alkynyl, -S(O)xR2a, -C(O)R2a, -OC(O)R2a, and -C(O)OR2a, optionally wherein any of the Ci_6alkyl, C2.6alkenyl or C2.6alkynyl groups can be substituted by one or more substituents independently at each occurrence selected from the group consisting of: deuterium and ORa, e.g. OH.

[0182] In an embodiment, R2is selected from: deuterium, halo, -CN, -NO2, -NR2aR2b, -OR2a, =O, C1-6alkyl, C1-6haloalkyl, C2.6alkenyl, C2.6alkynyl, -S(O)xR2a, -C(O)R2a, -OC(O)R2a, and -C(O)OR2a.

[0183] In an embodiment, R2is selected from: deuterium, halo, -CN, -NO2, -NR2aR2b, -OR2a, =O, Ci-6alkyl, Ci_6haloalkyl, -S(O)xR2a, -C(O)R2a, optionally wherein the Ci_6alkyl group can be substituted by one or more substituents independently at each occurrence selected from the group consisting of: deuterium and ORa, e.g. OH.

[0184] In an embodiment, R2is selected from: deuterium, halo, -CN, -NO2, -NR2aR2b, -OR2a, =O, C1-6alkyl, C1-6haloalkyl, -S(O)xR2a, -C(O)R2a.

[0185] In an embodiment, R2is selected from: deuterium, halo, -CN, -NO2, -NR2aR2b, -OR2a, =O, Ci-6alkyl, Ci.6haloalkyl, optionally wherein the Ci.6alkyl group can be substituted by one or more substituents independently at each occurrence selected from the group consisting of: deuterium and ORa, e.g. OH.

[0186] In an embodiment, R2is selected from: deuterium, halo, -CN, -NO2, -NR2aR2b, -OR2a, =O, Ci-6alkyl, Ci.6haloalkyl.

[0187] In an embodiment, R2is selected from: deuterium, halo, -CN, -NO2, -NR2aR2b, -OR2a, =O, C1-3alkyl, C1-3haloalkyl, C2.3alkenyl, C2.3alkynyl, -S(O)xR2a, -C(O)R2a, -OC(O)R2a, and -C(O)OR2a, optionally wherein any of the Ci_3alkyl, C2.3alkenyl or C2.3alkynyl groups can be substituted by one or more substituents independently at each occurrence selected from the group consisting of: deuterium and ORa, e.g. OH.

[0188] In an embodiment, R2is selected from: deuterium, halo, -CN, -NO2, -NR2aR2b, -OR2a, =O, C1-3alkyl, C1-3haloalkyl, C2.3alkenyl, C2.3alkynyl, -S(O)xR2a, -C(O)R2a, -OC(O)R2a, and -C(O)OR2a.

[0189] In an embodiment, R2is selected from: deuterium, halo, -CN, -NO2, -NR2aR2b, -OR2a, =O, C1-3alkyl, C1-3haloalkyl, -S(O)xR2a, -C(O)R2a, optionally wherein the C1-3alkyl group can be substituted by one or more substituents independently at each occurrence selected from the group consisting of: deuterium and ORa, e.g. OH.

[0190] In an embodiment, R2is selected from: deuterium, halo, -CN, -NO2, -NR2aR2b, -OR2a, =O, C1-3alkyl, C1-3haloalkyl, -S(O)xR2a, -C(O)R2a.

[0191] In an embodiment, R2is selected from: deuterium, halo, -CN, -NO2, -NR2aR2b, -OR2a, =O, Ci-3alkyl, optionally wherein the Ci_3alkyl group can be substituted by one or more substituents independently at each occurrence selected from the group consisting of: deuterium and ORa, e.g. OH.

[0192] In an embodiment, R2is selected from: deuterium, halo, -CN, -NO2, -NR2aR2b, -OR2a, =O, Ci-3alkyl, Ci_3haloalkyl.

[0193] In an embodiment, R2is selected from: halo, -CN, -NO2, -NR2aR2b, -OR2a, =O, Ci.6alkyl, Ci-6haloalkyl, C2.6alkenyl, C2.6alkynyl, -S(O)xR2a, -C(O)R2a, -OC(O)R2a, and -C(O)OR2a, optionally wherein any of the Ci.6alkyl, C2.6alkenyl, C2.6alkynyl groups can be substituted by one or more substituents independently at each occurrence selected from the group consisting of: deuterium and ORa, e.g. OH.

[0194] In an embodiment, R2is selected from: halo, -CN, -NO2, -NR2aR2b, -OR2a, =O, Ci.6alkyl, Ci-6haloalkyl, C2.6alkenyl, C2.6alkynyl, -S(O)xR2a, -C(O)R2a, -OC(O)R2a, and -C(O)OR2a.

[0195] In an embodiment, R2is selected from: halo, -CN, -NO2, -NR2aR2b, -OR2a, =O, Ci_3alkyl, Ci-3haloalkyl, C2.3alkenyl, C2.3alkynyl, -S(O)xR2a, -C(O)R2a, -OC(O)R2a, and -C(O)OR2a, optionally wherein any of the Ci_3alkyl, C2.3alkenyl, C2.3alkynyl groups can be substituted by one or more substituents independently at each occurrence selected from the group consisting of: deuterium and ORa, e.g. OH.

[0196] In an embodiment, R2is selected from: halo, -CN, -NO2, -NR2aR2b, -OR2a, =O, Ci_3alkyl, Ci-3haloalkyl, C2.3alkenyl, C2.3alkynyl, -S(O)xR2a, -C(O)R2a, -OC(O)R2a, and -C(O)OR2a.

[0197] In an embodiment, R2is selected from: deuterium, halo, -CN, -NO2, -NR2aR2b, -OR2a, =O, Ci-6alkyl, Ci.6haloalkyl, optionally wherein the Ci.6alkyl, group can be substituted by oneor more substituents independently at each occurrence selected from the group consisting of: deuterium and ORa, e.g. OH.

[0198] In an embodiment, R2is selected from: deuterium, halo, -CN, -NO2, -NR2aR2b, -OR2a, =O, Ci-6alkyl, Ci.6haloalkyl.

[0199] In an embodiment, R2is selected from: deuterium, halo, -CN, -NO2, -NR2aR2b, -OR2a, =O, Ci-3alkyl, Ci_3haloalkyl, optionally wherein the Ci_3alkyl, group can be substituted by one or more substituents independently at each occurrence selected from the group consisting of: deuterium and ORa, e.g. OH.

[0200] In an embodiment, R2is selected from: deuterium, halo, -CN, -NO2, -NR2aR2b, -OR2a, =O, C1-3alkyl, C1-3haloalkyl.

[0201] In an embodiment, R2is selected from: deuterium, halo, Ci.6alkyl, and Ci.6haloalkyl, optionally wherein the Ci.6alkyl, group can be substituted by one or more substituents independently at each occurrence selected from the group consisting of: deuterium and ORa, e.g. OH.

[0202] In an embodiment, R2is selected from: deuterium, halo, Ci_6alkyl, and Ci_6haloalkyl.

[0203] In an embodiment, R2is selected from: deuterium, halo, Ci.3alkyl, and Ci.3haloalkyl, optionally wherein the Ci.3alkyl group can be substituted by one or more substituents independently at each occurrence selected from the group consisting of: deuterium and ORa, e.g. OH.

[0204] In an embodiment, R2is selected from: deuterium, halo, Ci.3alkyl, and Ci.3haloalkyl.

[0205] In an embodiment, R2is selected from: halo, -CN, -NO2, -NR2aR2b, -OR2a, =O, Ci.6alkyl, Ci-6haloalkyl, optionally wherein the Ci.6alkyl group can be substituted by one or more substituents independently at each occurrence selected from the group consisting of: deuterium and ORa, e.g. OH.

[0206] In an embodiment, R2is selected from: halo, -CN, -NO2, -NR2aR2b, -OR2a, =O, Ci.6alkyl, Ci-6haloalkyl.

[0207] In an embodiment, R2is selected from: halo, -CN, -NO2, -NR2aR2b, -OR2a, =O, Ci.3alkyl, Ci-3haloalkyl, optionally wherein the Ci.3alkyl group can be substituted by one or more substituents independently at each occurrence selected from the group consisting of: deuterium and ORa, e.g. OH.

[0208] In an embodiment, R2is selected from: halo, -CN, -NO2, -NR2aR2b, -OR2a, =O, Ci.3alkyl, Ci-3haloalkyl.

[0209] In an embodiment, R2is selected from: halo, Ci_6alkyl, and Ci_6haloalkyl, optionally wherein the Ci_6alkyl group can be substituted by one or more substituents independently at each occurrence selected from the group consisting of: deuterium and ORa, e.g. OH.

[0210] In an embodiment, R2is selected from: halo, Ci.6alkyl, and Ci.6haloalkyl.

[0211] In an embodiment, R2is selected from: halo, Ci_3alkyl, and Ci_3haloalkyl, optionally wherein the Ci.3alkyl group can be substituted by one or more substituents independently at each occurrence selected from the group consisting of: deuterium and ORa, e.g. OH.

[0212] In an embodiment, R2is selected from: halo, Ci.3alkyl, and Ci.3haloalkyl.

[0213] In an embodiment, R2is Ci.6alkyl. In an embodiment, R2is Ci.3alkyl. In an embodiment, R2is preferably methyl. In an embodiment, R2is ethyl. In an embodiment, R2is propyl, e.g. isopropyl. Optionally, any of the alkyl groups mentioned herein can be substituted with deuterium. In an embodiment, R2is CD3.

[0214] In an embodiment, R2is deuterium. In an embodiment, R2is halo (e.gfluoro, chloro, bromo or iodo). In an embodiment, R2is -CN. In an embodiment, R2is -NO2. In an embodiment, R2is -NR2aR2b. In an embodiment, R2is -OR2a(e.g. -OH). In an embodiment, R2is =O. In an embodiment, R2is Ci.6haloalkyl. In an embodiment, R2is Ci.3haloalkyl (e.g. CF3or CH2CHF2). In an embodiment, R2is C2.6alkenyl. In an embodiment, R2is C2.3alkenyl. In an embodiment, R2is C2-6alkynyl In an embodiment, R2is C2.3alkynyl In an embodiment, R2is C3.6cycloalkyl (e.g. cyclopropyl). In an embodiment, R2is 4- to 6-membered heterocycloalkyl. In an embodiment, R2is 4-membered heterocycloalkyl. In an embodiment, R2is 5-membered heterocycloalkyl. In an embodiment, R2is 6-membered heterocycloalkyl. In an embodiment, R2is S(O)xR2a. In an embodiment, R2is -C(O)R2a. In an embodiment, R2is -OC(O)R2a. In an embodiment, R2is -C(O)OR2a.

[0220] In an embodiment, R1is a 6-membered heteroaryl selected from:

[0221] In an embodiment, R1is a 5- or 6-membered heteroaryl selected from:

[0222] In an embodiment, R1is preferably selected from:,

[0223] In an embodiment,embodiment,In anan embodiment, R1is. In an embodiment, R1is. In an embodiment,embodiment,

[0224] In an embodiment, R1is -C(O)NR1aR1b.

[0225] In an embodiment, R1ais selected from: H, C1-3alkyl, and C1-3haloalkyl. In an embodiment, R1ais selected from: H and C1-3alkyl. In an embodiment, R1ais selected from: H and methyl. In an embodiment, R1ais H. In an embodiment, R1ais methyl.

[0226] In an embodiment, R1ais a C1-6alkyl. In an embodiment, R1ais a C1-3alkyl. In an embodiment, the C1-3alkyl is methyl, ethyl or propyl.

[0227] In an embodiment, R1ais a C1-6haloalkyl. In an embodiment, R1ais a C1-3haloalkyl (e.g. CF3).

[0228] In an embodiment, R1bis selected from: H, C1-3alkyl, and C1-3haloalkyl. In an embodiment, R1bis selected from: H and C1-3alkyl. In an embodiment, R1bis selected from: H and methyl. In an embodiment, R1bis H. In an embodiment, R1bis methyl.

[0229] In an embodiment, R1bis a C1-6alkyl. In an embodiment, R1bis a C1-3alkyl. In an embodiment, the C1-3alkyl is methyl, ethyl or propyl.

[0230] In an embodiment, R1bis a C1-6haloalkyl. In an embodiment, R1bis a C1-3haloalkyl (e.g. CF3).

[0231] In an embodiment, R1aand R1bare each C1-3alkyl. In an embodiment, R1ais H and R1bis C1-3alkyl.

[0232] In an embodiment, R1is -C(O)NH2. In an embodiment, R1is -C(O)NHMe. In an embodiment, R1is -C(O)NMe2.

[0233] In an embodiment, L is -C(O)-. Preferably, L is a C1-3alkylene, optionally substituted by one or more independently selected R3. More preferably L is -CH2-, -CH2CH2- or -CH2CH2CH2-.

[0234] In an embodiment, R3is selected from: deuterium, halo, -CN, -NO2, -NR3aR3b, -OR3a, =O, C1-3alkyl, C1-3haloalkyl, C2-3alkenyl, C2-3alkynyl, C3-6cycloalkyl, 4- to 6-membered heterocycloalkyl, -S(O)xR3a, -C(O)R3a, -OC(O)R3a, -C(O)OR3a.

[0235] In an embodiment, R3is selected from: deuterium, halo, -CN, -NO2, -NR3aR3b, -OR3a, =O, C1-3alkyl, C1-3haloalkyl, C2-3alkenyl, C2-3alkynyl, C3-6cycloalkyl, -C(O)OR3a.

[0236] In an embodiment, R3is selected from: deuterium, halo, -CN, -NO2, -NR3aR3b, -OR3a, =O, C1-3alkyl, C1-3haloalkyl.

[0237] In an embodiment, R3is selected from: deuterium, halo, -CN, -NO2, -NR3aR3b, -OR3a, =O, C1-3alkyl.

[0238] In an embodiment, R3is selected from: deuterium, halo, -NR3aR3b, =O, C1-3alkyl.

[0239] In an embodiment, R3is selected from: deuterium, -NR3aR3b, =O, C1-3alkyl.

[0240] In an embodiment, R3is selected from: halo, -NR3aR3b, =O, C1-3alkyl.

[0241] In an embodiment, R3is selected from: -NR3aR3b, =O, C1-3alkyl.

[0242] In an embodiment, R3is deuterium. In an embodiment, R3is halo (e.g. fluoro, chloro, bromo or iodo). In an embodiment, R3is -CN. In an embodiment, R3is -NO2. In an embodiment, R3is -NR3aR3b. In an embodiment, R3is -OR3a(e.g. -OH). In an embodiment, R3is =O. In an embodiment, R3is C1-6alkyl. In an embodiment, R3is C1-3alkyl. In an embodiment the C1-3alkyl is methyl, ethyl or propyl. In an embodiment, R3is C1-6haloalkyl. In an embodiment, R3is C1-3haloalkyl (e.g. CF3). In an embodiment, R3is C2-6alkenyl. In an embodiment, R3is C2-3alkenyl. In an embodiment, R3is C2-6alkynyl. In an embodiment, R3is C2-3alkynyl. In an embodiment, R3is C3-6cycloalkyl. In an embodiment, R3is C3-4cycloalkyl. In an embodiment, R3is 4- to 6-membered heterocycloalkyl. In an embodiment, R3is S(O)xR3awherein x is 0, e.g. R3is -S-. In an embodiment, R3is S(O)xR3awherein x is 1, e.g. R3is -S(O)-. In an embodiment, R3is S(O)xR3awherein x is 2, e.g. R3is -S(O)2-. In an embodiment, R3is -C(O)R3a. In an embodiment, R3is -OC(O)R3a. In an embodiment, R3is -C(O)OR3a.

[0243] In an embodiment, X1is: -O-. In an embodiment, X1is -S(O)x-, wherein x is 0, e.g. X1is -S-. In an embodiment, X1is -S(O)x-, wherein x is 1, e.g. X1is -S(O)-. In an embodiment, X1is -S(O)x-, wherein x is 2, e.g. X1is -S(O)2-.

[0244] Preferably, X1is -O-.

[0245] In an embodiment, the group of -L-X1- is selected from: -C1-3-alkylene-O-, -C1-3-alkylene-S-, -C1-3-alkylene-S(O)-, -C1-3-alkylene-S(O)2-; optionally wherein said alkylene is substituted by one or more R3.

[0246] In an embodiment, most preferably the group of -L-X1- is -CH2-O-. In an embodiment, the group of -L-X1- is -CH2CH2-O-.

[0247] In an embodiment, the group of -L-X1- is -CH2-S-. In an embodiment, the group of -L-X1- is -CH2CH2-S-.

[0248] In an embodiment, the group of -L-X1- is -CH2-S(O)2-. In an embodiment, the group of -L-X1- is -CH2CH2-S(O)2-.

[0249] In an embodiment Ring A is:wherein A1, A2, and A3are each independently selected from the group consisting of: carbon, nitrogen, oxygen, and sulphur, optionally wherein Ring A is substituted by one or more R4.

[0250] In an embodiment, A1is carbon, A2is carbon and A3is carbon In an embodiment, A1is nitrogen, A2is carbon and A3is carbon In an embodiment, A1is oxygen, A2is carbon and A3is carbon. In an embodiment, A1is sulphur, A2is carbon and A3is carbon.

[0251] In an embodiment, A1is carbon, A2is nitrogen and A3is carbon. In an embodiment, A1is carbon, A2is oxygen and A3is carbon. In an embodiment, A1is carbon, A2is sulphur and A3is carbon.

[0252] In an embodiment, A1is carbon, A2is carbon and A3is nitrogen. In an embodiment, A1is carbon, A2is carbon and A3is oxygen. In an embodiment, A1is carbon, A2is carbon and A3is sulphur.

[0253] In an embodiment, A1is nitrogen, A2is nitrogen and A3is carbon. In an embodiment, A1is nitrogen, A2is oxygen and A3is carbon. In an embodiment, A1is nitrogen, A2is sulphur and A3is carbon.

[0254] In an embodiment, A1is nitrogen, A2is carbon and A3is nitrogen. In an embodiment, A1is nitrogen, A2is carbon and A3is oxygen. In an embodiment, A1is nitrogen, A2is carbon and A3is sulphur.

[0255] In an embodiment, A1is oxygen, A2is nitrogen and A3is carbon. In an embodiment, A1is oxygen, A2is oxygen and A3is carbon. In an embodiment, A1is oxygen, A2is sulphur and A3is carbon.

[0256] In an embodiment, A1is oxygen, A2is carbon and A3is nitrogen. In an embodiment, A1is oxygen, A2is carbon and A3is oxygen. In an embodiment, A1is oxygen, A2is carbon and A3is sulphur.

[0257] In an embodiment, A1is sulphur, A2is nitrogen and A3is carbon. In an embodiment, A1is sulphur, A2is oxygen and A3is carbon. In an embodiment, A1is sulphur, A2is sulphur and A3is carbon.

[0258] In an embodiment, A1is sulphur, A2is carbon and A3is nitrogen In an embodiment, A1is sulphur, A2is carbon and A3is oxygen. In an embodiment, A1is sulphur, A2is carbon and A3is sulphur.

[0259] In an embodiment, A1is nitrogen, A2is nitrogen and A3is nitrogen. In an embodiment, A1is nitrogen, A2is oxygen and A3is nitrogen. In an embodiment, A1is nitrogen, A2is sulphur and A3is nitrogen.

[0260] In an embodiment, A1is oxygen, A2is nitrogen and A3is nitrogen. In an embodiment, A1is oxygen, A2is oxygen and A3is nitrogen. In an embodiment, A1is oxygen, A2is sulphur and A3is nitrogen.

[0261] In an embodiment, A1is sulphur, A2is nitrogen and A3is nitrogen In an embodiment, A1is sulphur, A2is oxygen and A3is nitrogen. In an embodiment, A1is sulphur, A2is sulphur and A3is nitrogen.

[0262] In an embodiment, A1is nitrogen, A2is nitrogen and A3is oxygen. In an embodiment, A1is nitrogen, A2is oxygen and A3is oxygen. In an embodiment, A1is nitrogen, A2is sulphur and A3is oxygen.

[0263] In an embodiment, A1is oxygen, A2is nitrogen and A3is oxygen In an embodiment, A1is oxygen, A2is oxygen and A3is oxygen. In an embodiment, A1is oxygen, A2is sulphur and A3is oxygen.

[0264] In an embodiment, A1is sulphur, A2is nitrogen and A3is oxygen. In an embodiment, A1is sulphur, A2is oxygen and A3is oxygen. In an embodiment, A1is sulphur, A2is sulphur and A3is oxygen.

[0265] In an embodiment, A1is nitrogen, A2is nitrogen and A3is sulphur. In an embodiment, A1is nitrogen, A2is oxygen and A3is sulphur. In an embodiment, A1is nitrogen, A2is sulphur and A3is sulphur.

[0266] In an embodiment, A1is oxygen, A2is nitrogen and A3is sulphur. In an embodiment, A1is oxygen, A2is oxygen and A3is sulphur. In an embodiment, A1is oxygen, A2is sulphur and A3is sulphur.

[0267] In an embodiment, A1is sulphur, A2is nitrogen and A3is sulphur. In an embodiment, A1is sulphur, A2is oxygen and A3is sulphur. In an embodiment, A1is sulphur, A2is sulphur and A3is sulphur.

[0268] In an embodiment, Ring A is selected from:,

[0270] In an embodiment, Ring A is:

[0271] In an embodiment, Ring A is preferably:

[0272] In an embodiment, Ring A is ii),, wherein A4, A5, A6, and A7are each independently selected from the group consisting of: carbon and nitrogen, optionally wherein Ring A is substituted by one or more R5; provided that Ring A is not a substituted orunsubstitutedsubstituted or unsubstituted

[0273] In an embodiment, A4is carbon, A5is carbon, A6is carbon and A7is carbon.

[0274] In an embodiment, A4is nitrogen, A5is carbon, A6is carbon and A7is carbon. In an embodiment, A4is carbon, A5is nitrogen, A6is carbon and A7is carbon. In an embodiment, A4is carbon, A5is carbon, A6is nitrogen and A7is carbon. In an embodiment, A4is carbon, A5is carbon, A6is carbon and A7is nitrogen.

[0275] In an embodiment, A4is nitrogen, A5is nitrogen, A6is carbon and A7is carbon. In an embodiment, A4is nitrogen, A5is carbon, A6is nitrogen and A7is carbon.

[0276] In an embodiment, A4is nitrogen, A5is nitrogen, A6is carbon and A7is carbon. In an embodiment, A4is carbon, A5is nitrogen, A6is nitrogen and A7is carbon. In an embodiment, A4is carbon, A5is nitrogen, A6is carbon and A7is nitrogen.

[0277] In an embodiment, A4is nitrogen, A5is carbon, A6is nitrogen and A7is carbon. In an embodiment, A4is carbon, A5is nitrogen, A6is nitrogen and A7is carbon.

[0278] In an embodiment, A4is carbon, A5is nitrogen, A6is nitrogen and A7is nitrogen. In an embodiment, A4is nitrogen, A5is carbon, A6is nitrogen and A7is nitrogen. In an embodiment, A4is nitrogen, A5is nitrogen, A6is carbon and A7is nitrogen. In an embodiment, A4is nitrogen, A5is nitrogen, A6is nitrogen and A7is carbon.

[0279] In an embodiment, A4is nitrogen, A5is nitrogen, A6is nitrogen and A7is nitrogen.

[0280] In an embodiment, Ring A is selected from:

[0281] In an embodiment, Ring A is selected from:

[0282] In an embodiment, Ring A is selected from:

[0283] In an embodiment, Ring A is selected from:

[0285] In an embodiment, Ring A is selected from:

[0286] Ring A is preferablyIn an embodiment, Ringan embodiment, Ringembodiment, Ring A is,

[0287] In an embodiment, Ring A is iii), wherein A8, A9, and A10are each independently selected from the group consisting of: carbon, nitrogen, oxygen, and sulphur, optionally wherein Ring A is substituted by one or more R4.

[0288] In an embodiment, A8is carbon, A9is carbon and A10is carbon. In an embodiment, A8is nitrogen, A9is carbon and A10is carbon. In an embodiment, A8is oxygen, A9is carbon and A10is carbon. In an embodiment, A8is sulphur, A9is carbon and A10is carbon.

[0289] In an embodiment, A8is carbon, A9is nitrogen and A10is carbon. In an embodiment, A8is carbon, A9is oxygen and A10is carbon. In an embodiment, A8is carbon, A9is sulphur and A10is carbon.

[0290] In an embodiment, A8is carbon, A9is carbon and A10is nitrogen. In an embodiment, A8is carbon, A9is carbon and A10is oxygen. In an embodiment, A8is carbon, A9is carbon and A10is sulphur.

[0291] In an embodiment, A8is nitrogen, A9is nitrogen and A10is carbon. In an embodiment, A8is nitrogen, A9is oxygen and A10is carbon. In an embodiment, A8is nitrogen, A9is sulphur and A10is carbon.

[0292] In an embodiment, A8is nitrogen, A9is carbon and A10is nitrogen. In an embodiment, A8is nitrogen, A9is carbon and A10is oxygen. In an embodiment, A8is nitrogen, A9is carbon and A10is sulphur.

[0293] In an embodiment, A8is oxygen, A9is nitrogen and A10is carbon In an embodiment, A8is oxygen, A9is oxygen and A10is carbon. In an embodiment, A8is oxygen, A9is sulphur and A10is carbon.

[0294] In an embodiment, A8is oxygen, A9is carbon and A10is nitrogen. In an embodiment, A8is oxygen, A9is carbon and A10is oxygen. In an embodiment, A8is oxygen, A9is carbon and A10is sulphur.

[0295] In an embodiment, A8is sulphur, A9is nitrogen and A10is carbon. In an embodiment, A8is sulphur, A9is oxygen and A10is carbon. In an embodiment, A8is sulphur, A9is sulphur and A10is carbon.

[0296] In an embodiment, A8is sulphur, A9is carbon and A10is nitrogen. In an embodiment, A8is sulphur, A9is carbon and A10is oxygen. In an embodiment, A8is sulphur, A9is carbon and A10is sulphur.

[0297] In an embodiment, A8is nitrogen, A9is nitrogen and A10is nitrogen. In an embodiment, A8is nitrogen, A9is oxygen and A10is nitrogen. In an embodiment, A8is nitrogen, A9is sulphur and A10is nitrogen.

[0298] In an embodiment, A8is oxygen, A9is nitrogen and A10is nitrogen. In an embodiment, A8is oxygen, A9is oxygen and A10is nitrogen. In an embodiment, A8is oxygen, A9is sulphur and A10is nitrogen.

[0299] In an embodiment, A8is sulphur, A9is nitrogen and A10is nitrogen. In an embodiment, A8is sulphur, A9is oxygen and A10is nitrogen. In an embodiment, A8is sulphur, A9is sulphur and A10is nitrogen.

[0300] In an embodiment, A8is nitrogen, A9is nitrogen and A10is oxygen. In an embodiment, A8is nitrogen, A9is oxygen and A10is oxygen. In an embodiment, A8is nitrogen, A9is sulphur and A10is oxygen.

[0301] In an embodiment, A8is oxygen, A9is nitrogen and A10is oxygen In an embodiment, A8is oxygen, A9is oxygen and A10is oxygen. In an embodiment, A8is oxygen, A9is sulphur and A10is oxygen.

[0302] In an embodiment, A8is sulphur, A9is nitrogen and A10is oxygen In an embodiment, A8is sulphur, A9is oxygen and A10is oxygen. In an embodiment, A8is sulphur, A9is sulphur and A10is oxygen.

[0303] In an embodiment, A8is nitrogen, A9is nitrogen and A10is sulphur. In an embodiment, A8is nitrogen, A9is oxygen and A10is sulphur. In an embodiment, A8is nitrogen, A9is sulphur and A10is sulphur.

[0304] In an embodiment, A8is oxygen, A9is nitrogen and A10is sulphur. In an embodiment, A8is oxygen, A9is oxygen and A10is sulphur. In an embodiment, A8is oxygen, A9is sulphur and A10is sulphur.

[0305] In an embodiment, A8is sulphur, A9is nitrogen and A10is sulphur. In an embodiment, A8is sulphur, A9is oxygen and A10is sulphur In an embodiment, A8is sulphur, A9is sulphur and A10is sulphur.

[0306] In an embodiment, Ring A is selected from: ',,

[0307] In an embodiment, Ring A is optionally substituted by one R4. In an embodiment, Ring A is optionally substituted by two independently selected R4groups. In an embodiment, Ring A is optionally substituted by three independently selected R4groups.

[0308] In an embodiment, R4is selected from: deuterium, halo, -CN, -NO2, -NR4aR4b, -OR4a, =O, Ci-3alkyl, Ci_3haloalkyl, C2.3alkenyl, C2.3alkynyl, C3.6cycloalkyl, 4- to 6-membered heterocycloalkyl, -S(O)xR4a, -C(O)R4a, -OC(O)R4a, and -C(O)OR4a.

[0309] In an embodiment, R4is selected from: deuterium, halo, -CN, -NO2, -NR4aR4b, -OR4a, =O, Ci-6alkyl, Ci_6haloalkyl, -C(O)R4a. In an embodiment, R4is selected from: halo, -CN, -NO2, -NR4aR4b, -OR4a, =O, Ci.3alkyl, Ci-3haloalkyl, -C(O)R4a.

[0310] In an embodiment, R4is selected from: deuterium, halo, -CN, -NO2, -NR4aR4b, -OR4a, =O, Ci-6alkyl. In an embodiment, R4is selected from: halo, -CN, -NO2, -NR4aR4b, -OR4a, =O, C1-3alkyl.

[0311] In an embodiment, R4is deuterium. In an embodiment, R4is halo (e.g. fluoro, chloro, bromo or iodo). In an embodiment, R4is -CN. In an embodiment, R4is -NO2. In an embodiment, R4is -NR4aR4b. In an embodiment, R4is -OR4a(e.g. -OH). In an embodiment, R4is =O. In an embodiment, R4is Ci_6alkyl. In an embodiment, R4is Ci.3alkyl. In an embodiment the Ci.3alkyl is methyl, ethyl or propyl. In an embodiment, R4is Ci_6haloalkyl. In an embodiment, R4is Ci.3haloalkyl (e.g. CF3). In an embodiment, R4is C2.6alkenyl. In an embodiment, R4is C2.3alkenyl.In an embodiment, R4is C2.6alkynyl. In an embodiment, R4is C2.3alkynyl. In an embodiment, R4is C3-6 cycloalkyl. In an embodiment, R4is C3.4cycloalkyl (e.g. cyclopropyl). In an embodiment, R4is 4- to 6-membered heterocycloalkyl. In an embodiment, R4is 4-membered heterocycloalkyl. In an embodiment, R4is 5-membered heterocycloalkyl. In an embodiment, R4is 6-membered heterocycloalkyl. In an embodiment, R4is -S(O)xR4a. In an embodiment, R4is -C(O)R4a. In an embodiment, R4is -OC(O)R4a. In an embodiment, R4is -C(O)OR4a.

[0312] In an embodiment, R4is fluoro. In an embodiment, R4is chloro. In an embodiment, R4is bromo. In an embodiment, R4is iodo. In an embodiment, R4is methyl. In an embodiment, R4is ethyl. In an embodiment, R4is propyl.

[0313] In an embodiment, Ring A is optionally substituted by one R5. In an embodiment, Ring A is optionally substituted by two independently selected R5groups. In an embodiment, Ring A is optionally substituted by three independently selected R5groups.

[0314] In an embodiment, R5is selected from: deuterium, halo, -CN, -NO2, -NR5aR5b, -OR5a, C1.3 alkyl, C1.3 haloalkyl, C2.3alkenyl, C2.3alkynyl, C3-6 cycloalkyl, 4- to 6-membered heterocycloalkyl, -S(O)xR5a, -C(O)R5a, -OC(O)R5a, and -C(O)OR5a.

[0315] In an embodiment, R5is selected from: deuterium, halo, -CN, -NO2, -NR5aR5b, -OR5a, C1-3alkyl, C1-3haloalkyl, C2.3alkenyl, C2.3alkynyl, C3-6 cycloalkyl, 4- or 5-membered heterocycloalkyl, -S(O)xR5a, -C(O)R5a, -OC(O)R5a, and -C(O)OR5a.

[0316] In an embodiment, R5is selected from: deuterium, halo, -CN, -NO2, -NR5aR5b, -OR5a, C1-3alkyl, C1-3haloalkyl, C2.3alkenyl, C2.3alkynyl, C3.6cycloalkyl, -S(O)xR5a, -C(O)R5a, -OC(O)R5a, and -C(O)OR5a.

[0317] In an embodiment, R5is selected from: deuterium, halo, -CN, -NO2, -NR5aR5b, -OR5a, C1-3alkyl, C1-3haloalkyl, C2.3alkenyl, C2.3alkynyl, -S(O)xR5a, -C(O)R5a, -OC(O)R5a, and -C(O)OR5a.

[0318] In an embodiment, R5is selected from: deuterium, halo, -CN, -NO2, -NR5aR5b, -OR5a, C1-6alkyl, C1-6haloalkyl, -C(O)R5a. In an embodiment, R5is selected from: halo, -CN, -NO2, -NR5aR5b, -OR5a, C1-3alkyl, C1-3haloalkyl, -C(O)R5a.

[0319] In an embodiment, R5is selected from: deuterium, halo, -CN, -NO2, -NR5aR5b, -OR5a, Ci-6alkyl. In an embodiment, R5is selected from: halo, -CN, -NO2, -NR5aR5b, -OR5a, Ci_3alkyl.

[0320] In an embodiment, R5is deuterium. In an embodiment, R5is halo (e.g. fluoro, chloro, bromo or iodo). In an embodiment, R5is -CN. In an embodiment, R5is -NO2. In an embodiment, R5is -NR5aR5b. In an embodiment, R5is -OR5a(e.g. -OH). In an embodiment, R5is Ci_6alkyl. In anembodiment, R5is Ci_3alkyl. In an embodiment the Ci_3alkyl is methyl, ethyl or propyl. In an embodiment, R5is Ci_6haloalkyl. In an embodiment, R5is Ci.3haloalkyl (e.g. CF3). In an embodiment, R5is C2.6alkenyl. In an embodiment, R5is C2.3alkenyl. In an embodiment, R5is C2.6alkynyl. In an embodiment, R5is C2.3alkynyl. In an embodiment, R5is C3.6cycloalkyl. In an embodiment, R5is C3.4cycloalkyl (e.g. cyclopropyl). In an embodiment, R5is 4- to 6-membered heterocycloalkyl. In an embodiment, R5is 4-membered heterocycloalkyl. In an embodiment, R5is 5-membered heterocycloalkyl. In an embodiment, R5is 6-membered heterocycloalkyl. In an embodiment, R5is -S(O)xR5a. In an embodiment, R5is -C(O)R5a. In an embodiment, R5is -OC(O)R5a. In an embodiment, R5is -C(O)OR5a.

[0321] R5is preferably fluoro. In an embodiment, R5is chloro. In an embodiment, R5is bromo. In an embodiment, R5is iodo. In an embodiment, R5is methyl. In an embodiment, R5is ethyl. In an embodiment, R5is propyl.

[0322] In an embodiment, Ring B is 5-membered heteroaryl.

[0323] In an embodiment, Ring B is a 5-membered heteroaryl, wherein B1is a bond, B3is -CH=, B2is -C= and B4is -NR62-.

[0324] In an embodiment, Ring B is a 5-membered heteroaryl, wherein B1is a bond, B3is -CR61=, B2is -C= and B4is -NR62-.

[0325] In an embodiment, Ring B is a 5-membered heteroaryl, wherein B1is a bond, B3is -CH=, B2is -N- and B4is -N=.

[0326] In an embodiment, Ring B is a 5-membered heteroaryl, wherein B1is a bond, B3is -CR61=, B2is -N- and B4is -N=.

[0327] In an embodiment, Ring B is a 5-membered heteroaryl, wherein B1is a bond, B3is -N=, B2is -N- and B4is -N=.

[0328] In an embodiment, Ring B is a 5-membered heteroaryl, wherein B1is -CH=, B3is a bond, B2is -C= and B4is -NR62-.

[0329] In an embodiment, Ring B is a 5-membered heteroaryl, wherein B1is -CR61=, B3is a bond, B2is -C- and B4is -NR62-.

[0330] In an embodiment, Ring B is a 5-membered heteroaryl, wherein B1is -N=, B3is a bond, B2is -C- and B4is -NR62-.

[0331] In an embodiment, Ring B is a 5-membered heteroaryl, wherein B1is -NR62-, B3is a bond and B2is -C- and B4is -N=.

[0332] In an embodiment, Ring B is a 5-membered heteroaryl, wherein B1is -N=, B3is a bond, B2is -N- and B4is -N=.

[0333] In an embodiment, the group

[0334] In an embodiment, the group:

[0335] In an embodiment, the group:

[0336] In an embodiment, the group:

[0337] In an embodiment, the group:

[0338] In an embodiment, the group:

[0339] In an embodiment, the group:

[0340] In an embodiment, the group:

[0341] In an embodiment, the group:

[0342] In an embodiment, the group:

[0343] In an embodiment, Ring B is 6-membered heteroaryl.

[0344] In an embodiment, Ring B is a 6-membered heteroaryl, wherein B1is -CH= and B2is -C=, B3is-CH= and B4is-N=.

[0345] In an embodiment, Ring B is a 6-membered heteroaryl, wherein B1is -CR61= and B2is -C=, B3is-CH= and B4is-N=.

[0346] In an embodiment, Ring B is a 6-membered heteroaryl, wherein B1is -CH= and B2is -C=, B3is -CR61= and B4is -N=.

[0347] In an embodiment, Ring B is a 6-membered heteroaryl, wherein B1is -CR61= and B2is -C=, B3is -CR61= and B4is -N=.

[0348] In an embodiment, Ring B is a 6-membered heteroaryl, wherein B1is -N= and B2is -C=, B3is -CH= and B4is -N=.

[0349] In an embodiment, Ring B is a 6-membered heteroaryl, wherein B1is -N= and B2is -C=, B3is -CR61= and B4is-N=.

[0350] In an embodiment, Ring B is a 6-membered heteroaryl, wherein B1is -CH= and B2is -C=, B3is -N= and B4is -N=.

[0351] In an embodiment, Ring B is a 6-membered heteroaryl, wherein B1is -CR61= and B2is -C=, B3is -N= and B4is -N=.

[0352] In an embodiment, Ring B is a 6-membered heteroaryl, wherein B1is -N= and B2is -C=, B3is -N= and B4is -N=.

[0353] In an embodiment, the group

[0354] In an embodiment, the group:

[0355] In an embodiment, the group:

[0356] In an embodiment, the group:

[0357] In an embodiment, the group:

[0358] In an embodiment, the group:

[0359] In an embodiment, the group:

[0360] In an embodiment, the group:

[0361] In an embodiment, the group:

[0362] In an embodiment, the group:

[0363] In an embodiment, the group

[0364] In an embodiment, R61is selected from: deuterium, halo, -CN, -NO2, -NR6aR6b, -OR6a, C1-3alkyl, C1-3haloalkyl, C2.3alkenyl, C2.3alkynyl, C3-6 cycloalkyl, 4- to 6-membered heterocycloalkyl, -S(O)xR6a, -C(O)R6a, -OC(O)R6a, and -C(O)OR6a.

[0365] In an embodiment, R61is selected from: deuterium, halo, -CN, -NO2, -NR6aR6b, -OR6a, C1-6alkyl, C1-6haloalkyl, C2.6alkenyl, C2.6alkynyl, -S(O)xR6a, -C(O)R6a, -OC(O)R6a, and -C(O)OR6a.

[0366] In an embodiment, R61is selected from: deuterium, halo, -CN, -NO2, -NR6aR6b, -OR6a, C1-3alkyl, C1-3haloalkyl, C2.3alkenyl, C2.3alkynyl, -S(O)xR6a, -C(O)R6a, -OC(O)R6a, and -C(O)OR6a.

[0367] In an embodiment, R61is halo (e.g. fluoro, chloro, bromo or iodo). In an embodiment, R61is -CN. In an embodiment, R61is -NO2. In an embodiment, R61is -NR6aR6b. In an embodiment, R61is -OR6a(e.g. -OH). In an embodiment, R61is =O. In an embodiment, R61is C1-6alkyl. In an embodiment, R61is C1-3alkyl. In an embodiment the C1-3alkyl is methyl, ethyl or propyl. In an embodiment, R61is C1-6haloalkyl (e.g. CF3). In an embodiment, R61is C1-3haloalkyl (e.g. CF3). In an embodiment, R61is C2.6alkenyl. In an embodiment, R61is C2.3alkenyl. In an embodiment, R61is C2-6alkynyl. In an embodiment, R61is C2.3alkynyl. In an embodiment, R61is C3-6 cycloalkyl. In an embodiment, R61is C3.4cycloalkyl (e.g. cyclopropyl). In an embodiment, R61is 4- to 6-membered heterocycloalkyl. In an embodiment, R61is 4-membered heterocycloalkyl. In an embodiment, R61is 5-membered heterocycloalkyl. In an embodiment, R61is 6-membered heterocycloalkyl. In an embodiment, R61is -S(O)xR6a. In an embodiment, R61is -C(O)R6a. In an embodiment, R61is -OC(O)R6a. In an embodiment, R61is -C(O)OR6a.

[0368] In an embodiment, R61is selected from: deuterium, halo, -OR6a, C1-6alkyl. In an embodiment, R61is selected from: deuterium, halo, -OR6a, C1-3alkyl. In an embodiment, R61is halo (e.g. fluoro, chloro, bromo or iodo). In an embodiment, R61is fluoro. In an embodiment, R61is deuterium. In an embodiment, R61is OH. In an embodiment, R61is methyl. In an embodiment, R61is ethyl.

[0369] In an embodiment, R62is selected from: C1-3alkyl, C1-3haloalkyl, C2.3alkenyl, C2.3alkynyl, C3.4cycloalkyl, 4- to 6-membered heterocycloalkyl, -S(O)xR6a, -C(O)R6a, and -C(O)OR6a.

[0370] In an embodiment, R62is selected from: C1-3alkyl, C1-3haloalkyl, C2.3alkenyl, C2.3alkynyl, C3.4cycloalkyl and 4- to 6-membered heterocycloalkyl.

[0371] In an embodiment, R62is C1-6alkyl. In an embodiment, R62is C1-3alkyl. In an embodiment the C1-3alkyl is methyl, ethyl or propyl. In an embodiment, R62is C1-6haloalkyl (e.g. CF3). In an embodiment, R62is C1-3haloalkyl (e.g. CF3). In an embodiment, R62is C2.6alkenyl. In an embodiment, R62is C2.3alkenyl. In an embodiment, R62is C2.6alkynyl. In an embodiment, R62is C2.3alkynyl. In an embodiment, R62is C3.6cycloalkyl. In an embodiment, R62is C3.4cycloalkyl (e.g. cyclopropyl). In an embodiment, R62is 4- to 6-membered heterocycloalkyl. In an embodiment, R62is 4-membered heterocycloalkyl. In an embodiment, R62is 5-membered heterocycloalkyl. In an embodiment, R62is 6-membered heterocycloalkyl. In an embodiment, R62is -S(O)xR6a. In an embodiment, R62is -C(O)R6a. In an embodiment, R62is -C(O)OR6a.

[0372] Preferably, R62is methyl.

[0373] In an embodiment, the groupis selected from:

[0374] In an embodiment, the group

[0375] In an embodiment, the group:

[0377] In an embodiment, the group:

[0378] In an embodiment, the group:

[0379] In an embodiment, the group:

[0380] In an embodiment, the group:

[0381] In an embodiment Ring C is selected from: 5- to 6-membered cycloalkyl, 5- to 6-membered cycloalkenyl, 5- to 6-membered heterocycloalkyl, 5- to 6-membered heterocycloalkenyl, phenyl, and 5- or 6-membered heteroaryl, wherein Ring C is optionally substituted by one or more R7or R8groups.

[0382] In an embodiment, Ring C is a 4-membered cycloalkyl optionally substituted by one or more R7. In an embodiment, RingC is a 5-membered cycloalkyl optionally substituted by one or more R7. In an embodiment, RingC is a 6-membered cycloalkyl optionally substituted by one or more R7. In an embodiment, RingC is a 7-membered cycloalkyl optionally substituted by one or more R7.

[0383] In an embodiment, RingC is a 5-membered cycloalkenyl optionally substituted byone or more R7. In an embodiment, Ring C is a 6-membered cycloalkenyl optionally substituted by one or more R7. In an embodiment, RingC is a 7-membered cycloalkenyl optionally substituted byone or more R7.

[0384] In an embodiment, Ring C is a 4-membered heterocycloalkyl optionally substituted by one or more R7. In an embodiment, Ring C is a 5-membered heterocycloalkyl optionally substituted by one or more R7. In an embodiment, Ring C is a 6-membered heterocycloalkyl optionally substituted by one or more R7. In an embodiment, Ring C is a 7-membered heterocycloalkyl optionally substituted by one or more R7.

[0385] In an embodiment, RingC is a 5-membered heterocycloalkenyl optionally substituted byone or more R7. In an embodiment, Ring C is a 6-membered heterocycloalkenyl optionally substituted by one or more R7. In an embodiment, Ring C is a 7-membered heterocycloalkenyl optionally substituted by one or more R7.

[0386] Preferably, Ring C is a phenyl which is optionally substituted by one or more R8. In an embodiment, Ring C is a 5-membered heteroaryl optionally substituted by one or more R8. In an embodiment, RingC is a 6-membered heteroaryl optionally substituted by one or more R8.

[0387] In an embodiment, Ring C is substituted by one R7. In an embodiment, Ring C is substituted by two independently selected R7groups. In an embodiment, Ring C is substituted by three independently selected R7groups. In an embodiment, Ring C is substituted by four independently selected R7groups. In an embodiment, Ring C is substituted by five independently selected R7groups.

[0388] In an embodiment, Ring C is substituted by one R8. In an embodiment, Ring C is substituted by two independently selected R8groups. In an embodiment, RingC is substituted by three independently selected R8groups. In an embodiment, Ring C is substituted by four independently selected R8groups.

[0389] In an embodiment, the group

[0390] In an embodiment, the group, wherein each Y is independently selected from: oxygen, nitrogen or sulphur and wherein said Ring C is optionally substituted by one or more R7or R8.

[0391] In an embodiment, the groupoptionally substituted by one or more R7or R8.

[0392] In an embodiment, the groupis selected from:

[0393] In an embodiment, the group10 is selected from:

[0394] In an embodiment, the group10 is selected from:

[0395] In paragraphs relating to RingC, RingC is optionally substituted by one or more R7.

[0396] In an embodiment, RingC is optionally substituted by one R7. In an embodiment, Ring C is optionally substituted by two independently selected R7groups. In an embodiment, Ring C is optionally substituted by three independently selected R7groups.

[0397] In an embodiment, R7is selected from: deuterium, halo, -CN, -NO2, -NR7aR7b, -OR7a, =O, Ci-3alkyl, Ci_3haloalkyl, C2.3alkenyl, C2.3alkynyl, C3.6cycloalkyl, 4- to 6-membered heterocycloalkyl, -S(O)xR7a, -C(O)R7a, -OC(O)R7a, and -C(O)OR7a.

[0398] In an embodiment, R7is selected from: deuterium, halo, -CN, -NO2, -NR7aR7b, -OR7a, C1-3alkyl, C1-3haloalkyl, C2.3alkenyl, C2.3alkynyl, C3.6cycloalkyl, 4- to 6-membered heterocycloalkyl, -S(O)xR7a, -C(O)R7a, -OC(O)R7a, and -C(O)OR7a.

[0399] In an embodiment, R7is selected from: deuterium, halo, -CN, -NO2, -NR7aR7b, -OR7a, =O, Ci-3alkyl, Ci.3haloalkyl, C2.3alkenyl, C2.3alkynyl, C3.4cycloalkyl, 4- to 6-membered heterocycloalkyl, -S(O)xR7a, -C(O)R7a, -OC(O)R7a, and -C(O)OR7a.

[0400] In an embodiment, R7is selected from: deuterium, halo, -CN, -NO2, -NR7aR7b, -OR7a, C1-3alkyl, C1-3haloalkyl, C2.3alkenyl, C2.3alkynyl, C3.4cycloalkyl, 4- to 6-membered heterocycloalkyl, -S(O)xR7a, -C(O)R7a, -OC(O)R7a, and -C(O)OR7a.

[0401] In an embodiment, R7is selected from: deuterium, halo, -CN, -NO2, -NR7aR7b, -OR7a, =O, C1-6alkyl, C1-6haloalkyl, C2-6alkenyl, C2.6alkynyl, -S(O)xR7a, -C(O)R7a, -OC(O)R7a, and -C(O)OR7a.

[0402] In an embodiment, R7is selected from: deuterium, halo, -CN, -NO2, -NR7aR7b, -OR7a, C1-6alkyl, C1-6haloalkyl, C2.6alkenyl, C2.6alkynyl, -S(O)xR7a, -C(O)R7a, -OC(O)R7a, and -C(O)OR7a.

[0403] In an embodiment, R7is selected from: deuterium, halo, -CN, -NO2, -NR7aR7b, -OR7a, =O, C1-3alkyl, C1-3haloalkyl, C2.3alkenyl, C2.3alkynyl, -S(O)xR7a, -C(O)R7a, -OC(O)R7a, and -C(O)OR7a.

[0404] In an embodiment, R7is selected from: deuterium, halo, -CN, -NO2, -NR7aR7b, -OR7a, C1-3alkyl, C1-3haloalkyl, C2.3alkenyl, C2.3alkynyl, -S(O)xR7a, -C(O)R7a, -OC(O)R7a, and -C(O)OR7a.

[0405] In an embodiment, R7is deuterium. In an embodiment, R7is halo (e.g fluoro, chloro, bromo or iodo). In an embodiment, R7is -CN. In an embodiment, R7is -NO2. In an embodiment, R7is -NR7aR7b. In an embodiment, R7is -OR7a(e.g. -OH). In an embodiment, R7is =O. In an embodiment, R7is Ci_6alkyl. In an embodiment, R7is Ci_3alkyl. In an embodiment the Ci_3alkyl is methyl, ethyl or propyl. In an embodiment, R7is Ci_6haloalkyl. In an embodiment, R7is Ci_3haloalkyl (e.g. CF3). In an embodiment, R7is C2.6alkenyl. In an embodiment, R7is C2.3alkenyl. In an embodiment, R7is C2.6alkynyl. In an embodiment, R7is C2.3alkynyl. In an embodiment, R7is C3-6 cycloalkyl. In an embodiment, R7is C3.4cycloalkyl (e.g. cyclopropyl). In an embodiment, R7is 4- to 6-membered heterocycloalkyl. In an embodiment, R7is 4-membered heterocycloalkyl. In an embodiment, R7is 5-membered heterocycloalkyl. In an embodiment, R7is 6-membered heterocycloalkyl. In an embodiment, R7is -S(O)xR7a. In an embodiment, R7is -C(O)R7a. In an embodiment, R7is -OC(O)R7a. In an embodiment, R7is -C(O)OR7a.

[0406] In paragraphs relating to RingC, RingC is optionally substituted by one or more R8.

[0407] In an embodiment, RingC is optionally substituted by one R8. In an embodiment, Ring C is optionally substituted by two independently selected R8groups. In an embodiment, Ring C is optionally substituted by three independently selected R8groups.

[0408] In an embodiment, where Ring C is a 4- to 7-membered heterocycloalkyl, 5- to 7-membered hetero cyclo alkenyl or 5- or 6-membered heteroaryl comprising one or more nitrogen, said nitrogen is selected from -N=, -NR7- or -NR8-.

[0409] In an embodiment, R8is selected from: deuterium, halo, -CN, -NO2, -NR8aR8b, -OR8a, C1-3alkyl, C1-3haloalkyl, C2.3alkenyl, C2.3alkynyl, C3-6 cycloalkyl, 4- to 6-membered heterocycloalkyl, -S(O)xR8a, -C(O)R8a, -OC(O)R8a, and -C(O)OR8a.

[0410] In an embodiment, R8is selected from: deuterium, halo, -CN, -NO2, -NR8aR8b, -OR8a, C1-3 alkyl, C1-3 haloalkyl, C2.3alkenyl, C2.3alkynyl, C3-6 cycloalkyl, 4- to 6-membered heterocycloalkyl, -C(O)R8a, -OC(O)R8a, and -C(O)OR8a.

[0411] In an embodiment, R8is selected from: deuterium, halo, -CN, -NO2, -NR8aR8b, -OR8a, C1-3 alkyl, C1-3 haloalkyl, C2.3alkenyl, C2.3alkynyl, C3.4cycloalkyl, 4- to 6-membered heterocycloalkyl, -S(O)xR8a, -C(O)R8a, -OC(O)R8a, and -C(O)OR8a.

[0412] In an embodiment, R8is selected from: deuterium, halo, -CN, -NO2, -NR8aR8b, -OR8a, C1-3 alkyl, C1-3 haloalkyl, C2.3alkenyl, C2.3alkynyl, C3.4cycloalkyl, 4- to 6-membered heterocycloalkyl, -C(O)R8a, -OC(O)R8a, and -C(O)OR8a.

[0413] In an embodiment, R8is selected from: deuterium, halo, -CN, -NO2, -NR8aR8b, -OR8a, C1-6alkyl, C1-6haloalkyl, C2.6alkenyl, C2.6alkynyl, -S(O)xR8a, -C(O)R8a, -OC(O)R8a, and -C(O)OR8a.

[0414] In an embodiment, R8is selected from: deuterium, halo, -CN, -NO2, -NR8aR8b, -OR8a, C1-6alkyl, C1-6haloalkyl, C2.6alkenyl, C2.6alkynyl, -C(O)R8a, -OC(O)R8a, and -C(O)OR8a.

[0415] In an embodiment, R8is selected from: deuterium, halo, -CN, -NO2, -NR8aR8b, -OR8a, C1-3alkyl, C1-3haloalkyl, C2.3alkenyl, C2.3alkynyl, -S(O)xR8a, -C(O)R8a, -OC(O)R8a, and -C(O)OR8a.

[0416] In an embodiment, R8is selected from: deuterium, halo, -CN, -NO2, -NR8aR8b, -OR8a, C1-3alkyl, C1-3haloalkyl, C2.3alkenyl, C2.3alkynyl, -C(O)R8a, -OC(O)R8a, and -C(O)OR8a.

[0417] In an embodiment, R8is selected from: deuterium, halo, -CN, -NO2, -NR8aR8b, -OR8a, C1-6alkyl, C1-6haloalkyl, C2.6alkenyl, C2.6alkynyl, -C(O)R8aand -C(O)OR8a.

[0418] In an embodiment, R8is selected from: deuterium, halo, -CN, -NO2, -NR8aR8b, -OR8a, C1-6alkyl, C1-6haloalkyl and C2.6alkynyl.

[0419] In an embodiment, R8is selected from: deuterium, halo, -CN, -NO2, -NR8aR8b, -OR8a, C1-3alkyl, C1-3haloalkyl and C2.3alkynyl.

[0420] In an embodiment, R8is selected from: deuterium, halo, -CN, -OR8a, Ci_6alkyl and Ci-6haloalkyl.

[0421] In an embodiment, R8is selected from: deuterium, halo, -CN, -OR8a, Ci_6alkyl.

[0422] Preferably, R8is selected from: deuterium, halo, -CN, -OR8a, Ci_3alkyl and Ci_3haloalkyl.

[0423] Preferably, R8is selected from: deuterium, halo, -CN, -OR8a, C1.3 alkyl.

[0424] In an embodiment, R8is deuterium. In an embodiment, R8is halo. In an embodiment, R8is halo (e.g. fluoro, chloro, bromo or iodo). In an embodiment, R8is -CN. In an embodiment, R8is -NO2. In an embodiment, R8is -NR8aR8b. In an embodiment, R8is -OR8a(e.g. -OH). In an embodiment, R8is Ci_6alkyl. In an embodiment, R8is C1.3 alkyl. In an embodiment the Ci.3alkyl is methyl, ethyl or propyl. In an embodiment, R8is Ci_6haloalkyl. In an embodiment, R8is Ci.3haloalkyl (e.g. CF3). In an embodiment, R8is C2.6alkenyl. In an embodiment, R8is C2.3alkenyl. In an embodiment, R8is C2.6alkynyl. In an embodiment, R8is C2.3alkynyl. In an embodiment, R8is C3-6cycloalkyl. In an embodiment, R8is C3.4cycloalkyl (e.g. cyclopropyl). In an embodiment, R8is 4- to 6-membered heterocycloalkyl. In an embodiment, R8is 4-membered heterocycloalkyl. In an embodiment, R8is 5-membered heterocycloalkyl. In an embodiment, R8is 6-membered heterocycloalkyl. In an embodiment, R8is -S(O)xR8a. In an embodiment, R8is -C(O)R8a. In an embodiment, R8is -OC(O)R8a. In an embodiment, R8is -C(O)OR8a.

[0425] In an embodiment, R8is fluoro. In an embodiment, R8is chloro. In an embodiment, R8is bromo. In an embodiment, R8is iodo. In an embodiment, R8is OH. In an embodiment, R8is methyl. In an embodiment, R8is ethyl. In an embodiment, R8is propyl.

[0426] In an embodiment, the group

[0427] In an embodiment, the group

[0428] In an embodiment, the groupis selected from:

[0430] In an embodiment, the group

[0431] In an embodiment, the group

[0433] In an embodiment, the groupis selected from:

[0434] In an embodiment, Ring B is a 5-membered heteroaryl, wherein B1is a bond, B3is -CH=, B2is -C= and B4is -NR62- and Ring C is selected from: 5- to 6-membered cycloalkyl, 5- to 6-membered cycloalkenyl, 5- to 6-membered heterocycloalkyl and 5- to 6-membered heterocycloalkenyl, wherein Ring C is optionally substituted by one or more R7groups.

[0435] In an embodiment, Ring B is a 5-membered heteroaryl, wherein B1is a bond, B3is -CH=, B2is -C= and B4is -NR62- and Ring C is selected from: phenyl and 5-6-membered heteroaryl, wherein Ring C is optionally substituted by one or more R8groups.

[0436] In an embodiment, Ring B is a 5-membered heteroaryl, wherein B1is a bond, B3is -CR61=, B2is -C= and B4is -NR62- and Ring C is selected from: 5- to 6-membered cycloalkyl, 5- to 6-membered cycloalkenyl, 5- to 6-membered heterocycloalkyl and 5- to 6-membered heterocycloalkenyl, wherein Ring C is optionally substituted by one or more R7groups.

[0437] In an embodiment, Ring B is a 5-membered heteroaryl, wherein B1is a bond, B3is -CR61=, B2is -C= and B4is -NR62= and Ring C is selected from: phenyl and 5-6-membered heteroaryl, wherein Ring C is optionally substituted by one or more R8groups.

[0438] In an embodiment, Ring B is a 5-membered heteroaryl, wherein B1is a bond, B3is -CH=, B2is -N- and B4is -N= and Ring C is selected from: 5- to 6-membered cycloalkyl, 5- to 6-membered cycloalkenyl, 5- to 6-membered heterocycloalkyl and 5- to 6-membered heterocycloalkenyl, wherein Ring C is optionally substituted by one or more R7groups.

[0439] In an embodiment, Ring B is a 5-membered heteroaryl, wherein B1is a bond, B3is -CH=, B2is -N- and B4is -N= and Ring C is selected from: phenyl and 5-6-membered heteroaryl, wherein Ring C is optionally substituted by one or more R8groups.

[0440] In an embodiment, Ring B is a 5-membered heteroaryl, wherein B1is a bond, B3is -CR61=, B2is -N- and B4is -N= and Ring C is selected from: 5- to 6-membered cycloalkyl, 5- to 6-membered cycloalkenyl, 5- to 6-membered heterocycloalkyl and 5- to 6-membered heterocycloalkenyl, wherein Ring C is optionally substituted by one or more R7groups.

[0441] In an embodiment, Ring B is a 5-membered heteroaryl, wherein B1is a bond, B3is -CR61=, B2is -N- and B4is -N= and Ring C is selected from: phenyl and 5-6-membered heteroaryl, wherein Ring C is optionally substituted by one or more R8groups.

[0442] In an embodiment, Ring B is a 5-membered heteroaryl, wherein B1is a bond, B3is -N=, B2is -N- and B4is -N= and Ring C is selected from: 5- to 6-membered cycloalkyl, 5- to 6-membered cycloalkenyl, 5- to 6-membered heterocycloalkyl and 5- to 6-membered heterocycloalkenyl, wherein Ring C is optionally substituted by one or more R7groups.

[0443] In an embodiment, Ring B is a 5-membered heteroaryl, wherein B1is a bond, B3is -N=, B2is -N- and B4is -N= and Ring C is selected from: phenyl and 5-6-membered heteroaryl, wherein Ring C is optionally substituted by one or more R8groups.

[0444] In an embodiment, Ring B is a 5-membered heteroaryl, wherein B1is -CH=, B3is a bond, B2is -C= and B4is -NR62- and Ring C is selected from: 5- to 6-membered cycloalkyl, 5- to 6-membered cycloalkenyl, 5- to 6-membered heterocycloalkyl and 5- to 6-membered heterocycloalkenyl, wherein Ring C is optionally substituted by one or more R7groups.

[0445] In an embodiment, Ring B is a 5-membered heteroaryl, wherein B1is -CH=, B3is a bond, B2is -C= and B4is -NR62- and Ring C is selected from: phenyl and 5-6-membered heteroaryl, wherein Ring C is optionally substituted by one or more R8groups.

[0446] In an embodiment, Ring B is a 5-membered heteroaryl, wherein B1is -CR61=, B3is a bond, B2is -C= and B4is -NR62- and Ring C is selected from: 5- to 6-membered cycloalkyl, 5- to 6-membered cycloalkenyl, 5- to 6-membered heterocycloalkyl and 5- to 6-membered heterocycloalkenyl, wherein Ring C is optionally substituted by one or more R7groups.

[0447] In an embodiment, Ring B is a 5-membered heteroaryl, wherein B1is -CR61=, B3is a bond, B2is -C= and B4is -NR62- and Ring C is selected from: phenyl and 5-6-membered heteroaryl, wherein Ring C is optionally substituted by one or more R8groups.

[0448] In an embodiment, Ring B is a 5-membered heteroaryl, wherein B1is -N=, B3is a bond, B2is -C= and B4is -NR62- and Ring C is selected from: 5- to 6-membered cycloalkyl, 5- to 6-membered cycloalkenyl, 5- to 6-membered heterocycloalkyl and 5- to 6-membered heterocycloalkenyl, wherein Ring C is optionally substituted by one or more R7groups.

[0449] In an embodiment, Ring B is a 5-membered heteroaryl, wherein B1is -N=, B3is a bond, B2is -C= and B4is -NR62- and Ring C is selected from: phenyl and 5-6-membered heteroaryl, wherein Ring C is optionally substituted by one or more R8groups.

[0450] In an embodiment, Ring B is a 5-membered heteroaryl, wherein B1is -NR62-, B3is a bond and B2is -C= and B4is -N= and Ring C is selected from: 5- to 6-membered cycloalkyl, 5-to 6-membered cycloalkenyl, 5- to 6-membered heterocycloalkyl and 5- to 6-membered heterocycloalkenyl, wherein Ring C is optionally substituted by one or more R7groups.

[0451] In an embodiment, Ring B is a 5-membered heteroaryl, wherein B1is -NR62-, B3is a bond and B2is -C= and B4is -N= and Ring C is selected from: phenyl and 5-6-membered heteroaryl, wherein Ring C is optionally substituted by one or more R8groups.

[0452] In an embodiment, Ring B is a 5-membered heteroaryl, wherein B1is -N=, B3is a bond, B2is -N- and B4is -N= and Ring C is selected from: 5- to 6-membered cycloalkyl, 5- to 6-membered cycloalkenyl, 5- to 6-membered heterocycloalkyl and 5- to 6-membered heterocycloalkenyl, wherein Ring C is optionally substituted by one or more R7groups.

[0453] In an embodiment, Ring B is a 5-membered heteroaryl, wherein B1is -N=, B3is a bond, B2is -N- and B4is -N= and Ring C is selected from: phenyl and 5-6-membered heteroaryl, wherein Ring C is optionally substituted by one or more R8groups.

[0454] In an embodiment, Ring B is a 6-membered heteroaryl, wherein B1is -CH= and B2is -C=, B3is -CH= and B4is -N= and Ring C is selected from: 5- to 6-membered cycloalkyl, 5- to 6-membered cycloalkenyl, 5- to 6-membered heterocycloalkyl and 5- to 6-membered heterocycloalkenyl, wherein Ring C is optionally substituted by one or more R7groups.

[0455] In an embodiment, Ring B is a 6-membered heteroaryl, wherein B1is -CH= and B2is -C=, B3is -CH= and B4is -N= and Ring C is selected from: phenyl and 5-6-membered heteroaryl, wherein Ring C is optionally substituted by one or more R8groups.

[0456] In an embodiment, Ring B is a 6-membered heteroaryl, wherein B1is -CR61= and B2is -C=, B3is -CH= and B4is -N= and Ring C is selected from: 5- to 6-membered cycloalkyl, 5- to 6-membered cycloalkenyl, 5- to 6-membered heterocycloalkyl and 5- to 6-membered heterocycloalkenyl, wherein Ring C is optionally substituted by one or more R7groups.

[0457] In an embodiment, Ring B is a 6-membered heteroaryl, wherein B1is -CR61= and B2is -C=, B3is-CH=and B4is-N=and RingC is selected from: phenyland 5-6-membered heteroaryl, wherein Ring C is optionally substituted by one or more R8groups.

[0458] In an embodiment, Ring B is a 6-membered heteroaryl, wherein B1is -CH= and B2is -C=, B3is -CR61= and B4is -N= and Ring C is selected from: 5- to 6-membered cycloalkyl, 5- to 6-membered cycloalkenyl, 5- to 6-membered heterocycloalkyl and 5- to 6-membered heterocycloalkenyl, wherein Ring C is optionally substituted by one or more R7groups.

[0459] In an embodiment, Ring B is a 6-membered heteroaryl, wherein B1is -CH= and B2is -C=, B3is-CR61=and B4is-N=and RingC is selected from: phenyland 5-6-membered heteroaryl, wherein Ring C is optionally substituted by one or more R8groups.

[0460] In an embodiment, Ring B is a 6-membered heteroaryl, wherein B1is -CR61= and B2is -C=, B3is -CR61= and B4is -N= and Ring C is selected from: 5- to 6-membered cycloalkyl, 5- to 6-membered cycloalkenyl, 5- to 6-membered heterocycloalkyl and 5- to 6-membered heterocycloalkenyl, wherein Ring C is optionally substituted by one or more R7groups.

[0461] In an embodiment, Ring B is a 6-membered heteroaryl, wherein B1is -CR61= and B2is -C=, B3is -CR61= and B4is -N= and Ring C is selected from: phenyl and 5-6-membered heteroaryl, wherein Ring C is optionally substituted by one or more R8groups.

[0462] In an embodiment, Ring B is a 6-membered heteroaryl, wherein B1is -N= and B2is -C=, B3is -CH= and B4is -N= and Ring C is selected from: 5- to 6-membered cycloalkyl, 5- to 6-membered cycloalkenyl, 5- to 6-membered heterocycloalkyl and 5- to 6-membered heterocycloalkenyl, wherein Ring C is optionally substituted by one or more R7groups.

[0463] In an embodiment, Ring B is a 6-membered heteroaryl, wherein B1is -N= and B2is -C=, B3is -CH= and B4is -N= and Ring C is selected from: phenyl and 5-6-membered heteroaryl, wherein Ring C is optionally substituted by one or more R8groups.

[0464] In an embodiment, Ring B is a 6-membered heteroaryl, wherein B1is -N= and B2is -C=, B3is -CR61= and B4is -N= and Ring C is selected from: 5- to 6-membered cycloalkyl, 5- to 6-membered cycloalkenyl, 5- to 6-membered heterocycloalkyl and 5- to 6-membered heterocycloalkenyl, wherein Ring C is optionally substituted by one or more R7groups.

[0465] In an embodiment, Ring B is a 6-membered heteroaryl, wherein B1is -N= and B2is -C=, B3is -CR61= and B4is -N= and Ring C is selected from: phenyl and 5-6-membered heteroaryl, wherein Ring C is optionally substituted by one or more R8groups.

[0466] In an embodiment, Ring B is a 6-membered heteroaryl, wherein B1is -CH= and B2is -C=, B3is -N= and B4is -N= and Ring C is selected from: 5- to 6-membered cycloalkyl, 5- to 6-membered cycloalkenyl, 5- to 6-membered heterocycloalkyl and 5- to 6-membered heterocycloalkenyl, wherein Ring C is optionally substituted by one or more R7groups.

[0467] In an embodiment, Ring B is a 6-membered heteroaryl, wherein B1is -CH= and B2is -C=, B3is -N= and B4is -N= and Ring C is selected from: phenyl and 5-6-membered heteroaryl, wherein Ring C is optionally substituted by one or more R8groups.

[0468] In an embodiment, Ring B is a 6-membered heteroaryl, wherein B1is -CR61= and B2is -C=, B3is -N= and B4is -N= and Ring C is selected from: 5- to 6-membered cycloalkyl, 5- to 6-membered cycloalkenyl, 5- to 6-membered heterocycloalkyl and 5- to 6-membered heterocycloalkenyl, wherein Ring C is optionally substituted by one or more R7groups.

[0469] In an embodiment, Ring B is a 6-membered heteroaryl, wherein B1is -CR61= and B2is -C=, B3is -N= and B4is -N= and Ring C is selected from: phenyl and 5-6-membered heteroaryl, wherein Ring C is optionally substituted by one or more R8groups.

[0470] In an embodiment, Ring B is a 6-membered heteroaryl, wherein B1is -N= and B2is -C=, B3is -N= and B4is -N= and Ring C is selected from: 5- to 6-membered cycloalkyl, 5- to 6-membered cycloalkenyl, 5- to 6-membered heterocycloalkyl and 5- to 6-membered heterocycloalkenyl, wherein Ring C is optionally substituted by one or more R7groups.

[0471] In an embodiment, Ring B is a 6-membered heteroaryl, wherein B1is -N= and B2is -C=, B3is -N= and B4is -N= and Ring C is selected from: phenyl and 5-6-membered heteroaryl, wherein Ring C is optionally substituted by one or more R8groups.

[0472] In an embodiment, the groupis selected from:C is substituted by one or more R7or R8.

[0473] In an embodiment, the groupis selected from:

[0474] In an embodiment, the group

[0475] In an embodiment, the group5

[0476] In an embodiment, the groupis selected from:10

[0478] In an embodiment, the group

[0480] In an embodiment, the group

[0481] In an embodiment, the group

[0482] In an embodiment, the group

[0483] In an embodiment, the group

[0484] In an embodiment, the group

[0485] In an embodiment, the group

[0486] In an embodiment, the group

[0487] In an embodiment, the group

[0488] In an embodiment, R2a, R3a, R4a, R5a, R6a, R7a, and R8aare each independently selected from: H, deuterium, C1-3 alkyl, C1-3 haloalkyl, C3-6cycloalkyl, and 4- to 6-membered heterocycloalkyl.

[0489] In an embodiment, R2a, R3a, R4a, R5a, R6a, R7a, and R8aare each independently selected from: H, deuterium, C1-3alkyl, C1-3haloalkyl.

[0490] In an embodiment, R2a, R3a, R4a, R5a, R6a, R7a, and R8aare each independently H.

[0491] In an embodiment, R2a, R3a, R4a, R5a, R6a, R7a, and R8aare each independently deuterium.

[0492] In an embodiment, R2a, R3a, R4a, R5a, R6a, R7a, and R8aare each independently C1-3alkyl (e.g. methyl, ethyl or propyl).

[0493] In an embodiment, R2a, R3a, R4a, R5a, R6a, R7a, and R8aare each independently C1-3haloalkyl (e.g. CF3).

[0494] In an embodiment, R2ais selected from: H, deuterium, C1-3alkyl, C1-3haloalkyl, C3-4cycloalkyl, and 4- to 6-membered heterocycloalkyl. In an embodiment, R3ais selected from: H, deuterium, C1-3alkyl, C1-3haloalkyl, C3-4cycloalkyl, and 4- to 6-membered heterocycloalkyl. In an embodiment, R4ais selected from: H, deuterium, C1-3alkyl, C1-3haloalkyl, C3-4cycloalkyl, and 4- to 6-membered heterocycloalkyl. In an embodiment, R5ais selected from: H, deuterium, C1-3alkyl, C1-3haloalkyl, C3-4cycloalkyl, and 4- to 6-membered heterocycloalkyl. In an embodiment, R6ais selected from: H, deuterium, C1-3alkyl, C1-3haloalkyl, C3-4cycloalkyl, and 4- to 6-membered heterocycloalkyl. In an embodiment, R7ais selected from: H, deuterium, C1-3alkyl, C1-3haloalkyl, C3-4cycloalkyl, and 4- to 6-membered heterocycloalkyl. In an embodiment, R8ais selected from: H, deuterium, C1-3alkyl, C1-3haloalkyl, C3-4cycloalkyl, and 4- to 6-membered heterocycloalkyl.

[0495] In an embodiment, R2b, R3b, R4b, R5b, R6b, R7b, and R8bare each independently selected from: H, deuterium, C1-3alkyl, C1-3haloalkyl, C3-6cycloalkyl, 4- to 6-membered heterocycloalkyl, and -C(O)-Ci-3alkyl.

[0496] In an embodiment R2b, R3b, R4b, R5b, R6b, R7b, and R8bare each independently selected from: H, deuterium, C1-3alkyl, C1-3haloalkyl.

[0497] In an embodiment, R2b, R3b, R4b, R5b, R6b, R7b, and R8bare each independently H.

[0498] In an embodiment, R2b, R3b, R4b, R5b, R6b, R7b, and R8bare each independently deuterium.

[0499] In an embodiment, R2b, R3b, R4b, R5b, R6b, R7b, and R8bare each independently C1-3 alkyl (e.g. methyl, ethyl or propyl).

[0500] In an embodiment, R2b, R3b, R4b, R5b, R6b, R7b, and R8bare each independently C1-3 haloalkyl (e.g. CF3).

[0501] In an embodiment, R2bis selected from: H, deuterium, C1-3alkyl, C1-3haloalkyl, C3-4cycloalkyl, and 4- to 6-membered heterocycloalkyl. In an embodiment, R3bis selected from: H, deuterium, C1-3alkyl, C1-3haloalkyl, C3-4cycloalkyl, and 4- to 6-membered heterocycloalkyl. In an embodiment, R4bis selected from: H, deuterium, C1-3alkyl, C1-3haloalkyl, C3-4cycloalkyl, and 4- to 6-membered heterocycloalkyl. In an embodiment, R5bis selected from: H, deuterium, C1-3alkyl, C1-3haloalkyl, C3-4cycloalkyl, and 4- to 6-membered heterocycloalkyl. In an embodiment, R6bis selected from: H, deuterium, C1-3alkyl, C1-3haloalkyl, C3-4cycloalkyl, and 4- to 6-membered heterocycloalkyl. In an embodiment, R7bis selected from: H, deuterium, C1-3alkyl, C1-3haloalkyl, C3-4cycloalkyl, and 4- to 6-membered heterocycloalkyl. In an embodiment, R8bis selected from: H, deuterium, C1-3alkyl, C1-3haloalkyl, C3-4cycloalkyl, and 4- to 6-membered heterocycloalkyl.

[0502] In an embodiment, at each occurrence, R2aand R2b, together with the nitrogen atom to which they are attached, form a 4- to 6-membered heterocycloalkyl ring. In an embodiment, at each occurrence, R2aand R2b, together with the nitrogen atom to which they are attached, form a 4-membered hetero cyclo a Iky I ring. In an embodiment, at each occurrence, R2aand R2b, together with the nitrogen atom to which they are attached, form a 5-membered heterocycloalkyl ring. In an embodiment, at each occurrence, R2aand R2b, together with the nitrogen atom to which they are attached, form a 6-membered heterocycloalkyl ring.

[0503] In an embodiment, at each occurrence, R3aand R3b, together with the nitrogen atom to which they are attached, form a 4- to 6-membered heterocycloalkyl ring. In an embodiment, at each occurrence, R3aand R3b, together with the nitrogen atom to which they are attached, form a 4-membered hetero cyclo a Iky I ring. In an embodiment, at each occurrence, R3aand R3b, together with the nitrogen atom to which they are attached, form a 5-membered heterocycloalkyl ring. In an embodiment, at each occurrence, R3aand R3b, together with the nitrogen atom to which they are attached, form a 6-membered heterocycloalkyl ring.

[0504] In an embodiment, at each occurrence, R4aand R4b, together with the nitrogen atom to which they are attached, form a 4- to 6-membered heterocycloalkyl ring. In an embodiment,at each occurrence, R4aand R4b, together with the nitrogen atom to which they are attached, form a 4-membered hetero cyclo a Iky I ring. In an embodiment, at each occurrence, R4aand R4b, together with the nitrogen atom to which they are attached, form a 5-membered heterocycloalkyl ring. In an embodiment, at each occurrence, R4aand R4b, together with the nitrogen atom to which they are attached, form a 6-membered heterocycloalkyl ring.

[0505] In an embodiment, at each occurrence, R5aand R5b, together with the nitrogen atom to which they are attached, form a 4- to 6-membered heterocycloalkyl ring. In an embodiment, at each occurrence, R5aand R5b, together with the nitrogen atom to which they are attached, form a 4-membered hetero cyclo a Iky I ring. In an embodiment, at each occurrence, R5aand R5b, together with the nitrogen atom to which they are attached, form a 5-membered heterocycloalkyl ring. In an embodiment, at each occurrence, R5aand R5b, together with the nitrogen atom to which they are attached, form a 6-membered heterocycloalkyl ring.

[0506] In an embodiment, at each occurrence, R6aand R6b, together with the nitrogen atom to which they are attached, form a 4- to 6-membered heterocycloalkyl ring. In an embodiment, at each occurrence, R6aand R6b, together with the nitrogen atom to which they are attached, form a 4-membered hetero cyclo a Iky I ring. In an embodiment, at each occurrence, R6aand R6b, together with the nitrogen atom to which they are attached, form a 5-membered heterocycloalkyl ring. In an embodiment, at each occurrence, R6aand R6b, together with the nitrogen atom to which they are attached, form a 6-membered heterocycloalkyl ring.

[0507] In an embodiment, at each occurrence, R7aand R7b, together with the nitrogen atom to which they are attached, form a 4- to 6-membered heterocycloalkyl ring. In an embodiment, at each occurrence, R7aand R7b, together with the nitrogen atom to which they are attached, form a 4-membered hetero cyclo a Iky I ring. In an embodiment, at each occurrence, R7aand R7b, together with the nitrogen atom to which they are attached, may form a 5-membered heterocycloalkyl ring. In an embodiment, at each occurrence, R7aand R7b, together with the nitrogen atom to which they are attached, form a 6-membered heterocycloalkyl ring.

[0508] In an embodiment, at each occurrence, R8aand R8b, together with the nitrogen atom to which they are attached, form a 4- to 6-membered heterocycloalkyl ring. In an embodiment, at each occurrence, R8aand R8b, together with the nitrogen atom to which they are attached, form a 4-membered heterocycloalkyl ring. In an embodiment, at each occurrence, R8aand R8b, together with the nitrogen atom to which they are attached, form a 5-membered heterocycloalkyl ring. In an embodiment, at each occurrence, R8aand R8b, together with the nitrogen atom to which they are attached, form a 6-membered heterocycloalkyl ring.

[0509] In an embodiment, each x is independently 0. In an embodiment, each x is independently 1. In an embodiment, each x is independently 2.

[0510] In an embodiment, any of the aforementioned alkyl, alkylene, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, phenyl, or heteroaryl groups is optionally substituted, where chemically possible, by one or more substituents independently at each occurrence selected from the group consisting of: C1-3alkyl, C1-3alkyl-ORa, deuterium, oxo, halo, nitro, cyano, NRaRb, ORa, SRa, CO2Ra, C(O)Ra, CONRaRa, S(O)Ra, and S(O)2Ra.

[0511] In an embodiment, Rais independently at each occurrence H. In an embodiment, Rais independently at each occurrence C1-4alkyl (e.g. methyl, ethyl, propyl or butyl).

[0512] In an embodiment, Rais independently at each occurrence C1-3alkyl (e.g. methyl, ethyl or propyl).

[0513] In an embodiment, Rbis independently at each occurrence H. In an embodiment, Rbis independently at each occurrence C1-4alkyl. In an embodiment the C1-4alkyl is methyl, ethyl, propyl or butyl. In an embodiment, Rbis independently at each occurrence C(O)-C1-4alkyl. In an embodiment, Rbis independently at each occurrence S(O)2-C1-4alkyl.

[0514] In an embodiment, Rbis independently at each occurrence C1-3alkyl. In an embodiment the C1-3alkyl is methyl, ethyl or propyl. In an embodiment, Rbis independently at each occurrence C(O)-C1-3alkyl. In an embodiment, Rbis independently at each occurrence S(O)2-C1-3alkyl.

[0515] The compound according to formula (I) per se is not a compound selected from:

[0516] In an embodiment, the compound of the invention is a compound selected from Compound List 1, or a pharmaceutically salt and / or solvate thereof:Compound List 1

[0517] In another embodiment there is provided a compound selected from any one of the Examples herein, or a pharmaceutically acceptable salt and / or solvate thereof.

[0518] Particular compounds of the invention are those that have an EC50≤1000 nM, preferably ≤500 nM, still more preferably ≤100 nM, when measured in the TrkB dimerization protein complementation assay (PCA) described in the Examples.

[0519] Particular compounds of the invention are those that have an EC50of ≥10 μM, when measured in the 5-HT2aR p-arrestin recruitment assay described in the Examples.

[0520] Particular compounds of the invention are those that are able to induce dendritogenesis, when measured in the dendritogenesis assay described in the Examples.

[0521] Particular compounds of the invention are those that are able to induce dendritogenesis, when measured in the dendritogenesis assay described in the Examples, whilst also having an EC50≥10 μM, when measured in the 5-HT2aR β-arrestin recruitment assay described in the Examples. Such compounds exhibit the induction of neuronal plasticity without causing hallucinations mediated by the serotonin 2A (5-HT2A) receptor.

[0522] Suitably the compounds of the invention exhibit a favourable pharmacokinetic and / or pharmacodynamic profile, for example, one or more of favourable oral bioavailability, metabolic stability, plasma half-life.

[0523] Compounds of the invention may exhibit one or more beneficial properties. In embodiments, compounds of the invention demonstrate one or more beneficial Absorption, Distribution, Metabolism, and Excretion (ADME) property.PHARMACEUTICAL COMPOSITIONS

[0524] In accordance with another aspect, the present invention provides a pharmaceutical composition comprising a compound of the invention, except that the compounds of List A are not excluded, or a pharmaceutically acceptable salt and / or solvate thereof, and a pharmaceutically acceptable excipient.

[0525] In an embodiment, there is provided a pharmaceutical composition comprising a compound of the invention, or a pharmaceutically acceptable salt and / or solvate thereof, and a pharmaceutically acceptable excipient.

[0526] Conventional procedures for the selection and preparation of suitable pharmaceutical compositions are described in, for example, " Pharmaceuticals - The Science of Dosage Form Designs", M. E. Aulton, Churchill Livingstone, 1988.

[0527] The compositions of the invention may be in a form suitable for oral use (for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), for sublingual use, for topical use (forexample as creams, ointments, gels, or aqueous or oily solutions or suspensions), for administration by inhalation (for example as a finely divided powder or a liquid aerosol), for administration by insufflation (for example as a finely divided powder) or for parenteral administration (for example as a sterile aqueous or oily solution for intravenous, subcutaneous, intramuscular or intraperitoneal dosing or as a suppository for rectal dosing).

[0528] The compositions of the invention may be obtained by conventional procedures using conventional pharmaceutical excipients, well known in the art. Thus, compositions intended for oral use may contain, for example, one or more colouring, sweetening, flavouring and / or preservative agents.

[0529] An effective amount of a compound of the present invention for use in therapy of a condition is an amount sufficient to symptomatically relieve in a warm-blooded animal, particularly a human the symptoms of the condition orto slowthe progression of the condition.

[0530] The amount of active ingredient that is combined with one or more excipients to produce a single dosage form will necessarily vary depending upon the host treated and the particular route of administration. For example, a formulation intended for oral administration to humans will generally contain, for example, from 0.1 mg to 0.5 g of active agent (more suitably from 0.5 to 100 mg, for example from 1 to 30 mg) compounded with an appropriate and convenient amount of excipients which may vary from about 5 to about 98 percent by weight of the total composition.

[0531] The size of the dose for therapeutic or prophylactic purposes of a compound of the invention will naturally vary according to the nature and severity of the conditions, the age and sexof the animal or patient and the route of administration, according to well- known principles of medicine.

[0532] In usinga compound of the invention for therapeutic or prophylactic purposes it will generally be administered so that a daily dose in the range, for example, a daily dose selected from 0.1 mg / kgto 100 mg / kg, 1 mg / kgto 75mg / kg, 1 mg / kgto 50 mg / kg, 1 mg / kgto 20 mg / kgor 5 mg / kgto 10 mg / kg body weight is received, given if required in divided doses. In general, lower doses will be administered when a parenteral route is employed. Thus, for example, for intravenous, subcutaneous, intramuscular or intraperitoneal administration, a dose in the range, for example, 0.1 mg / kg to 30 mg / kg body weight may be suitable. Similarly, for administration by inhalation, a dose in the range, for example, 0.05 mg / kg to 25 mg / kg body weight may be suitable. When administered orally a total daily dose of a compound of the invention may be, for example, selected from: 1 mg to 1000 mg, 5 mg to 1000 mg, 10 mg to 750mg or 25 mg to 500 mg. Typically, unit dosage forms will contain about 0.5 mg to 0.5 g of a compound of the invention. In a particular embodiment the compound of the invention is administered parenterally, for example by intravenous administration. In another particular embodiment the compound of the invention is administered orally.THERAPEUTIC USES AND APPLICATIONS

[0533] In this section describing therapeutic uses, applications and methods of treatment reference to “a compound of the invention” includes compounds according to formula (I), except that the compounds of List A are not excluded, or a pharmaceutically acceptable salt and / or solvate thereof. It may be that reference to “a compound of the invention” includes compounds according to formula (I), or a pharmaceutically acceptable salt and / or solvate thereof, i.e., where the compounds of List A are excluded.

[0534] In accordance with anotheraspect, the present invention provides a compound of the invention, or a pharmaceutically acceptable salt and / or solvate thereof, for use as a medicament.

[0535] A further aspect of the invention provides a compound of the invention, or a pharmaceutically acceptable salt and / or solvate thereof, for use in the prevention ortreatment of a disease or medical disorder associated with dysregulation of tropomyosin receptor kinase B (TrkB or NTRK2).

[0536] Also provided is a method of preventing or treating a disease or medical disorder associated with dysregulation of tropomyosin receptor kinase B (TrkB or NTRK2) in a subject, the method comprising administering to the subject an effective amount of a compound of the invention, or a pharmaceutically acceptable salt and / or solvate thereof.

[0537] In the following sections of the application reference is made to a compound of the invention, ora pharmaceutically acceptable salt and / or solvate thereof for use in the treatment of certain diseases or medical disorders. It is to be understood that any reference herein to a compound fora particular use is also intended to be a reference to (i) the use of the compound of the invention, or pharmaceutically acceptable salt and / or solvate thereof, in the manufacture of a medicament for the treatment of that disease or disorder; and (ii) a method for the treatment of the disease or disorder in a subject, the method comprising administering to the subject a therapeutically effective amount of the compound of the invention, or pharmaceutically acceptable salt and / or solvate thereof.

[0538] In certain embodiments the disease or medical disorder associated with dysregulation of tropomyosin receptor kinase B (TrkB or NTRK2) is selected from: autism spectrum disorder (ASD), intellectual disability, Rett Syndrome, Down’s Syndrome (DS), Major Depressive Disorder (MDD), Bipolar Disorder (BD), Post-Traumatic Stress Disorder (PTSD), Generalized Anxiety Disorder (GAD), NeuroAIDS (HIV-associated neurocognitive disorder), Fetal Alcohol Spectrum Disorder (FASD), Hypoxia-Ischemic Encephalopathy (HIE), and Traumatic Brain Injury (TBI).

[0539] In certain embodiments there is provided a compound of the invention, or a pharmaceutically acceptable salt and / or solvate thereof, for use in the treatment of a disease or medicaldisorderselected from: autism spectrum disorder (ASD), intellectual disability, Rett Syndrome, Down’s Syndrome (DS), Major Depressive Disorder (MDD), Bipolar Disorder (BD), Post-Traumatic Stress Disorder (PTSD), Generalized Anxiety Disorder (GAD), NeuroAIDS (HIV-associated neurocognitive disorder), Fetal Alcohol Spectrum Disorder (FASD), Hypoxia-Ischemic Encephalopathy (HIE), and Traumatic Brain Injury (TBI).

[0540] In certain embodiments there is provided a compound of the invention, or a pharmaceutically acceptable salt and / or solvate thereof, for use in the treatment of a disease or medical disorder selected from: Major Depressive Disorder (MDD), Post-Traumatic Stress Disorder (PTSD), Generalized Anxiety Disorder (GAD), Bipolar Disorder (BD) and Traumatic Brain Injury (TBI).

[0541] In certain embodiments there is provided a compound of the invention, or a pharmaceutically acceptable salt and / or solvate thereof, for use in the treatment of a disease or medical disorder selected from: Major Depressive Disorder (MDD), Post-Traumatic Stress Disorder (PTSD), Generalized Anxiety Disorder (GAD), and Traumatic Brain Injury (TBI).Combination Therapies

[0542] The compounds of the invention may be used alone to provide a therapeutic effect. The compounds of the invention may also be used in combination with one or more additional therapeutic agents.

[0543] Such combination treatment maybe achieved byway of the simultaneous, sequential or separate dosing of the individual components of the treatment. Such combination products employ the compounds of this invention within a therapeutically effective dosage range described hereinbefore and the other pharmaceutically-active agent within its approved dosage range.

[0544] Herein, where the term “combination” is used it is to be understood that this refers to simultaneous, separate or sequential administration. In one aspect of the invention “combination” refers to simultaneous administration. In another aspect of the invention “combination” refers to separate administration. In a further aspect of the invention “combination” refers to sequential administration. Where the administration is sequential or separate, the delay in administering the second component should not be such as to lose the beneficial effect of the combination.

[0545] In some embodiments in which a combination treatment is used, the amount of the compound of the invention and the amount of the other pharmaceutically active agent(s) are, when combined, therapeutically effective to treat a targeted disorder in the patient. In this context, the combined amounts are “therapeutically effective amount” if they are, when combined, sufficient to reduce or completely alleviate symptoms or other detrimental effects of the disorder; cure the disorder; reverse, completely stop, or slow the progress of the disorder; or reduce the risk of the disorder getting worse. Typically, such amounts may be determined by one skilled in the art by, for example, starting with the dosage range described in this specification for the compound of the invention and an approved or otherwise published dosage range(s) of the other pharmaceutically active compound(s).Biological Assays5-HT2aR β-arrestin recruitment assay

[0546] Compounds of the invention were tested for agonism of the 5-HT2aR using the PathHunter® 5-HT2aR β-arrestin recruitment assay. PathHunter® U2OS HTR2A β-arrestin cells (Cat # 93-0401 C3, DiscoverX, France) are cultured as per DiscoverXs’s protocol, with cells seeded onto white 384-well plates at 5000 cells per well-1, and incubated overnight at 37°C, 5% CO2 in a humidified atmosphere.

[0547] On the day of assay compounds are added to the cells using a Multidrop™ Pico 8 to generate 10-point concentration response curves ranging between 10 pM and 5 pM, with a final [DMSO] concentration of 1% v / v. Cells are then incubated with compound for 2 hours at 37°C, 5% CO2 in a humidified atmosphere, followed by addition of the PathHunter® detection reagents (Cat #93-0001, DiscoverX, France) as per the suppliers protocol. Following a 1 hour incubation in the dark, at room temperature, luminescence is determined via use of a PHERastar FSX. All data is normalised to the activity observed for 10 pM LSD.Dendritogenesis assay

[0548] Dendritogenesis was measured in response to treatment with compounds of the invention in vitro. 384-well PhenoVue Plates (6057302, Rewity) were coated with poly-L-lysine hydrobromide (PLL; 10 pg / mL; P4707, SigmaAldrich) for 18 hours at 37°C. PLL-was aspirated followed by washing three times with Dulbecco’s phosphate-buffered saline (DPBS; D8537, SigmaAldrich) PLL-coated plates were left to dry in a laminar flow hood prior to use.

[0549] Cryovials of day-18 embryonic Fisher 334 rat cortical neurons (A1084001, ThermoFisher) were rapidly thawed in a 37°C water bath transferred into falcon tubes and diluted with pre-warmed Neurobasal™ Plus Medium (A3582901, ThermoFisher) supplemented with B-27™ plus (2% v / v; A3582801, ThermoFisher) and GlutaMAX™ (0.5 mM; 35050061, ThermoFisher) henceforth termed “neurobasal complete”). Addition of neurobasal complete to suspensions was performed in a dropwise manner. Neurons were seeded into PLL-coated plates at a density of 2000 cells per well-1, and incubated overnight (37°C, 5% CO2, humidified atmosphere). 24 hours post seeding a 50% media change was performed, followed by incubation (37°C, 5% CO2, humidified atmosphere) for 4 days.

[0550] Prior to compound addition neuronal cultures received a 50% media change with fresh, pre-warmed neurobasal complete. Compounds were dispensed onto neuronal cultures using the Multidrop™ Pico 8 digital dispenser (ThermoFisher) to final concentrations of 1, 0.1 or 0.01 pM, with a final [DMSO]concentration of 0.1 % v / v. 100 nM LSD (L001, SigmaAldrich) and 50 ng / ml BDNF (2837, Biotechne) were utilised as positive controls. For each tested condition 10-12 wells were treated. Following treatment, wells were immediately imaged (TO) in phase at 20X magnification using the Incucyte® S3 under incubating conditions (37°C, 5% CO2, humidified atmosphere), then again after 72 hours (T72). Neuronal neurite length and branch points were detected using the Incucyte® S3’s built-in neurotrack analysis software. To normalise dendritogenesis across wells, TO values from each analysis were subtracted from their respective T72 values. To account for plate-to-plate variation in culture responsiveness to LSD, analyses values were normalised to the observed activity of 100 nM LSD.TrkB dimerization protein complementation assay (PCA)

[0551] PCA was used as a protein- protein interaction assay in live N2a cells to evaluate TrkB dimerization in response to treatment with test compounds (1 nM - 1 pM). Split humanized Gaussia princeps luciferase (hGLuc) was cloned on the C-terminus of the reporter proteins TrkB. If the reporter proteins that carry complementary halves of the luciferase interact, the enzyme can refold in its functional conformation and, upon addition of its substrate, produce luminescence proportionally to the amount of reporter proteins interacting at a given time. N2a cells were seeded in 96-well plates with opaque walls and transparent bottom (PerkinElmer,ViewPlate96). Cells were transfected with Lipofectamine 2000 (Invitrogen, Ref: 11668019) according to manufacturer instructions 24 h post-plating with the PCA pair plasmids: phGLuc(1C)-TrkB(WT) and phGLuc(2C)-TrkB(WT) for the dimerization experiments. 48 h post transfection, cells were treated (40 min, 37 °C) in phenol-red free Dulbecco’s Modified Eagle Medium (PRF-free DMEM) without serum. PCA signal was detected with the substrate for the luciferase, coelenterazine (Coelenterazine Native: NanoLight Technology, Cat: #303-5; NanoFuel-Solvent: NanoLight Techonology, Cat: #399-10), which was injected into each well directly in the plate reader at a final concentration of 17.7 pM.Spinogenesis assay

[0552] Spinogenesis experiments were performed using cultures of hippocampal neurons from E18 rat embryos, derived from pregnant Wistar rats (strain HNL1 RccHan: WIST, Inotiv, Envigo). 50,000 cells per well were plated in 24 well plates containing 1.5H glass coverslips and grown for 21 days. Neuronal cultures were treated for 24 hours with DMSO (vehicle) ortest compounds (100 nM) with a final [DMSO] concentration of 0.1% v / v. After 24 hours, the coverslips were fixed with 4% PFAfor 20 minutes at room temperature, then washed with PBS. Afterwards they were incubated with blocking buffer (0.1% Triton X-100, 0.05% Tween-20, 10% normal donkey serum, 1% BSA and 0.1% gelatin in PBS) for 1 hour at room temperature and subsequently incubated overnightwith rabbit anti-MAP2 (Invitrogen, Ab32454; 1: 1000) primary antibody at 4 °C. Another series of PBS washes was performed, coverslips were incubated with donkey anti-rabbit antibody (Invitrogen, AF488; 1:1000) for 1 hour at room temperature. Another round of PBS washes was followed by incubation with Alexa Fluor 647-conjugated phalloidin (Invitrogen, A22287; 1:40) overnight at 4 °C. Then, coverslips were briefly washed in phosphate buffer (PB) and mounted on slides with Dako mounting medium (Agilent Technologies). Images were acquired with a Zeiss LSM 980 confocal with a PlanApochromat 63* / 1.4 NA objective. Six single plane pictures were taken of randomly selected neurons per coverslip. Finally, image analysis was conducted using ImageJ by experimenters blinded to treatment, with spine quantification performed on 15-pm-long dendrite segments.Synthesis

[0553] In the description of the synthetic methods described below and in the referenced synthetic methods that are used to prepare the staring materials, it is to be understood that all proposed reaction conditions, including choice of solvent, reaction atmosphere, reaction temperature, duration of the experiment and workup procedures, can be selected by a person skilled in the art.

[0554] It is understood by one skilled in the art of organic synthesis that the functionality presenton various portions of the molecule must be compatible with the reagents and reaction conditions utilised.

[0555] Necessary starting materials may be obtained by standard procedures of organic chemistry. The preparation of such starting materials is described in conjunction with the following representative process variants and within the accompanying Examples. Alternatively, necessary starting materials are obtainable by analogous procedures to those illustrated which are within the ordinary skill of an organic chemist.

[0556] It will be appreciated that during the synthesis of the compounds of the invention in the processes defined below, or during the synthesis of certain starting materials, it may be desirable to protect certain substituent groups to prevent their undesired reaction. The skilled chemist will appreciate when such protection is required, and howsuch protectinggroups may be put in place, and later removed.

[0557] For examples of protectinggroups see one of the many general texts on the subject, for example, ‘Protective Groups in Organic Synthesis’ by Theodora Green (publisher: John Wiley & Sons). Protecting groups may be removed by any convenient method described in the literature or known to the skilled chemist as appropriate for the removal of the protecting group in question, such methods being chosen so as to effect removal of the protecting group with the minimum disturbance of groups elsewhere in the molecule.

[0558] 1H-NMR: Spectra are obtained on a Jeol ECS 400 MHz spectrometer. Spectra are measured at 294K (unless otherwise stated) and chemical shifts (5-values) are reported in parts per million (ppm), referenced to either tetramethylsilane (0.0 ppm), DMSO-d6(2.50 ppm), CDCl3(7.26 ppm), acetonitrile-d3(1.94 ppm), CD2Cl2(5.32 ppm). Coupling constants (J) are reported in Hertz (Hz), spectra splitting pattern are designated as singlet (s), doublet (d), triplet (t), quadruplet (q), multiplet or more overlapping signals (m), broad signal (br); solvent is given in parentheses.1H-NMR integrations have been quantified when visible. When expected integrals are not observed, some proton signals are (partially) obscured by residual NMR solvent and / or water peak, and may be denoted as such, or assumed.

[0559] EXAMPLES

[0560] Abbreviations

[0561] The following abbreviations are used in the Examples and other parts of the description.Ac: acetateBicarb: bicarbonateBSA: Bovine Serum AlbuminC: (degrees) CelsiusCAN: Ceric ammonium nitrateDa: DaltonDBU: 1,8-Diazabicyclo[5.4.0]undec-7-eneDCE: DichloroethaneDCM: DichloromethaneDMAP: 4-(Dimethylamino)pyridineDMF: N, N-DimethylformamideDMSO: Dimethylsulfoxidedppf: 1,1 ’-bis(diphenylphosphino)ferroceneESi: Electrospray ionizationEq: equivalentsEtOAc: Ethyl acetateGM: general methodh: hour(s)HPLC: high-performance liquid chromatographyIPA: Isopropyl alcoholmin: minute(s)LCMS: liquid chromatography – mass spectrometryM: molarMeCN: AcetonitrileMgSO4: Magnesium sulfateMS: mass spectroscopyMs: methanesulfonylN2: nitrogenNaHCO3: Sodium bicarbonateNa2SO4: Sodium sulfateNEt3: TriethylamineNMR: Nuclear Magnetic ResonancePBS: Phosphate Buffered SalinePDA: photo diode arrayPFA: paraformaldehydePrep: preparativequant.: quantitative (conversion)Rt: retention timeRT: room temperatureSat.: saturatedSCX: strong cation exchangeT: temperatureTBAF: Tetra-n-butylammonium fluorideTFA: Trifluoroacetic acidTHF: Tetra hydrofuranTMS: trimethylsilylTs: 4-toluenesulfonylTsCl: Tosyl chlorideUPLC: Ultra-performance liquid chromatography

[0562] Analytical methods

[0563] Analysis of products and intermediates has been carried out using reversed phase analytical HPLC-MS using the parameters set out below.

[0564] UPLC analytical methods were run on Waters Acquity UPLC with Waters QDA mass spectrometer

[0565] UPLC_PH9_MECN_QC_V1: Waters CSH C181.7 pm, 100 x 2.1 mm; A = pH 9 Aq 10 mM Ammonium Bicarb water (adjusted with ammonia); B = MeCN; 50 °C; %B: 0.05 min 5 %, 5 min 95 %, 6.6 min 5 %, 0.35 mL / min. With PDA210-400nm and MS detection 120-1000 Da, ESi + / - (Waters QDA LCMS)

[0566] UPLC_PH7.4_MECN_QC_V1: Waters CSH C181.7 pm, 100 x 2.1 mm; A = pH 7.4 Aq 10 mM Ammonium Bicarb water (adjusted with carbon dioxide); B = MeCN; 50 °C; %B: 0.05 min 5 %, 5 min 95 %, 6.6 min 5 %, 0.35 mL / min. With PDA210-400nm and MS detection 120-1000 Da, ESi + / - (Waters QDA LCMS)

[0567] UPLC_PH2_MECN_QC_V1: Waters CSH C181.7 pm, 100 x 2.1 mm; A = water + 0.1 % formic acid; B = MeCN + 0.1 % formic acid; 50 °C; %B: 0.05 min 5 %, 5.00 min 95 %, 6.60 min 5 % 0.35 mL / min. With PDA 210-400nm and MS detection 120-1000 Da, ESi + / - (Waters QDA LCMS)

[0568] UPLC_pH9_MECN_2.6MIN_V1: Waters BEH C181.7 pm, 50 x 2.1 mm; A = pH 9 Aq 10 mM Ammonium Bicarb water (adjusted with ammonia); B = MeCN; 50 °C; %B: 0.05 min 5 %, 1.60 min 95 %, 2.25 min 5 %, 0.6 mL / min. With PDA210-400nm and MS detection 120-1000 Da, ESi + / - (Waters QDA LCMS)

[0569] UPLC_PH2_MECN_2.6MIN_V1: Waters BEH C181.7 pm, 50 x 2.1 mm; A = water + 0.1 % formic acid; B = MeCN + 0.1 % formic acid; 50 °C; %B: 0.05 min 5 %, 1.60 min 95 %, 2.25 min 5 %, 0.6 mL / min. With PDA210-400nm and MS detection 120-1000 Da, ESi + / - (Waters QDA LCMS)

[0570] General Methods

[0571] General Method 1: O-Alkylation

[0572] To a stirred mixture of the phenol (1.0 eq.) and potassium carbonate (1.0 - 3.0 eq.) in A / , A / -dimethylformamide under a nitrogen atmosphere was added a solution of the alkylating reagent (such as tosylate, mesylate, alkyl halide; 0.8 - 3.0 eq.) in DMF, and the reaction mixture heated at 60-100 °C for1-16h.

[0573] The reaction mixture was allowed to cool, water added, and the aqueous layer extracted with EtOAc (x2). The combined organic extracts were optionally washed with water,sodium bicarbonate (aq. sat.), brine (aq. Sat.), dried over Na2SO4or MgSO4, passed through a phase separator and concentrated under reduced pressure. The crude material was purified either by flash column chromatography or preparative HPLC or used in the subsequent reaction without further purification.

[0574] General Method 2: Miyaura borylation

[0575] A mixture of the aryl halide (1.0 eq), palladium catalyst such as 1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex withdichloromethane (0.05-0.25 eq), base such as potassium acetate (1 -3 eq), and bis(pinacolato)diboron (1.5-2 eq) were dissolved in 1,4-dioxane under a nitrogen atmosphere, degassed, and heated to 80-100°C for 1 -16h.

[0576] The reaction mixture was allowed to cool, filtered through celite and the filtrate concentrated under reduced pressure. The residue was dissolved in EtOAc or DCM. Water was added and the product extracted with EtOAc or DCM. The organic phase was optionally washed with brine, dried over Na2SO4or MgSO4and concentrated under reduced pressure.

[0577] The crude material was either purified by flash column chromatography or preparative HPLC, or used in the subsequent reaction without further purification

[0578] General Method 3: Suzuki coupling

[0579] To a solution of the aryl boronate (1 eq.) in 1,4-dioxane was added aryl halide (1.0 -1.1 eq.), palladium catalyst such as 1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.03 - 0.2 eq.) or [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex withdichloromethane (0.03 - 0.2 eq.), base such as lithium hydroxide or potassium carbonate (1.0 - 3.0 eq.), and water under a nitrogen atmosphere, degassed, and heated at 80-90 °C for 1 -16h.

[0580] The reaction mixture was allowed to cool, diluted with water and extracted with EtOAc or DCM. The organic phase was optionally washed with brine (aq. sat.), dried over Na2SO4or MgSO4, or passed through a phase separator and concentrated under reduced pressure. The crude material was either purified by precipitation, flash column chromatography or preparative HPLC or used in the subsequent reaction without further purification.

[0581] General Method 4: Acid catalysed-deprotection

[0582] The protected amine, amide or carbamate was stirred in a solution ofTFAin DCM (0.1 M - neat) at 25-150 °C for 1 - 16h. The reaction mixture was concentrated under reducedpressure to yield the crude material, which was optionally resuspended in DCM, washed with sodium bicarbonate (aq. sat.), brine (aq. sat.) and the organic layer concentrated under reduced pressure or purified by catch-release cartridge (Biotage SCX-2) washing with methanol and eluting with 0.7 - 7 M ammonia-methanol and concentrated under reduced pressure. The crude product was either used directly in the subsequent reaction or purified by flash column chromatography or preparative HPLC.

[0583] General Method 5: Tosylation of Alcohols

[0584] To a stirred solution of the alcohol (1 eq., 0.5 M in DCM) was added pyridine (20 eq.) followed by tosyl chloride (1 -2 eq.). The reaction mixture was stirred at room temperature for 16-72h, diluted with EtOAc and washed successively with water, hydrochloric acid (aq., 1 M), NaHCO3(aq. sat.) and brine (aq. sat.). The organic extract was then dried (Na2SO4), filtered and concentrated under reduced pressure. The crude product was then either used directly in the next step without further purification or purified by flash column chromatography.

[0585] General Method 6: Reduction of methyl esters to alcohols

[0586] To a stirred solution of the methyl ester (1 eq., 0.3 M in TH F) at 0 °C was added dropwise, over 5-10 min. a 2 M solution of lithium borohydride in THF (2.4 eq.). Upon completion of the addition, the reaction mixture was allowed to warm to room temperature and stirred at room temperature for 1 - 16h.

[0587] The reaction mixture was quenched with ammonium chloride (aq., half sat.) and extracted with EtOAc. The combined organic extracts were washed with brine (aq. sat.), dried (Na2SO4), filtered and concentrated in vacuo. The crude product was then either used directly in the next step without further purification or purified by flash column chromatography.

[0588] General Method 7: N-Alkylation of lactams, carbamates, ureas, anilines, or pyrazoles

[0589] To a solution of the NH containing intermediate (0.1 - 0.5 M in THF or DMF) at -10 - 0 °C was added sodium hydride (60 % dispersion in oil, 3.0 -5.0 eq.) and the reaction mixture stirred at -10 - 0 °C for 10 - 30 min. Iodomethane (3.0 -5.0 eq.) was added and the reaction mixture stirred at -10- 25 °C for 1 - 16h.

[0590] The reaction mixture was cooled to -10 - 0 °C and quenched with ammonium chloride (aq., half sat.) and extracted with EtOAc. The combined organic extracts were washed with brine (aq. sat.) and then either dried (Na2SO4) and filtered or passed through a phase separator and concentrated in vacuo. The crude product was then either used directlyin the next step without further purification or purified by flash column chromatography or preparative HPLC.

[0591] General Method 8: Ullman C-N couplings of lodoarenes to benzimidazoles

[0592] The NH benzimidazole derivative (1.1 - 2.0 eq.), iodoarene coupling partner (1 eq.), Cui (1 eq.), picolinic acid (0.6 eq.) and potassium phosphate tribasic (2.0 eq.) were suspended in 1,4-dioxane or DMSO and sparged with N2at RT. The mixture was then stirred at 80-130 °C for 2- 18 h.

[0593] The reaction mixture was cooled to room temperature, diluted with EtOAc and filtered through celite. To the filtrate was added sodium hydroxide solution (aq., 1 M) and the layers were separated. The aqueous phase was washed with EtOAc (3x) and the organic fractions were combined, washed with brine (aq. sat.) and concentrated under reduced pressure. The crude product was then purified by flash column chromatography and then either used in the next step or further purified by preparative HPLC.General Scheme 1: Alkyation, Miyaura & SuzukiStep 5

[0594] Example 1: 1-Methyl-4-((3-(1-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)phenoxy)methyl)pyrrolidin-2-one

[0595] Synthesis of (1 -methyl-5-oxopyrrolidin-3-yl)methyl 4-methylbenzenesulfonate

[0596] 4-(Hydroxymethyl)-1 -methylpyrrolidin-2-one (CAS 59887-20-6, 1.00 g, 7.74 mmol) was dissolved in DCM (15.5 mL) and pyridine (7.5 mL) and the solution was stirred for30 min. p-Toluene sulfonyl chloride (1.48 g, 7.74 mmol) was added portion-wise, and the reaction mixture stirred for 16h. at room temperature. The reaction mixture was diluted with EtOAc (40 mL) and washed successively with water (100 mL), hydrochloric acid (aq., 1 M, 2 x 100 mL), sodium bicarbonate (aq. sat., 100 mL) and brine (aq. sat.,100 mL). The solution was then dried, filtered, and concentrated to give (1 -methyl-5-oxo-pyrrolidin-3-yl)methyl 4-methylbenzenesulfonate (1.23 g, 56 %) as an off-white waxy solid.

[0597] UPLC_PH2_MECN_2.6MIN_V1; Rt 1.51 min., m / z 284.1 [M+H]++

[0598] UPLC_PH9_MECN_2.6MIN_V1; Rt 1.50 min., m / z 284.1 [M+H]++

[0599] 1H-NMR (400 MHz, Chloroform-d) 57.80-7.77 (m, 2H), 7.38-7.36 (m, 2H), 3.98 (dq, J = 19.9, 5.6 Hz, 2H), 3.47 (dd, J = 10.1, 8.2 Hz, 1H), 3.16 (dd, J= 10.1, 5.0 Hz, 1H), 2.80 (s, 3H), 2.77-2.67 (m, 1 H), 2.49 (dd, J = 15.8, 8.0 Hz, 1 H), 2.46 (s, 3H), 2.06 (dd, J = 17.2, 6.2 Hz, 1 H).

[0600] Synthesis of 4-((3-bromophenoxy)methyl)-1-methyl-pyrrolidin-2-one

[0601] (1-Methyl-5-oxo-pyrrolidin-3-yl)methyl 4-methylbenzenesulfonate (CAS 94221-99-5, 4.00 g, 12.0 mmol), potassium carbonate (4.98 g, 36.0 mmol) and 3-bromophenol (1.30 mL, 12.0 mmol) were dissolved in DMF (20 mL) and stirred at 100 °C for 3 hours. The reaction mixture was cooled, diluted with water and ethyl acetate and the layers separated. The aqueous layer was extracted with ethyl acetate and the combined organic layers washed withwater, sodium carbonate (aq. sat.), and brine (aq., sat.). The solution was filtered, concentrated, and purified by flash column chromatography, elutin with 0 - 5 % methanol in ethyl acetate to give 4-((3-bromophenoxy)methyl)-1-methylpyrrolidin-2-one (2.95 g,10.4 mmol, 86 %) as a pink / orange oil.

[0602] UPLC_PH2_MECN_2.6MIN_V1; Rt 1.66 min., m / z 284.1 and 286.1 [M+H]+

[0603] 1H-NMR (400 MHz, Chloroform-d) 57.16-7.09 (m, 2H), 7.07-7.04 (m, 1 H), 6.83-6.77 (m, 1 H), 3.97-3.86 (m, 2H), 3.62-3.54 (m, 1 H), 3.33-3.28 (m, 1 H), 2.86 (s, 3H), 2.85-2.81 (m, 1H), 2.61 (dd,7= 17.2, 9.4 Hz, 1H), 2.30 (dd,7= 16.9, 6.0 Hz, 1H).

[0604] 1 -Methyl-4-((3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)methyl)pyrrolidin-2-one

[0605] 4-((3-Bromophenoxy)methyl)-1 -methylpyrrolidin-2-one (1.00 g, 3.52 mmol), potassium acetate (1.04 g, 10.6 mmol) and bis(pinacolato)diboron (1.34 g, 5.28 mmol) were dissolved in 1,4-dioxane (13 mL) under nitrogen and sparged with nitrogen before [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex withdichloromethane (144 mg, 0.176 mmol) was added and the reaction mixture sparged with nitrogen. The reaction mixture was stirred at 90 °C for 2h., allowed to cool, filtered through celite and the filtrate concentrated. The residue was purified by flash column chromatography elutingwith 0 - 5 % methanol in dichloromethane to give 1 -methyl-4-((3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)methyl)pyrrolidin-2-one (1.30 g, 78 %) as a brown oil.

[0606] UPLC_PH2_MECN_2.6MIN_V1; Rt 1.79 min., m / z 332.2 [M+H]+

[0607] 1-Methyl-4-((3-(1-methyl-1 H-pyrazolo[3,4-b]pyridin-5-yl)phenoxy)methyl)pyrrolidin- 2-one (Example 1)

[0608] 1 -Methyl-4-((3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)methyl)pyrrolidin-2-one (120 mg, 0.362 mmol), 5-bromo-1 -methyl-1 H-pyrazolo[3,4-b]pyridine (88.0 mg, 0.417 mmol), and lithium hydroxide monohydrate (15 mg, 0.362 mmol) were dissolved in 1,4-dioxane (8.0 mL) and water (1.0 mL) under nitrogen and sparged with nitrogen before [1,1 '-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex withdichloromethane (15 mg, 0.0181 mmol) was added and the reaction mixture sparged with nitrogen. The reaction mixture was stirred at 90 °C for 16h., allowed to cool, and filtered through celite. The filtrate was diluted with dichloromethane and water. The layers were separated, the aqueous layer extracted with ethyl acetate and the combined organic layers dried, filtered and concentrated in vacuo. The crude product was purified by flash column chromatography, elutingwith 0 - 100 % ethyl acetate in isohexane. The combined fractions were concentrated and lyophilised to give 1 -methyl-4-((3-(1 -methyl- 1 H-pyrazolo[3,4-b]pyridin-5-yl)phenoxy)methyl)pyrrolidin-2-one (40.9 mg, 33 %) as a yellow solid.

[0609] 1H-NMR (400 MHz, DMSO-D6) 58.89 (d, J = 2.3 Hz, 1 H), 8.50 (d, J = 2.3 Hz, 1 H), 8.19 (s, 1 H), 7.42 (t, J = 8.2 Hz, 1 H), 7.34-7.32 (m, 2H), 6.98 (dt, J = 7.5, 1.5 Hz, 1 H), 4.09 (s, 3H), 4.08-4.05 (m, 2H), 3.56-3.52 (m, 1 H), 3.24 (q, J = 5.0 Hz, 1 H), 2.85-2.77 (m, 1 H), 2.73 (s, 3H), 2.47-2.43 (m, 1H), 2.15 (dd, J= 16.7, 6.2 Hz, 1H).

[0610] UPLC_PH2_MECN_QC_V1: Rt 4.17 min., m / z 337.2 [M+H]+

[0611] UPLC_PH9_MECN_QC_V1: Rt 4.22 min., m / z 337.1 [M+H]+

[0612] The following compounds were made by analogous methods to phenol alkylation (step 1) above:

[0613] The following compounds were made analogous to step 2 above using General Method 2:

[0614] Suzuki Coupling

[0615] The following compounds were made by analogous methods to Step 3 above:

[0616] Chiral separation of 1-Methyl-4-((3-(quinolin-3-yl)phenoxy)methyl)pyrrolidin-2- one (Example 5) into (S)-1-methyl-4-((3-(quinolin-3-yl)phenoxy)methyl)pyrrolidin-2-one (EXAMPLE 43) and (R)-1-methyl-4-((3-(quinolin-3-yl)phenoxy)methyl)pyrrolidin-2-one (EXAMPLE 44)

[0617] The two stereoisomers were separated by chiral chromatography (Column: Chiralcel OD, 250 mm x20 mm, 10µm. Mobile phase: 35 % IPA-isohexane plus 0.1 % diethylamine v / v) and each collected peak further purified by prep HPLC eluting with 20 - 60 % acetonitrile- aqueous ammonium carbonate (pH9). The eluted fractions were concentrated in vacuo and lyophilised to give two samples:

[0618] Diastereomer A as the first-eluting peak (11.7 mg, 31 %) as an off-white solid:1H-NMR (400 MHz, Chloroform-D) δ9.16 (d, J = 2.3 Hz, 1 H), 8.30 (d, J = 2.3 Hz, 1 H), 8.14 (d, J = 8.7 Hz, 1 H), 7.88 (d, J = 8.2 Hz, 1 H), 7.75-7.71 (m, 1 H), 7.59 (td, J = 7.6, 1.4 Hz, 1 H), 7.44 (t, J = 7.8 Hz, 1 H), 7.33-7.31 (m, 1 H), 7.22 (t, J = 2.1 Hz, 1 H), 6.97-6.94 (m, 1 H), 4.07 (dd, J = 8.9, 5.7 Hz, 1 H), 4.00 (t, J = 8.2 Hz, 1 H), 3.62 (dd, J = 9.7, 8.1 Hz, 1 H), 3.38 (q, J = 5.0 Hz, 1 H), 2.96-2.89 (m, 1H), 2.86 (d, J = 9.6 Hz, 3H), 2.64 (dd,J= 16.9, 9.6 Hz, 1H), 2.35 (dd,J= 17.2, 6.2 Hz, 1H). UPLC_PH2_MECN_QC_V1, Rt 4.08 min., m / z 333.2 [M+H]+UPLC_PH9_MECN_QC_V1, Rt 4.46 min., m / z 333.2 [M+H]+

[0619] and Diastereomer B as the second-eluting peak (12.2 mg, 32 %) as an off-white solid:1H-NMR (400 MHz, Chloroform-D) δ9.15 (d, J = 2.3 Hz, 1 H), 8.30 (d, J = 2.3 Hz, 1 H), 8.14 (d, J = 8.7 Hz, 1 H), 7.90-7.87 (m, 1 H), 7.75-7.71 (m, 1 H), 7.60-7.56 (m, 1 H), 7.44 (t, J = 7.8 Hz, 1 H), 7.33-7.31 (m, 1 H), 7.22 (t, J = 2.1 Hz, 1 H), 6.96-6.94 (m, 1 H), 4.07 (dd, J = 8.9, 5.7 Hz, 1 H), 3.99 (t, J = 8.5 Hz, 1 H), 3.62 (dd, J= 10.1, 8.2 Hz, 1 H), 3.38 (q, J = 5.0 Hz, 1 H), 2.96-2.89 (m, 1 H), 2.87 (s, 3H), 2.64 (dd,J= 17.2, 9.4 Hz, 1H), 2.35 (dd,J= 17.2, 6.2 Hz, 1H).UPLC_PH2_MECN_QC_V1, Rt 4.07 min., m / z 333.2 [M+H]+UPLC_PH9_MECN_QC_V1, Rt4.47 min., m / z 333.1 [M+H]+The absolute stereochemistry of diastereomers A and B was not confirmed.

[0620] 7-Bromo-3-iodo-1,2,4-benzotriazine

[0621] Guanidine hydrochloride (1.66 g, 17.3 mmol) and potassium tert-butoxide (5.55 g, 49.5 mmol were dissolved in DMSO (30 mL). 1-Bromo-3-nitrobenzene (2.00 g, 9.90 mmol) was added in one portion and the reaction stirred for 30 minutes at room temperature. The reaction mixture was quenched with ammonium chloride (aq. sat., 150 mL), extracted with ethyl acetate (4 x 100 mL) and the combined organic layers dried, filtered and concentrated. The crude amine residue, copper (I) iodide (2.86 g, 15.0 mmol), iodine (254 mg, 1.00 mmol), and tert-butyl nitrite (2.4 mL, 20.0 mmol) were dissolved in THF (50 mL) under nitrogen and heated to 80 °C for 16 hours. The reaction mixture was filtered through celite and concentrated. The residue was purified by flash column chromatography, eluting with 0 - 20 % ethyl acetate in isohexane to give 7-bromo-3-iodo-1,2,4-benzotriazine (115 mg, 3 %) as a tan solid.

[0622] UPLC_pH9_MECN_2.6MIN_V1; Rt 1.73 min., m / z 343.4 [M+H]+

[0623] Synthesis of 3-iodobenzo[e][1,2,4]triazine

[0624] 3-Aminobenzo[e][1,2,4]triazine

[0625] To a stirring mixture of guanidine hydrochloride (2.64 g, 27.6 mmol) and potassium tert-butoxide (10.9 g, 97.5 mmol) in DMSO (54 mL) was added nitrobenzene (1.70 mL, 16.2 mmol). The reaction mixture was stirred at RT for 30 mins. The reaction mixture was quenched with NH4Cl (sat. aq., 200 mL) and extracted with 20% IPA-EtOAc (4 x 50 mL). The combined organics were dried (Na2SO4), passed through a phase separator and the filtrate concentrated in vacuo. The crude product was triturated from cold MeOH (3x) to provide a first crop of product as an orange solid. The mother liquors were concentrated in vacuo and purified by flash column chromatography eluting with 0 - 60% EtOAc-DCM to provide a second crop of product as an orange solid. The two crops were combined in DCM and concentrated in vacuo to provide 3-iodobenzo[e][1,2,4]triazine (2.37 g, 100 %) as an orange solid.UPLC_pH2_MECN_2.6MIN_V1; Rt 1.11 min., m / z 147.0 [M+H]+

[0626] 3-iodobenzo[e][1,2,4]triazine

[0627] To a mixture of 3-iodobenzo[e][1,2,4]triazine (2.37 g, 16.2 mmol), copper (I) Iodide (4.63 g, 24.3 mmol) and iodine (82 mg, 0.324 mmol) in dry tetrahydrofuran (23 mL) was added tert-butyl nitrite (2.9 mL, 24.3 mmol) and the reaction mixture was stirred at reflux for 6 hours. The reaction mixture was carefully added to ice-cold water (50 mL) and extracted with DCM (3 x 20 mL). The combined organic extracts were washed with brine (sat. ag., 50 mL), passed through a phase separator and the filtrate concentrated in vacuo. The crude product was purified by flash column chromatography eluting with 0 - 20% EtOAc-isohexane to provide 3-iodobenzo[e][1,2,4]triazine (450 mg, 11 %) as an orange solid.UPLC_pH2_MECN_2.6MIN_V1; Rt 1.51 min., m / z 258.0 [M+H]+

[0628] Synthesis of 3-iodo-7-(trifluoromethyl)benzo[e][1,2,4]triazine

[0629] 7-(Trifluoromethyl)benzo[e][1,2,4]triazin-3-amine

[0630] Guanidine hydrochloride (0.85 g, 8.90 mmol) and potassium tert-butoxide (3.52 g, 31.4 mmol) were suspended in dimethyl sulfoxide (20 mL). 3-Nitrobenzotrifluoride (0.70 mL, 5.23 mmol) was added, and the reaction mixture was stirred at room temperature for 3 h. The reaction mixture was poured into aqueous NH4Cl solution (sat. aq., 1 L), resulting in formation of a yellow precipitate. The resulting suspension was filtered and the residue washed with water (2 x 50 mL) and cold MeOH (2 x 20 mL) to give 7-(trifluoromethyl)benzo[e][1,2,4]triazin-3-amine (650 mg, 48 %) as a yellow solid.UPLC_pH2_MECN_2.6MIN_V1; Rt 1.48 min., m / z 215.1 [M+H]+

[0631] 3-lodo-7-(trifluoromethyl)benzo[e][1,2,4]triazine

[0632] 7-(Trifluoromethyl)benzo[e][1,2,4]triazin-3-amine (650 mg, 3.03 mmol), copper (I) Iodide (866 mg, 4.55 mmol), iodine (77 mg, 0.303 mmol), and tert-butyl nitrite (0.72 mL, 6.07 mmol) were dissolved in tetrahydrofuran (50 mL) under nitrogen and the reaction mixture stirred at 80 °C for 1 hour. The reaction mixture was cooled to room temperature, filtered through celite, concentrated in vacuo and resuspended in EtOAc (30 mL) and water (10 mL). The organic layer was washed with brine (sat. aq., 10 mL), passed through a phase separator and concentrated in vacuo. The crude product was purified by flash column chromatography eluting with 0 - 100% EtOAc-isohexane to provide 3-iodo-7-(trifluoromethyl)benzo[e][1,2,4]triazine (360 mg, 37 %) as a brown solid.UPLC_pH2_MECN_2.6MIN_V1; Rt 1.75 min., m / z 326.2 [M+H]+

[0633] Synthesis of 3-iodo-6-(trifluoromethyl)benzo[e][1,2,4]triazine

[0634] 6-(Trifluoromethyl)benzo[e][1,2,4]triazin-3-amine

[0635] Guanidine Hydrochloride (1.70 g, 17.8 mmol) and potassium tert-butoxide (7.05 g, 62.8 mmol) were suspended in DMSO (42 mL). 4-Nitrobenzotrifluoride (2.00 g, 10.5 mmol) was added and the reaction mixture stirred at room temperature for 30 min. The reaction mixture was quenched with NH4Cl (sat. aq., 100 mL) and the solution filtered. The precipitatewas washed sequentially with water and cold methanol then dried in vacuo to provide 6-(trifluoromethyl)benzo[e][1,2,4]triazin-3-amine (504 mg, 22 %) as a black solid.UPLC_pH2_MECN_2.6MIN_V1; Rt 1.46 min., m / z215.1 [M+H]+

[0636] 3-lodo-6-(trifluoromethyl)benzo[e][1,2,4]triazine

[0637] 6-(trifluoromethyl)benzo[e][1,2,4]triazin-3-amine (504 mg, 2.35 mmol), copper (I) Iodide (672 mg, 3.53 mmol) and iodine (60 mg, 0.235 mmol) were dissolvedin tetrahydrofuran (24 mL). tert-Butyl nitrite (0.56 mL, 4.71 mmol) was added and the reaction mixture stirred at 80 °C for 2 hr. The reaction mixture was cooled to room temperature, filtered through celite, concentrated in vacuo and the residue resuspended in dichloromethane (5 mL). Sodium thiosulphate solution (10 mL) was added and the layers separated. The aqueous phase was extracted with dichloromethane (2x5 mL) and the combined organic layers dried, filtered and the solvent evaporated in vacuo. The crude product was purified by flash column chromatography eluting with 0 - 20% EtOAc-isohexane to yield 3-iodo-6-(trifluoromethyl)benzo[e][1,2,4]triazine (96.9 mg, 13 %) as an orange solid. UPLC_pH9_MECN_2.6MIN_V1; Rt 1.84 min., m / z 326.0 [M+H]+

[0638] Synthesis of (3-((((R)-1-((R)-1-(4-methoxyphenyl)ethyl)-5-oxopyrrolidin-3-yl)methyl)thio)phenyl)boronic acid

[0639] (R)-4-(((3-Bromophenyl)thio)methyl)-1-((R)-1-(4-methoxyphenyl)ethyl)pyrrolidin-2-one

[0640] 3-Bromothiophenol (0.038 mL, 0.325 mmol) was dissolved in DMF (1.0 mL) under nitrogen. Potassium carbonate (67 mg, 0.487 mmol) was added and the reaction mixture stirred at room temperature for 10 min. A solution of [(3R)-1-[(1 R)-1-(4-methoxyphenyl)ethyl]-5-oxo-pyrrolidin-3-yl]methyl4-methylbenzenesulfonate (197 mg, 0.487 mmol) in N, N-dimethylformamide (1.0 mL) was added and the reaction mixture stirred at 100 °C for 1 hour. The reaction mixture was cooled, diluted with water (5 mL) and extracted with dichloromethane (3x5 mL). The combined organics were washed with water (5 mL) and brine (aq. sat., 5 mL), and concentrated. The residue was purified by flash column chromatography, eluting with 10-60 % ethyl acetate in isohexane to give (R)-4-(((3-bromophenyl)thio)methyl)-1-((R)-1-(4-methoxyphenyl)ethyl)pyrrolidin-2-one (151 mg) as a colourless oil which was used without further purification.

[0641] UPLC_pH9_MECN_2.6MIN_V1; Rt 2.00 min., m / z 422.2 [M+H]+

[0642] (3-((((R)-1 -((R)-1 -(4-Methoxyphenyl)ethyl)-5-oxopyrrolidin-3-yl)methyl)thio)phenyl)boronic acid

[0643] Using GM2 and (R)-4-(((3-bromophenyl)thio)methyl)-1 -((R)-1 -(4-methoxyphenyl)ethyl)pyrrolidin-2-one yielded ((3-((((R)-1-((R)-1-(4-methoxyphenyl)ethyl)-5-oxopyrrolidin-3-yl)methyl)thio)phenyl)boronic acid (81 mg, 100 %) as a brown solid.

[0644] UPLC_pH9_MECN_2.6MIN_V1; Rt 1.62 min., m / z 386.3 [M+H]+

[0645] Acid catalysed Deprotection

[0646] The following compounds were made by analogous methods to Step 4 above (using General method 4):

[0647] (R)-4-((3-(3-Fluoroquinoxalin-2-yl)phenoxy)methyl)-1 -(( R)-1 -(4-methoxyphenyl)ethyl)pyrrolidin-2-one

[0648] (R)-4-((3-(3-Chloroquinoxalin-2-yl)phenoxy)methyl)-1 -((R)-1 -(4-methoxyphenyl)ethyl)pyrrolidin-2-one (87 mg, 0.178 mmol) and potassium fluoride (53 mg, 0.891 mmol) were dissolved in DMSO (2.0 mL) and the mixture stirred at 80 °C for 16 hours. The crude product was purified by prep. HPLC to yield (R)-4-((3-(3-fluoroquinoxalin-2-yl)phenoxy)methyl)-1-((R)-1-(4-methoxyphenyl)ethyl)pyrrolidin-2-one (64 mg, 76 %) as a yellow oil.

[0649] UPLC_PH9_MECN_2.6MIN_V1; Rt 2.05 mins., m / z 472.3 [M+H]+

[0650] (R)-4-((3-(3-Deuteroquinoxalin-2-yl)phenoxy)methyl)-1-((R)-1-(4-methoxyphenyl)ethyl)pyrrolidin-2-one

[0651] (4R)-4-[[3-(3-Chloroquinoxalin-2-yl)phenoxy]methyl]-1-[(1 R)-1-(4-methoxyphenyl)ethyl]pyrrolidin-2-one (50 mg, 0.102 mmol) and tetrakis(triphenylphosphine)palladium(O) (5.9 mg, 0.00512 mmol) were dissolved in DMF (1.0 mL) and triethylamine (0.21 mL, 1.54 mmol) under nitrogen before being cooled to 0 °C and formic acid D2 (CAS: 920-42-3) (0.039 mL, 1.02 mmol) was added dropwise. The reaction mixture was stirred at 110 °C for one hour, cooled and diluted with ethyl acetate (20 mL) and water (20 mL). The layers were separated and the aqueous layer extracted with ethyl acetate (3 x 20 mL) and the combined organic layers dried, filtered and concentrated in vacuo. The crude product was purified by flash column chromatography, eluting with 50-100 % ethyl acetate in isohexane to give (R)-4-((3-(3-deuteroquinoxalin-2-yl)phenoxy)methyl)-1 -((R)-1 -(4-methoxyphenyl)ethyl)pyrrolidin-2-one (120 mg) as a yellow oil which was used without further purification.

[0652] UPLC_PH9_MECN_2.6MIN_V1; Rt 1.96 mins., m / z 455.1 [M+H]+

[0653] (R)-4-(((6-Bromopyridin-2-yl)oxy)methyl)-1-((R)-1-(4-methoxyphenyl)ethyl)pyrrolidin- 2-one

[0654] (4R)-4-(Hydroxymethyl)-1 -[(1 R)-1 -(4-methoxyphenyl)ethyl]pyrrolidin-2-one (250 mg, 0.902 mmol) and caesium carbonate (882 mg, 2.71 mmol) were dissolved in DMF (5 mL). 2-Bromo-6-fluoropyridine (238 mg, 1.35 mmol) was added and the mixture stirred at room temperature for 2 hours. The reaction mixture was diluted with dichloromethane (20 mL) andwater (20 mL) and the layers separated. The aqueous layer was extracted with dichloromethane (2 x 20 mL) and the combined organic layers dried, filtered and concentrated in vacuo. The crude product was purified by flash column chromatography, eluting with 20 - 80 % ethyl acetate in isohexane to give (R)-4-(((6-bromopyridin-2-yl)oxy)methyl)-1 -((R)-1 -(4-methoxyphenyl)ethyl)pyrrolidin-2-one (330 mg, 90 %) as a white solid.

[0655] UPLC_PH9_MECN_2.6MIN_V1; Rt 1.88 mins., m / z 405.2 [M+H]+

[0656] (R)-4-(((6-Bromopyrazin-2-yl)oxy)methyl)-1-((R)-1-(4-methoxyphenyl)ethyl)pyrrolidin-2-one

[0657] (4R)-4-(Hydroxymethyl)-1 -[(1 R)-1 -(4-methoxyphenyl)ethyl]pyrrolidin-2-one (250 mg, 0.902 mmol) and caesium carbonate (882 mg, 2.71 mmol) were dissolved in DMF (5.0 mL).2,6-Dibromopyrazine (322 mg, 1.35 mmol) was added and the mixture stirred at 80 °C for 16 hours. The reaction mixture was diluted with dichloromethane (20 mL) and water (20 mL) and the layers separated. The aqueous layer was extracted with dichloromethane (2 x 20 mL) and the combined organic layers dried, filtered and concentrated in vacuo. The crude product was purified by flash column chromatography, eluting with 20 -100 % ethyl acetate in isohexane to yield (R)-4-(((6-bromopyrazin-2-yl)oxy)methyl)-1 -((R)-1 -(4-methoxyphenyl)ethyl)pyrrolidin-2-one (380 mg, 89 %) as a colourless oil.

[0658] UPLC_PH9_MECN_2.6MIN_V1; Rt 1.77 mins., m / z 408.2 [M+H]+

[0659] Sodium quinoxaline-2-sulfinate

[0660] 2-Chloroquinoxaline (1.00 g, 6.08 mmol) and sodium hydrogen sulphide (681 mg, 12.2 mmol) were dissolved in DMF (10 mL) and stirred at 100 °C for 2 hours. The reaction mixture was cooled and diluted with water (30 mL) and ethyl acetate (50 mL). The layers were separated and the organic layer extracted with ethyl acetate (3 x 50 mL). The combined organic layers were dried, filtered and concentrated in vacuo. The residue was dissolved in ethanol (20 mL), water (20 mL), and sodium hydroxide solution (aq., 7M, 1.1 mL, 7.93 mmol). Hydrogen Peroxide, (aq, 30 %, 0.76 mL, 6.71 mmol) was added and the solutionstirred at room temperature for one hour. The reaction mixture was concentrated in vacuo, washed with cold ethyl acetate thrice and freeze-dried to give sodium quinoxaline-2-sulfinate (1.20 g, 91 %) as a pale-yellow solid.

[0661] UPLC_PH2_MECN_2.6MIN_V1; Rt 0.86 mins

[0662] (R)-1-((R)-1-(4-Methoxyphenyl)ethyl)-4-(((6-(quinoxalin-2-yl)pyridin-2-yl)oxy)methyl)pyrrolidin-2-one

[0663] (4R)-4-[(6-Bromo-2-pyridyl)oxymethyl]-1-[(1 R)-1-(4-methoxyphenyl)ethyl]pyrrolidin-2-one (330 mg, 0.814 mmol), cataCXium® A Pd G3 (CAS: 1651823-59-4) (59 mg, 0.0814 mmol), potassium carbonate (338 mg, 2.44 mmol), and sodium quinoxaline-2-sulfinate (352 mg, 1.63 mmol) were dissolved in 1,4-dioxane (10 mL) and stirred at 110 °C for 16 hours. The reaction was cooled, diluted with water (20 mL) and dichloromethane (20 mL) and the layers separated. The aqueous layer was extracted with dichloromethane (2 x 20 mL) and the combined organic extracts, dried, filtered and concentrated in vacuo. The crude product was purified by flash column chromatography, eluting with 20 - 80 % ethyl acetate in isohexane to give (R)-1-((R)-1-(4-methoxyphenyl)ethyl)-4-(((6-(quinoxalin-2-yl)pyridin-2-yl)oxy)methyl)pyrrolidin-2-one (130 mg, 18 %) as a red oil.

[0664] UPLC_PH9_MECN_2.6MIN_V1; Rt 2.03 mins., m / z 455.3 [M+H]+

[0665] (R)-1-((R)-1-(4-Methoxyphenyl)ethyl)-4-(((6-(quinoxalin-2-yl)pyrazin-2-yl)oxy)methyl)pyrrolidin-2-one

[0666] (4R)-4-[(6-Bromopyrazin-2-yl)oxymethyl]-1-[(1 R)-1-(4-methoxyphenyl)ethyl]pyrrolidin-2-one (380 mg, 0.804 mmol), cataCXium® A Pd G3 (59 mg, 0.0804 mmol), potassium carbonate (334 mg, 2.41 mmol), and sodium quinoxaline-2-sulfinate (348 mg, 1.61 mmol) were dissolved in DMF (10 mL) and stirred at 110 °C for 24 hours. The reaction mixture was filtered through a silica plug and the crude product purified by reversed-phase flash column chromatography (Teledyne RediSep Gold C1830g) elutingwith 0 - 70 % acetonitrile in aqueous ammonium carbonate (pH9) to give (R)-1-((R)-1-(4-methoxyphenyl)ethyl)-4-(((6-(quinoxalin-2-yl)pyrazin-2-yl)oxy)methyl)pyrrolidin-2-one (24 mg, 7 %) as an orange gum.

[0667] UPLC_PH9_MECN_2.6MIN_V1; Rt 1.87 mins., m / z 456.3 [M+H]+

[0668] N-Methylation

[0669] The following compounds were made by analogous methods to Step 5 above (using General method 7):

[0670] Synthesis of methyl-d3 4-methylbenzenesulfonate

[0671] Methanol-13C,d4 (0.33 mL, 8.09 mmol) and p-toluene sulfonyl chloride (1.85 g, 9.71 mmol) were diluted in toluene (10 mL) and the mixture cooled to 0 °C. Sodium hydroxide (1.2 mL, 8.09 mmol) was added dropwise and the reaction mixture warmed to room temperature and stirred at RT for 2 hours. The reaction mixture was quenched with water, extracted with dichloromethane, and the combined organic extracts dried, filtered, concentrated in vacuo, and the crude product purified by flash column chromatography, eluting with 0 - 20 % EtOAc-isohexane to give methyl-d3 4-methylbenzenesulfonate (374 mg, 24 %) as a white solid.

[0672] UPLC_PH9_MECN_2.6MIN_V1; Rt 1.82 mins., no ionisation

[0673] General Scheme 2: Syntheses of biaryl phenols (e.g. via Miyaura then Suzuki) followed by biarylphenol alkylationMiyaura BorylationGeneral Method 3:Suzuki couplingGeneral Method 4:Acid catalysed TFA / DCMdeprotectionMel General Method 7:N-alkylation

[0674] Synthesis of 3-(6-fluoroquinoxalin-2-yl)phenol

[0675] To a mixture of 3-hydroxyphenylboronic acid (100 mg, 0.725 mmol), 2-chloro-6-fluoroquinoxaline (132 mg, 0.725 mmol), potassium carbonate (301 mg, 2.18 mmol) and bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex withdichloromethane (17.8 mg, 0.0218 mmol) was added 1,4-dioxane (3.3 mL) followed by deionized water (0.33 mL) and the reaction mixture evacuated and backfilled with nitrogen three times then sparged with nitrogen for 10 minutes. The reaction mixture was then stirred at 80 °C for 16 hours. The reaction mixture was diluted with ethyl acetate (5 mL) and water (10 mL) and the aqueous layer acidified to pH 7 with hydrochloric acid (aq., 1 M). The organic layer was separated, and the aqueous layer extracted with ethyl acetate (3x3 mL). The combined organic extracts were dried (Na2SO4), filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography eluting with 0-6 % methanol in dichloromethane to provide 3-(6-fluoroquinoxalin-2-yl)phenol (161 mg, 92 %) as a brown solid.

[0676] 1H-NMR (400 MHz, DMSO-D6) 59.76 (s, 1 H), 9.53 (s, 1 H), 8.21 (dd, J = 9.2, 6.0 Hz, 1 H), 7.91 (dd, J = 9.2, 2.7 Hz, 1 H), 7.82 (td, J = 8.8, 2.9 Hz, 1 H), 7.76-7.73 (m, 2H), 7.40 (t, J = 8.0 Hz, 1 H), 6.97 (ddd, J = 8.0, 2.5, 0.9 Hz, 1 H)

[0677] UPLC_PH2_MECN_2.6MIN_V1; Rt 1.68 mins., m / z 241.1 [M+H]+

[0678] UPLC_PH9_MECN_2.6MIN_V1; Rt 1.71 mins., m / z 241.1 [M+H]+

[0679] The following intermediates were made by analogous methods:

[0680] Synthesis of 3-(quinoxalin-2-yl)phenol

[0681] To a solution of 3'-hydroxyacetophenone (5.00 g, 36.7 mmol) in 1,4-dioxane (20 mL) and water (1.0 mL) was added selenium (IV) oxide (4.07 g, 36.7 mmol). The solvent was degassed for 15 mins and then stirred at 100 °C under a nitrogen atmosphere for 16h. Thesolution turned from a pale-yellow to a viscous, deep purple / black solution. The reaction mixture was cooled to room temperature, filtered through celite, and the filtrate concentrated in vacuo to give 2-(3-hydroxyphenyl)-2-oxoacetaldehyde (9.9g, assumed quantitative) as a dark brown oil which was used directly in the subsequent reaction.

[0682] The crude 2-(3-hydroxyphenyl)-2-oxoacetaldehyde (9.9 g, assumed 36.6 mmol) was heated in water (50 mL) at 65 °C for 20 mins to give a dark brown solution. A solution of 1,2-phenylenediamine (3.96 g, 36.6 mmol) in 1,4-dioxane (8.0 mL) was added and a light brown precipitate formed instantly. The reaction mixture was cooled to 25 °C and stirred for 65h. Ice was then added to the stirred reaction mixture and a light brown solid was collected by filtration. The solid was dissolved in hot EtOAc (250 mL) and stirred in MgSO4and charcoal for 3hr. The reaction mixture was filtered hot through celite and the filtrate concentrated under reduced pressure to afford 3-quinoxalin-2-ylphenol (5.45 g, 67 %) as a brown solid.

[0683] 1H-NMR (400 MHz, DMSO-D6) 59.75 (s, 1 H), 9.51 (s, 1 H), 8.14-8.11 (m, 2H), 7.91-7.82 (m, 2H), 7.76 (dd, J = 8.5, 1.6 Hz, 2H), 7.40 (t, J = 8.0 Hz, 1 H), 6.97 (dq, J = 8.0, 1.1 Hz, 1 H)

[0684] UPLC_PH2_MECN_2.6MIN_V1; Rt 1.56 mins., m / z 223.1 [M+H]+

[0685] The following compounds were made by analogous methods:

[0686] Synthesis of 3-(benzo[e][1,2,4]triazin-3-yl)phenol

[0687] 2-Iodoaniline (1.00 g, 4.57 mmol), caesium carbonate (2.98 g, 9.13 mmol), copper(I) oxide (65 mg, 0.457 mmol), and 3-hydroxybenzohydrazide (1.04 g, 6.85 mmol) were dissolvedin 1,4-dioxane (10 mL) and DMF (10 mL) under nitrogen and stirred at 90 °C for 16 hours. The reaction was diluted with dichloromethane (100 mL) and water (100 mL) and the layers separated. The aqueous layer was extracted with dichloromethane (2 x 100 mL) and the combined organic layers dried, filtered and concentrated in vacuo. The residue was purified by flash column chromatography, eluting with 0 - 20 % ethyl acetate in isohexane to give 3- (benzo[e][1,2,4]triazin-3-yl)phenol (407 mg, 40 %) as a brown solid.

[0688] UPLC_PH9_MECN_2.6MIN_V1; Rt 1.54 mins., m / z 224.2 [M+H]+

[0689] Synthesis of 1 -(quinoxalin-2-yl)-1 H-pyrazol-4-ol

[0690] 2-(4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1 H-pyrazol-1 -yl)quinoxaline

[0691] To 2-chloroquinoxaline (300 mg, 1.82 mmol), 4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1 H-pyrazole (424 mg, 2.19 mmol) and potassium carbonate (756 mg, 5.47 mmol) was added DMF (20 mL), and the reaction mixture stirred at 100 °C for 18 h. The reaction was cooled to room temperature and diluted with EtOAc (20 mL) and the layers separated. The aqueous layer was washed successively with EtOAc (2 x 10 mL), before the combined organic layers were washed with brine (aq. sat., 20 mL), passed through a phase separator and concentrated in vacuo. The crude product was purified by flash column chromatography, eluting with 20 % ethyl acetate in isohexane to give 2-[4-(4, 4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazol-1 -yl]quinoxaline (380 mg, 65 %) as a yellow solid.

[0692] UPLC_PH2_MECN_2.6MIN_V1; Rt 2.05 mins., m / z 323.2 [M+H]+

[0693] 1 -(Quinoxalin-2-yl)-1 H-pyrazol-4-ol

[0694] To a solution of 2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazol-1 -yl]quinoxaline (380 mg, 1.18 mmol) in tetrahydrofuran (2.0 mL) at 0 °C was added sodiumhydroxide (0.94 mL, 2.36 mmol) and hydrogen peroxide, 30 wt.% in water (80 mg, 2.36 mmol) and the mixture was stirred for 30 min at RT.

[0695] Aq. HCl (2 M) was added until the mixture reached pH7, then extracted with EtOAc (3 x 5 mL). The combined organic layers were dried, filtered, concentrated in vacuo and the crude product purified by flash column chromatography, eluting with 0 - 100 % ethyl acetate in isohexane to give 1-(quinoxalin-2-yl)-1 H-pyrazol-4-ol (180 mg, 72 %) as a yellow solid.

[0696] UPLC_PH2_MECN_2.6MIN_V1; Rt 1.50 mins., m / z 213.1 [M+H]+

[0697] Synthesis of 2-(3-hydroxyphenyl)-1-methyl-1 H-benzo[d]imidazole-7-carbonitrile

[0698] 2-(Methylamino)-3-nitrobenzonitrile

[0699] 2-Amino-3-nitrobenzonitrile (400 mg, 2.45 mmol, CAS: 87331-46-2) wasdissolved in DMF (10 mL) and cooled to 0 °C. Sodium hydride (60 % dispersion in oil) (108 mg, 2.70 mmol) was added and the reaction mixture stirred for 15 minutes at roomtemperature, Iodomethane (0.72 mL, 11.6 mmol) was added and the reaction allowed to warm to room temperature and stirred at room temperature for 90 minutes. The reaction was quenched by addition of water (30 mL), and the precipitate filtered. The filter cake was washed with water and dried in vacuo to yield 2-(methylamino)-3-nitro-benzonitrile (400 mg, 87 %) as an orange solid.

[0700] UPLC_PH2_MECN_2.6MIN_V1; Rt 1.53 mins., m / z 178.1 [M+H]+

[0701] 3-Amino-2-(methylamino)benzonitrile

[0702] To a mixture of 2-(methylamino)-3-nitro-benzonitrile (416 mg, 2.35 mmol) and ammonium chloride (1256 mg, 23.5 mmol) in tetrahydrofuran (15 mL) and methanol (15 mL) at 0 °C was added zinc dust (1535 mg, 23.5 mmol) portion-wise. The mixture was stirred at room temperature for one hour, filtered through celite and concentrated in vacuo to give 3-amino-2-(methylamino)benzonitrile (615 mg) as a brown solid which was used without further purification.

[0703] UPLC_PH2_MECN_2.6MIN_V1; Rt 1.20 mins., m / z 148.2 [M+H]+

[0704] 2-(3-Hydroxyphenyl)-1 -methyl-1 H-benzo[d]imidazole-7-carbonitrile

[0705] 3- Hydroxybenzaldehyde (287 mg, 2.35 mmol), 3-amino-2-(methylamino)benzonitrile (346 mg, 2.35 mmol), and sodium bisulfite (367 mg, 3.53 mmol) were dissolved in DMF (20 mL). The mixture was stirred at reflux for 16 hours. The reaction was cooled, diluted with water (50 mL) and filtered. The precipitate was washed with water and isohexane and dried in vacuo to yield 2-(3-hydroxyphenyl)-3-methyl-benzimidazole-4-carbonitrile (397.5 mg, 67 %) as a peach solid.

[0706] 1H-NMR (400 MHz, DMSO-D6) 59.88 (s, 1 H), 8.05 (dd, J = 8.2, 0.9 Hz, 1 H), 7.78 (dd, J = 7.8, 0.9 Hz, 1 H), 7.40 (t, J = 7.8 Hz, 2H), 7.23-7.19 (m, 2H), 7.01 -6.98 (m, 1 H), 4.07 (s, 3H).

[0707] UPLC_PH9_MECN_2.6MIN_V1; Rt 1.48 mins., m / z 250.2 [M+H]+

[0708] Synthesis of 3-(7-fluoro-1 -methyl-1 H-benzo[d]imidazol-2-yl)phenol

[0709] 6-Fluoro-N1 -methylbenzene-1,2-diamine

[0710] To a mixture of 2-Fluoro-N-methyl-6-nitroaniline (400 mg, 2.35 mmol) and ammonium chloride (1256 mg, 23.5 mmol) in tetrahydrofuran (15 mL) and methanol (15 mL) at 0 °C was added zinc dust (1535 mg, 23.5 mmol) portion-wise. The mixture was stirred at room temperature for 2 hours. The reaction mixture was filtered through celite and the filtrate concentrated in vacuo to yield 3-fluoro-N2-methyl-benzene-1,2-diamine (420 mg) as a brown solid which was used without further purification.

[0711] UPLC_PH9_MECN_2.6MIN_V1; Rt 1.27 mins., m / z 141.2 [M+H]+

[0712] 3-(7-Fluoro-1 -methyl-1 H-benzo[d]imidazol-2-yl)phenol

[0713] 3- Hydroxybenzaldehyde (287 mg, 2.35 mmol), 3-fluoro-N2-methyl-benzene-1,2-diamine (329 mg, 2.35 mmol), and sodium bisulfite (367 mg, 3.53 mmol) were dissolved in DMF (20 mL) and stirred at 140 °C for 2 hours. The reaction was cooled, quenched with cold water (20 mL) and extracted with ethyl acetate (4 x 30 mL). The combined organic extracts were washed with water (2 x 20 mL), dried, filtered, and concentrated in vacuo. The residue was purified by reversed-phase flash column chromatography, eluting with 0 - 100 % acetonitrile in pH9 ammonium bicarbonate. The eluted fractions were concentrated in vacuo to give 3-(7-fluoro-1-methyl-benzimidazol-2-yl)phenol (158 mg, 26 %) as a light orange solid.

[0714] 1H-NMR (400 MHz, DMSO-D6) 59.83 (s, 1 H), 7.50 (d, J = 8.2 Hz, 1 H), 7.38 (t, J = 7.8 Hz, 1 H), 7.24-7.16 (m, 3H), 7.13-7.06 (m, 1 H), 6.96 (dd, J = 8.2, 2.3 Hz, 1 H), 3.98 (s, 3H)

[0715] UPLC_PH9_MECN_2.6MIN_V1; Rt 1.56 mins., m / z 243.2 [M+H]+

[0716] Synthesis of 3-(6-fluoro-1 -methyl-1 H-benzo[d]imidazol-2-yl)phenol

[0717] 5-Fluoro-N1 -methylbenzene-1,2-diamine

[0718] To a mixture of 5-fluoro-N-methyl-2-nitroaniline (400 mg, 2.35 mmol) and ammonium chloride (1256 mg, 23.5 mmol) in tetrahydrofuran (15 mL) and methanol (15 mL) at 0 °C was added zinc dust (1535 mg, 23.5 mmol) portion-wise. The mixture was stirred at room temperature for 2 hours. The reaction was filtered through celite and concentrated in vacuo to yield 4-fluoro-N2-methyl-benzene-1,2-diamine (557 mg) as a brown solid which was used without further purification.

[0719] UPLC_PH9_MECN_2.6MIN_V1; Rt 1.33 mins., m / z 141.2 [M+H]+

[0720] 3-(6-Fluoro-1 -methyl-1 H-benzo[d]imidazol-2-yl)phenol

[0721] 3- Hydroxybenzaldehyde (287 mg, 2.35 mmol), 4-fluoro-N2-methyl-benzene-1,2- diamine (329 mg, 2.35 mmol), and sodium bisulfite (367 mg, 3.53 mmol) were dissolved in DMF (20 mL) and stirred at 140 °C for 17 hours. The reaction was cooled, poured onto cold water (125 mL) and filtered. The precipitate was dried in vacuo to yield 3-(6-fluoro-1 -methyl- benzimidazol-2-yl)phenol (293 mg, 48 %) as a brown solid.

[0722] UPLC_PH9_MECN_2.6MIN_V1; Rt 1.50 mins., m / z 243.2 [M+H]+

[0723] Synthesis of (R)-3-(2,3-dihydrobenzo[b][1,4]dioxin-2-yl)phenol

[0724] 2-(2-Bromophenoxy)-1 -(3-chlorophenyl)ethan-1 -one

[0725] To a stirred solution of 2-bromophenol (0.91 mL, 8.67 mmol) in acetone (23 mL) was added caesium carbonate (3.39 g, 10.4 mmol) and 2-bromo-1-(3-chlorophenyl)ethanone (2.02 g, 8.67 mmol) at room temperature, then the reaction was stirred at room temperature for 18 h. The reaction mixture was diluted with water and the precipitate isolated by filtration and further dried under reduced pressure to give the crude product as a brown solid.Purification by trituration with hexanes (3 x20 mL) gave 2-(2-bromophenoxy)-1-(3- chlorophenyl)ethan-1 -one (2.5g, 89 %) as an off-white solid.

[0726] 1H-NMR (400 MHz, Chloroform-D) 58.02 (t, J = 1.8 Hz, 1 H), 7.91 (dt, J = 7.8, 1.4 Hz, 1 H), 7.59-7.54 (m, 2H), 7.43 (t, J = 8.0 Hz, 1 H), 7.24-7.19 (m, 1 H), 6.87 (td, J = 7.8, 1.4 Hz, 1 H), 6.82 (dd, J = 8.2, 1.4 Hz, 1 H), 5.26 (s, 2H).

[0727] UPLC_PH2_MECN_2.6MIN_V1; Rt 1.96 mins., No ionisation

[0728] (R)-2-(2-Bromophenoxy)-1 -(3-chlorophenyl)ethan-1 -ol

[0729] To DMF (3.0 mL) were added 2-(2-bromophenoxy)-1-(3-chlorophenyl)ethan-1-one (0.90 g, 2.76 mmol), N-((1S,2S)-2-amino-1,2-diphenylethyl)-4-methylbenzenesulfonamide (20 mg, 0.0553 mmol) and dichloro(pentamethylcyclopentadienyl rhodium(III) dimer (18 mg, 0.0276 mmol) and the resulting mixture was stirred at 0 °C under N2sparging for 20 min. Formic acid (0.10 mL) was added drop-wise, then triethylamine (0.28 mL, 2.00 mmol) added and the mixture stirred at 0 °C for 2 h. The reaction mixture was diluted with EtOAc (10 mL) and sat. NaHCO3(aq) (5 mL). The organic phase was collected, washed with sat. brine solution (3x10 mL), dried, filtered, concentrated in vacuo and the crude product purified by flash column chromatography, eluting with 0 - 100 % ethyl acetate in isohexane to give (R)-2-(2-bromophenoxy)-1 -(3-chlorophenyl)ethan-1 -ol (750 mg, 83 %) as a colourless oil.

[0730] 1H-NMR (400 MHz, Chloroform-D) 57.56-7.53 (m, 1 H), 7.49 (s, 1 H), 7.35-7.28 (m, 3H), 7.26-7.22 (m, 1 H), 6.89-6.85 (m, 2H), 5.14 (dd, J = 8.2, 3.2 Hz, 1 H), 4.18 (dd, J = 9.4, 3.4 Hz, 1 H), 3.98 (dd, J = 9.4, 8.5 Hz, 1 H), 3.04 (s, 1 H).

[0731] UPLC_PH2_MECN_2.6MIN_V1; Rt 1.93 mins., No ionisation

[0732] (R)-3-(2,3-Dihydrobenzo[b][1,4]dioxin-2-yl)phenol

[0733] (R)-2-(2-Bromophenoxy)-1 -(3-chlorophenyl)ethan-1 -ol (500 mg, 1.53mmol), methanesulfonato(2-di-t-butylphosphino-2',4',6'-tri-i-propyl-1,1'-biphenyl)(2'-amino-1,1 '-biphenyl-2-yl)palladium(ll) [t-BuXPhos Palladacycle Gen. 3] (121 mg, 0.153 mmol), and sodium tert-butoxide (293 mg, 3.05 mmol) were combined in 1,4-dioxane (3.0 mL) and the mixture was degassed with N2for 10 min. The reaction mixture was then stirred at 70 °C for 16 hours. The reaction mixture was cooled to rt, then diluted with EtOAc (20 mL). Water (20 mL) was added and the layers separated, the aqueous phase further washed with EtOAc (3x10 mL) before the organic fractions were combined, washed with brine (aq. sat., 10 mL), dried, filtered, concentrated in vacuo, and purified by flash column chromatography, elutingwith 0 - 100 % ethyl acetate in isohexane to give (R)-3-(2,3-dihydrobenzo[b][1,4]dioxin-2-yl)phenol (260 mg, 75 %) as an off-white solid.

[0734] 1H-NMR (400 MHz, DMSO-D6) 59.50 (s, 1 H), 7.16 (t, J = 7.8 Hz, 1 H), 6.93-6.79 (m, 6H), 6.73-6.70 (m, 1 H), 5.10 (dd, J = 8.2, 2.3 Hz, 1 H), 4.35 (dd, J = 11.4, 2.3 Hz, 1 H), 4.01-3.95 (m, 1H)

[0735] UPLC_PH2_MECN_2.6MIN_V1; Rt 1.71 mins., No ionisation

[0736] Synthesis of 3-(7-methoxybenzo[e][1,2,4]triazin-3-yl)phenol

[0737] 3-Hydroxy-N'-(5-methoxy-2-nitrophenyl)benzohydrazide

[0738] 3-Fluoro-4-nitroanisole (2.25 g, 13.1 mmol) and 3-hydroxybenzohydrazide (2.00 g, 13.1 mmol) were dissolved in dimethyl sulfoxide (15 mL) and the reaction stirred at 90 °C for 16 hours. The reaction mixture was cooled, diluted with ethyl acetate and water, the layers separated and the aqueous layer extracted with ethyl acetate. The combined organics were dried, filtered, and concentrated in vacuo to give 3-hydroxy-N'-(5-methoxy-2-nitro- phenyl)benzohydrazide (4.20 g, 13.2 mmol, 100 %) as an orange solid.

[0739] UPLC_PH2_MECN_2.6MIN_V1; Rt 1.43 mins., m / z 304.1 [M+H]+

[0740] 3-(7-Methoxybenzo[e][1,2,4]triazin-3-yl)phenol

[0741] 3-Hydroxy-N'-(5-methoxy-2-nitro-phenyl)benzohydrazide (4.20 g, 13.2 mmol) was dissolved in acetic acid (50 mL). Tin (6.35 g, 52.6 mmol) was added and the reaction mixture stirred at room temperature for one hour, followed by 30 minutes at 120 °C. The reaction mixture was cooled to RT, diluted with water and ethyl acetate and the solution filtered. The layers were separated and the aqueous layer extracted with ethyl acetate. The combinedorganic layers were dried, filtered, and concentrated in vacuo to give 3-(7-methoxy-1,2,4-benzotriazin-3-yl)phenol (2200 mg, 6.95 mmol, 53 %) as a brown oil.UPLC_PH9_MECN_2.6MIN_V1; Rt 1.62 mins., m / z 254.2 [M+H]+

[0742] Alkylation of biaryl phenols

[0743] Example 110 - Synthesis of 1 -methyl-4-((3-(quinoxalin-2-yl)phenoxy)methyl)pyrrolidin-2-one

[0744] (1 -Methyl-5-oxopyrrolidin-3-yl)methyl 4-methylbenzenesulfonate (439 mg, 1.55 mmol) was dissolved in acetonitrile (9.0 mL). Potassium carbonate (642 mg, 4.65 mmol) and 3-quinoxalin-2-ylphenol (344 mg, 1.55 mmol) were added. The reaction mixture was stirred at 60 °C for 16 hours, potassium iodide (257 mg, 1.55 mmol) was added and heating continued at 60 °C for a further 16hr. The reaction mixture was cooled, passed through a phase separator and concentrated under reduced pressure to give an orange / brown oil. The crude product was purified by flash column chromatography, eluting with EtOAc in isohexane. The product-containing fractions were combined and concentrated under reduced pressure to give 1 -methyl-4-((3-quinoxalin-2-yl)phenoxy)methyl)pyrrolidin-2-one (68.6mg, 13.3 %) as an off-white solid.

[0745] Chiral separation of Example 110 to give (S)-1-methyl-4-((3-(quinoxalin-2-yl)phenoxy)methyl)pyrrolidin-2-one (Example 110a)

[0746] The two stereoisomers were separated by chiral chromatography (Column: Daicel ChiralPak IA, 250 mm x 4.6mm, 5pm. Mobile phase: methanol plus 0.1 % diethylamine v / v) to afford:

[0747] (S)-1-methyl-4-((3-(quinoxalin-2-yl)phenoxy)methyl)pyrrolidin-2-one (Example 110a) as the first-eluting peak 1 (19.9 mg) as a white solid:

[0748] 1H-NMR (400 MHz, Chloroform-D) 59.33 (s, 1 H), 8.23-8.17 (m, 2H), 7.85-7.75 (m, 4H), 7.50 (t, J = 8.0 Hz, 1 H), 7.08-7.06 (m, 1 H), 4.16-4.05 (m, 2H), 3.64 (dd, 7= 10.1, 8.2 Hz,1 H), 3.41 (q, J = 5.0 Hz, 1 H), 2.98-2.90 (m, 1 H), 2.89 (s, 3H), 2.66 (q, J = 8.7 Hz, 1 H), 2.38 (dd, J = 17.2, 6.2 Hz, 1H).

[0749] UPLC_PH2_MECN_QC_V1, Rt 4.52 min., m / z 334.2 [M+H]+

[0750] UPLC_PH9_MECN_QC_V1, Rt 4.51 min., m / z 334.1 [M+H]+

[0751] and (R)-1-methyl-4-((3-(quinoxalin-2-yl)phenoxy)methyl)pyrrolidin-2-one (Example 2) as the second eluting peak. The enantioselective synthesis of this compound is described elsewhere in this patent.

[0752] The following compounds were made using General Method 1:

[0753] Syntheses of tosylates and mesylates

[0754] ((R)-1-((R)-1-(4-Methoxyphenyl)ethyl)-5-oxopyrrolidin-3-yl)methyl4-methylbenzenesulfonate and ((S)-1 -((R)-1 -(4-methoxyphenyl)ethyl)-5-oxopyrrolidin-3-yl)methyl 4-methylbenzenesulfonate

[0755] Methyl (R)-1-((R)-1-(4-methoxyphenyl)ethyl)-5-oxopyrrolidine-3-carboxylate and methyl (S)-1-((R)-1-(4-methoxyphenyl)ethyl)-5-oxopyrrolidine-3-carboxylate

[0756] A solution of dimethyl itaconate (10.5 g, 66.1 mmol) and (R)-1-(4-methoxyphenyl)ethan-1 -amine (9.80 mL, 66.1 mmol) in methanol (63 mL) was stirred at room temperature for 16 hours. The reaction mixture was concentrated under reduced pressure, resuspended in toluene (42 mL) and p-toluenesulfonic acid monohydrate (1.26 g, 6.61 mmol) was added and the reaction mixture was stirred at reflux for 1.5 hours. The reaction mixturewas then concentrated under reduced pressure and the crude product purified by flash column chromatography eluting with 0 - 100 % ethyl acetate in isohexane to provide:

[0757] methyl (R)-1-((R)-1-(4-methoxyphenyl)ethyl)-5-oxopyrrolidine-3-carboxylate (8.44 g, 46 %) as a pale-yellow oil

[0758] 1H-NMR (400 MHz, Chloroform-D) δ 7.24-7.20 (m, 2H), 6.88-6.84 (m, 2H), 5.44 (q, J = 7.0 Hz, 1 H), 3.79 (s, 3H), 3.71 (s, 3H), 3.52 (dd, J = 9.6, 6.4 Hz, 1 H), 3.17 (t, J = 9.4 Hz, 1 H), 3.12-3.04 (m, 1 H), 2.77-2.62 (m, 2H), 1.50 (d, J = 7.6 Hz, 3H).

[0759] UPLC_PH2_MECN_2.6MIN_V1; Rt 1.61 mins., m / z 278.2 [M+H]+

[0760] UPLC_PH9_MECN_2.6MIN_V1; Rt 1.70 mins., m / z 278.2 [M+H]+

[0761] and:

[0762] Methyl (S)-1-((R)-1-(4-methoxyphenyl)ethyl)-5-oxopyrrolidine-3-carboxylate (7.13 g, 39 %) as a pale-yellow oil

[0763] 1H-NMR (400 MHz, Chloroform-D) δ 7.22-7.19 (m, 2H), 6.88-6.84 (m, 2H), 5.45 (q, J = 7.2 Hz, 1 H), 3.80 (s, 3H), 3.65 (s, 3H), 3.51 (dd, J = 9.4, 8.0 Hz, 1 H), 3.22-3.11 (m, 2H), 2.75-2.63 (m, 2H), 1.50 (d, J = 6.9 Hz, 3H).

[0764] UPLC_PH2_MECN_2.6MIN_V1; Rt 1.60 mins., m / z 278.2 [M+H]+

[0765] UPLC_PH9_MECN_2.6MIN_V1; Rt 1.68 mins., m / z 278.2 [M+H]+

[0766] Synthesis of ((R)-1 -((R)-1 -(4-methoxyphenyl)ethyl)-5-oxopyrrolidin-3-yl)methyl 4-methylbenzenesulfonate

[0767] (R)-4-(Hydroxymethyl)-1-((R)-1-(4-methoxyphenyl)ethyl)pyrrolidin-2-one

[0768] Using methyl (R)-1-((R)-1-(4-methoxyphenyl)ethyl)-5-oxopyrrolidine-3-carboxylate (7.38 g, 26.6 mmol) with GM6, gave a crude sample of (R)-4-(hydroxymethyl)-1-((R)-1-(4-methoxyphenyl)ethyl)pyrrolidin-2-one which was used directly in the next step without further purification.

[0769] 1H-NMR (400 MHz, Chloroform-D) 67.24-7.20 (m, 2H), 6.88-6.84 (m, 2H), 5.44 (q, J = 7.0 Hz, 1H), 3.80 (s, 3H), 3.65 (dd,7= 10.5, 6.0 Hz, 1H), 3.57 (dd,7= 10.5, 7.3 Hz, 1H), 3.17 (dd, J = 9.8, 5.3 Hz, 1 H), 3.08 (dd, J = 9.8, 8.0 Hz, 1 H), 2.53 (dd, J = 16.3, 8.9 Hz, 1 H), 2.48-2.37 (m, 1 H), 2.26 (dd, J = 16.5, 6.0 Hz, 1 H), 1.49 (d, J = 7.3 Hz, 3H).

[0770] UPLC_PH2_MECN_2.6MIN_V1; Rt 1.37 mins., m / z 250.3 [M+H]+

[0771] UPLC_PH9_MECN_2.6MIN_V1; Rt 1.35 mins., m / z 250.3 [M+H]+

[0772] ((R)-1-((R)-1-(4-Methoxyphenyl)ethyl)-5-oxopyrrolidin-3-yl)methyl4-methylbenzenesulfonate

[0773] Using (R)-4-(hydroxymethyl)-1-((R)-1-(4-methoxyphenyl)ethyl)pyrrolidin-2-one and TsCl (1.05 eq.) in GM5 with purification by flash column chromatography eluting with 0-80 % ethyl acetate in isohexane gave ((R)-1-((R)-1-(4-methoxyphenyl)ethyl)-5-oxopyrrolidin-3-yl)methyl 4-methylbenzenesulfonate as a clear orange oil (4.59 g, 43 %).

[0774] 1H-NMR (400 MHz, Chloroform-D) 57.78-7.76 (m, 2H), 7.36 (d, J = 7.8 Hz, 2H), 7.20-7.16 (m, 2H), 6.87-6.83 (m, 2H), 5.40 (q, J = 7.0 Hz, 1 H), 3.97 (dd, J = 9.8, 5.3 Hz, 1 H), 3.91 (dd, J = 9.6, 7.8 Hz, 1 H), 3.80 (s, 3H), 3.09-3.02 (m, 2H), 2.62-2.48 (m, 2H), 2.46 (s, 3H), 2.10 (dd, J = 16.3, 5.7 Hz, 1H), 1.41 (d, J = 7.3 Hz, 3H).

[0775] UPLC_PH2_MECN_2.6MIN_V1; Rt 1.83 mins., m / z 404.3 [M+H]+

[0776] UPLC_PH9_MECN_2.6MIN_V1; Rt 1.82 mins., m / z 404.3 [M+H]+

[0777] Synthesis of ((S)-1-((R)-1-(4-methoxyphenyl)ethyl)-5-oxopyrrolidin-3-yl)methyl4-methylbenzenesulfonate

[0778] (S)-4-(Hydroxymethyl)-1-((R)-1-(4-methoxyphenyl)ethyl)pyrrolidin-2-one

[0779] Using methyl (S)-1 -((R)-1 -(4-methoxyphenyl)ethyl)-5-oxopyrrolidine-3-carboxylate (7.12 g, 25.7 mmol) with GM6, gave a crude sample of (S)-4-(hydroxymethyl)-1-((R)-1-(4-methoxyphenyl)ethyl)pyrrolidin-2-one which was used directly in the next step without further purification.

[0780] 1H-NMR (400 MHz, Chloroform-D) 57.23-7.20 (m, 2H), 6.88-6.84 (m, 2H), 5.44 (q, J = 7.2 Hz, 1 H), 3.79 (s, 3H), 3.51 (dd, J = 10.5, 6.0 Hz, 1 H), 3.44-3.39 (m, 2H), 2.79 (dd, 7= 10.1, 5.0 Hz, 1 H), 2.58 (dd, J = 16.3, 8.9 Hz, 1 H), 2.53-2.45 (m, 1 H), 2.23 (dd, J = 16.5, 5.0 Hz, 1 H), 1.49 (d, 7 = 7.3 Hz, 3H).

[0781] UPLC_PH2_MECN_2.6MIN_V1; Rt 1.40 mins., m / z 250.3 [M+H]+

[0782] UPLC_PH9_MECN_2.6MIN_V1; Rt 1.47 mins., m / z 250.3 [M+H]+

[0783] ((S)-1 -((R)-1 -(4-Methoxyphenyl)ethyl)-5-oxopyrrolidin-3-yl)methyl 4-methylbenzenesulfonate

[0784] Using (S)-4-(hydroxymethyl)-1-((R)-1-(4-methoxyphenyl)ethyl)pyrrolidin-2-one and TsCl (1.05 eq.) in GM5 with purification by flash column chromatography eluting with 0-80 % ethyl acetate in isohexane gave ((S)-1-((R)-1-(4-methoxyphenyl)ethyl)-5-oxopyrrolidin-3-yl)methyl 4-methylbenzenesulfonate (9.08 g, 85 %) as a colourless oil.

[0785] 1H-NMR (400 MHz, Chloroform-D) 57.69-7.66 (m, 2H), 7.32 (d, J = 7.8 Hz, 2H), 7.18- 7.14 (m, 2H), 6.87-6.83 (m, 2H), 5.40 (q, J = 7.2 Hz, 1 H), 3.85 (dd, J = 9.8, 5.7 Hz, 1 H), 3.82 (s, 3H), 3.78 (dd, J = 9.8, 7.6 Hz, 1 H), 3.42-3.37 (m, 1 H), 2.71-2.59 (m, 2H), 2.53 (dd, J = 16.5, 9.2 Hz, 1 H), 2.45 (s, 3H), 2.08 (dd, 7= 17.1, 5.8 Hz, 1 H), 1.46 (d, J = 7.3 Hz, 3H).

[0786] UPLC_PH2_MECN_2.6MIN_V1; Rt 1.81 mins., m / z 404.5 [M+H]+

[0787] UPLC_PH9_MECN_2.6MIN_V1; Rt 1.80 mins., m / z 404.5 [M+H]+

[0788] Methyl 1-((S)-1-(4-methoxyphenyl)ethyl)-5-oxopyrrolidine-3-carboxylate

[0789] A mixture of (S)-1 -(4-methoxyphenyl)ethan-1 -amine (1.00 g, 6.61 mmol) and dimethyl itaconate (1.10 g, 6.94 mmol) was stirred at 100 °C for 1 hour and then at 150 °C for 2 hours. The reaction mixture was then allowed to room temperature and purified by flash column chromatography eluting with 0 - 100 % ethyl acetate in isohexane to provide methyl 1- ((S)-1-(4-methoxyphenyl)ethyl)-5-oxopyrrolidine-3-carboxylate (1.33 g, 73 %) as a colourless oil, as a mixture of diastereomers and used in the subsequent step without further purification.

[0790] UPLC_PH2_MECN_2.6MIN_V1; Rt 1.54 & 1.56 mins., m / z 278.3 [M+H]+

[0791] UPLC_PH9_MECN_2.6MIN_V1; Rt 1.53 & 1.55 mins., m / z 278.2 [M+H]+

[0792] Methyl 1-((S)-1-(4-methoxyphenyl)ethyl)-3-methyl-5-oxopyrrolidine-3-carboxylate

[0793] To a stirred solution of methyl 1-((S)-1-(4-methoxyphenyl)ethyl)-3-methyl-5-oxopyrrolidine-3-carboxylate (200 mg, 0.72 mmol) in DMF (2.6 mL) at 0 °C was added sodium hydride (60 % dispersion, 115 mg, 2.88 mmol) followed by methyl iodide (0.45 mL, 7.2 mmol). The reaction mixture was allowed to room temperature then warmed to 40 °C and stirred for 16 hours at 40 °C. The reaction mixture was cooled to 0 °C and quenched with ammonium chloride (aq. sat.) and the aqueous extracted with EtOAc (3x5 mL). The combined organic extracts were washed with brine (aq. sat., 10 mL), passed through a hydrophobic frit, and concentrated under reduced pressure. The crude product was purified by flash column chromatography, eluting with 0 - 70 % ethyl acetate in isohexane to provide methyl 1-((S)-1-(4-methoxyphenyl)ethyl)-3-methyl-5-oxopyrrolidine-3-carboxylate (168 mg, 80 %) as a colourless oil, as a mixture of diastereomers used in the subsequent step without further purification.

[0794] UPLC_PH2_MECN_2.6MIN_V1; Rt 1.62 & 1.64 mins., m / z 292.3 [M+H]+

[0795] UPLC_PH9_MECN_2.6MIN_V1; Rt 1.62 & 1.64 mins., m / z 292.2 [M+H]+

[0796] 4-(Hydroxymethyl)-1 -((S)-1 -(4-methoxyphenyl)ethyl)-4-methylpyrrolidin-2-one

[0797] 4-(Hydroxymethyl)-1-((S)-1-(4-methoxyphenyl)ethyl)-4-methylpyrrolidin-2-one (144 mg, 97 %), a pale-yellow oil, was synthesised using GM6 with methyl 1-((S)-1-(4-methoxyphenyl)ethyl)-3-methyl-5-oxopyrrolidine-3-carboxylate and purified by flash column chromatography eluting with 0 - 5 % methanol in dichloromethane.

[0798] UPLC_PH2_MECN_2.6MIN_V1; Rt 1.45 mins., m / z 264.3 [M+H]+

[0799] UPLC_PH9_MECN_2.6MIN_V1; Rt 1.42 mins., m / z 264.3 [M+H]+

[0800] (1-((S)-1-(4-Methoxyphenyl)ethyl)-3-methyl-5-oxopyrrolidin-3-yl)methyl4-methylbenzenesulfonate

[0801] (1-((S)-1-(4-Methoxyphenyl)ethyl)-3-methyl-5-oxopyrrolidin-3-yl)methyl4- methylbenzenesulfonate (167 mg, 78 %), a colourless oil, was synthesized using GM5 with 4- (hydroxymethyl)-l -((S)-1 -(4-methoxyphenyl)ethyl)-4-methylpyrrolidin-2-one and 1.05 eq.TsCl, and purified by flash column chromatography eluting with 0 - 100 % ethyl acetate in isohexane.

[0802] UPLC_PH2_MECN_2.6MIN_V1; Rt 1.85 & 1.87 mins., m / z 418.4 [M+H]+

[0803] UPLC_PH9_MECN_2.6MIN_V1; Rt 1.86 & 1.88 mins., m / z 418.4 [M+H]+

[0804] (1 -Methyl-6-oxopiperidin-3-yl)methyl 4-methylbenzenesulfonate

[0805] To a stirred solution of 5-(hydroxymethyl)-1-methylpiperidin-2-one (110 mg, 0.768 mmol) in dichloromethane (1.5 mL) was added triethylamine (1.1 mL, 7.68 mmol) and the reaction mixture cooled to -10 °C. p-Toluene sulfonyl chloride (161 mg, 0.845 mmol) was then added portion-wise over 5 mins and the reaction mixture was allowed to rt and stirred at rt for 4 hours. The reaction mixture was diluted with DCM (2.3 mL) and cellulose filter paper added and the mixture sonicated for 1.5 hour to quench the excess p-toluene sulfonyl chloride. The reaction mixture was filtered and the filtrate washed with water (15 mL), 1 M HCl(aq) (15 mL), NaHCO3(aq. sat., 15 mL), brine (aq. sat., 15 mL), passed through a phase separator and concentrated under reduced pressure to give (1 -methyl-6-oxopiperidin-3-yl)methyl 4- methylbenzenesulfonate (245 mg, 72 %) as a pale-yellow oil.

[0806] UPLC_PH2_MECN_2.6MIN_V1; Rt 1.58 mins., m / z 298.2 [M+H]+

[0807] (R)-(1 -Methyl-2-oxopiperidin-4-yl)methyl 4-methylbenzenesulfonate

[0808] Methyl (R)-1-methyl-2-oxopiperidine-4-carboxylate

[0809] To a suspension of (4R)-1-methyl-2-oxopiperidine-4-carboxylic acid (100 mg) (CAS 2200552-11 -8) and potassium carbonate (264 mg, 3 eq.) in dry DMF (1.3 mL) wasadded iodomethane (0.12 mL, 1.91 mmol) and the reaction mixture stirred at rt for 2 hr. The reaction mixture was diluted with DCM (5 mL), passed through a phase separator and concentrated in vacuo. The residue was purified by flash column chromatography (0-10 % MeOH-EtOAc) to provide methyl (R)-1 -methyl-2-oxopiperidine-4-carboxylate (85 mg, 78 %) as a pale-yellow oil.

[0810] 1H-NMR (400 MHz, Chloroform-D) 53.72 (s, 3H), 3.35-3.31 (m, 2H), 2.95 (s, 3H), 2.87-2.77 (m, 1H), 2.65 (ddd,7= 17.5, 5.6, 1.3 Hz, 1H), 2.57 (dd,7= 17.6, 9.8 Hz, 1H), 2.20-2.11 (m, 1H), 2.04-1.91 (m, 1H).

[0811] (R)-4-(Hydroxymethyl)-1-methylpiperidin-2-one

[0812] Using methyl (R)-1 -methyl-2-oxopiperidine-4-carboxylate (83 mg, 0.485 mmol) with GM6 provided a crude sample of (R)-4-(hydroxymethyl)-1 -methylpiperidin-2-one (65.5 mg, 94 %) used directly in the next step without further purification.

[0813] (R)-(1 -Methyl-2-oxopiperidin-4-yl)methyl 4-methylbenzenesulfonate

[0814] Using (R)-4-(hydroxymethyl)-1-methylpiperidin-2-one (64 mg, 0.447 mmol) and p-toluene sulfonyl chloride (2.0 eq.) in GM5 with purification by flash column chromatography eluting with 0 - 7 % methanol in ethyl acetate provided (R)-(1-methyl-2-oxopiperidin-4-yl)methyl 4-methylbenzenesulfonate (69.9 mg, 53 %) as a colourless oil.

[0815] 1H-NMR (400 MHz, DMSO-D6) 57.81-7.78 (m, 2H), 7.50-7.48 (m, 2H), 3.96-3.88 (m, 2H), 3.28-3.15 (m, 2H), 2.76 (s, 3H), 2.43 (s, 3H), 2.22-2.08 (m, 2H), 1.88 (dd, J = 16.0, 10.5 Hz, 1 H), 1.81 -1.75 (m, 1 H), 1.45-1.35 (m, 1 H).

[0816] UPLC_PH2_MECN_2.6MIN_V1; Rt 1.52 mins., m / z 298.4 [M+H]+

[0817] UPLC_PH9_MECN_2.6MIN_V1; Rt 1.51 mins., m / z 298.3 [M+H]+

[0818] (S)-(1 -Methyl-2-oxopiperidin-4-yl)methyl 4-methylbenzenesulfonate

[0819] Methyl (S)-1-methyl-2-oxopiperidine-4-carboxylate

[0820] To a suspension of (4S)-1-methyl-2-oxopiperidine-4-carboxylic acid (100 mg) (CAS 2306249-79-4) and potassium carbonate (264 mg, 3 eq.) in dry DMF (1.3 mL) wasadded iodomethane (0.12 mL, 1.91 mmol) and the reaction mixture stirred at rt for 2 hr. The reaction mixture was diluted with DCM (5 mL), passed through a phase separator and concentrated in vacuo. The residue was purified by flash column chromatography, eluting with 0 - 10 % methanol in ethyl acetate to provide methyl (S)-1-methyl-2-oxopiperidine-4- carboxylate (93 mg, 85 %) as a pale-yellow oil.

[0821] 1H-NMR (400 MHz, Chloroform-D) 53.72 (s, 3H), 3.35-3.31 (m, 2H), 2.95 (s, 3H), 2.87-2.77 (m, 1H), 2.65 (ddd,7= 17.5, 5.6, 1.3 Hz, 1H), 2.57 (dd,7= 17.6, 9.8 Hz, 1H), 2.20- 2.11 (m, 1H), 2.04-1.91 (m, 1H).

[0822] (S)-4-(Hydroxymethyl)-1-methylpiperidin-2-one

[0823] Using methyl (S)-1 -methyl-2-oxopiperidine-4-carboxylate (83 mg, 0.485 mmol) with GM6 provided a crude sample of (S)-4-(hydroxymethyl)-1 -methylpiperidin-2-one (67.0 mg, 88 %) used directly in the next step without further purification.

[0824] (S)-(1 -Methyl-2-oxopiperidin-4-yl)methyl 4-methylbenzenesulfonate

[0825] Using (S)-4-(hydroxymethyl)-1-methylpiperidin-2-one (65.3 mg, 0.447 mmol) and p-toluene sulfonyl chloride (2.0 eq.) in GM5 with purification by flash column chromatography eluting with 0 - 7 % methanol in ethyl acetate provided (S)-(1-methyl-2-oxopiperidin-4-yl)methyl 4-methylbenzenesulfonate (80.4 mg, 59 %) as a clear colourless oil.

[0826] 1H-NMR (400 MHz, DMSO-D6) 57.81-7.78 (m, 2H), 7.50-7.48 (m, 2H), 3.96-3.88 (m, 2H), 3.28-3.15 (m, 2H), 2.76 (s, 3H), 2.43 (s, 3H), 2.22-2.08 (m, 2H), 1.88 (dd, J = 16.0, 10.5 Hz, 1 H), 1.81 -1.75 (m, 1 H), 1.45-1.35 (m, 1 H).

[0827] UPLC_PH2_MECN_2.6MIN_V1; Rt 1.52 mins., m / z 298.4 [M+H]+

[0828] UPLC_PH9_MECN_2.6MIN_V1; Rt 1.51 mins., m / z 298.3 [M+H]+

[0829] ((R)-1 -Methyl-2-oxo-3-((R)-1 -phenylethyl)hexahydropyrimidin-5-yl)methyl 4-methylbenzenesulfonate

[0830] (R)-N-Benzyl-N-(methoxymethyl)-1 -phenylethan-1 -amine

[0831] To a mixture of (R)-N-benzyl-1-phenylethan-1 -amine (5.0 mL, 23.7 mmol), paraformaldehyde (3.55 g, 59.2 mmol), potassium carbonate (6.54 g, 47.3 mmol) and sodium sulfate (6.72 g, 47.3 mmol) was added dry methanol (24 mL). The reaction mixture was stirredat rt for 72 hr. The reaction mixture was filtered through a phase separator and the solid residue washed with DCM (10 mL). The filtrate was concentrated in vacuo. The mixture was dissolved in Et2O (30 mL), filtered through a pad of celite and Na2SO4with the pad washed with Et2O (3x6 mL). The combined filtrates were concentrated to ~ 20 mL, filtered through a pad of celite and Na2SO4, washed with Et2O (3x6 mL) and concentrated in vacuo to give the crude product as a colourless oil. The crude product was purified by Kugelrohr distillation at 0.4 mbar at 142-145 °C to provide (R)-N-benzyl-N-(methoxymethyl)-1-phenylethan-1 -amine (5.81 g, 96 %) as a colourless oil.

[0832] 1H-NMR (400 MHz, Chloroform-D) 57.41-7.38 (m, 2H), 7.31-7.15 (m, 8H), 4.15 (d, J = 9.6 Hz, 1 H), 4.03 (q, J = 6.6 Hz, 1 H), 3.90 (d, J = 9.6 Hz, 1 H), 3.75-3.67 (m, 2H), 3.13 (s, 3H), 1.42 (d, 7 = 7.1 Hz, 3H).

[0833] (R)-3-(Benzyl((R)-1-phenylethyl)amino)-2-(((tert-butyldimethylsilyl)oxy)methyl)propan-1-ol

[0834] To a solution of lithium bromide (680 mg, 7.83 mmol) in dry DMF (4.2 mL) at rt was added a solution of (S)-2-(diphenyl((trimethylsilyl)oxy)methyl)pyrrolidine (510 mg, 1.57 mmol) in dry DMF (2.3 mL) followed by glacial acetic acid (0.090 mL, 1.57 mmol) and a solution of 3-((trimethylsilyl)oxy)propanal (1.48 g, 7.83 mmol) in dry DMF (2.3 mL) and the reaction mixture cooled to -25 °C. A solution of (R)-N-benzyl-l -phenylethan-1 -amine (1.00 g, 3.92 mmol) in dry DMF (3.4 mL) was added dropwise and the reaction mixture stirred at -25 °C for 2 hr.Methanol (23 mL) was added to the reaction mixture followed by sodium borohydride (296 mg, 7.83 mmol) portion-wise at -25 °C. The reaction mixture was allowed to warm to 0 °C and after effervescence stopped, the reaction mixture was poured into NH4Cl (aq. sat., 25 mL) and Et2O (25 mL) at 0 °C. The aqueous layer was extracted with Et2O (2 x 25 mL) and the combined organics were further washed with brine (aq. sat., 25 mL), dried (Na2SO4), passed through a phase separator and concentrated in vacuo. The crude product was purified by flash column chromatography eluting with 0 - 5 % ethyl acetate in isohexane to provide (R)-3-(benzyl((R)-1 -phenylethyl)amino)-2-(((tert-butyldimethylsilyl)oxy)methyl)propan-1 -ol (1.40 g, 86 %) as a colourless oil.

[0835] 1H-NMR (400 MHz, Chloroform-D) 57.36-7.23 (m, 10H), 3.99 (q, J = 6.9 Hz, 1 H), 3.78 (d, J = 13.3 Hz, 1 H), 3.58 (dd, J = 10.8, 4.4 Hz, 1 H), 3.50 (dd, J = 9.8, 5.3 Hz, 1 H), 3.43 (d, J = 13.3 Hz, 1 H), 3.40 (dd, 1 H), 3.31 (dd, J = 10.5, 6.9 Hz, 1 H), 2.56 (dd, J = 12.8, 4.6 Hz, 1 H), 2.45 (dd, J = 13.3, 10.1 Hz, 1H), 2.10-2.03 (m, 1H), 1.37 (d,7 = 6.9 Hz, 3H), 0.86 (s, 9H), 0.01 (s, 6H).

[0836] UPLC_PH9_MECN_50-97_5MIN_V1; Rt 2.56 mins., m / z 414.5 [M+H]+

[0837] (R)-N-Benzyl-3-((tert-butyldimethylsilyl)oxy)-N-((R)-1-phenylethyl)-2- ((trityloxy)methyl)propan-1 -amine

[0838] To a solution of (R)-3-(benzyl((R)-1 -phenylethyl)amino)-2-(((tert-butyldimethylsilyl)oxy)methyl)propan-1 -ol (1.62 g, 3.92 mmol) in DCM (39 mL) was added trityl chloride (1.75 g, 6.28 mmol), DMAP (96 mg, 0.785 mmol) and NEt3(0.87 mL, 6.28 mmol) sequentially. The reaction mixture was stirred at rt for 72 hr. The reaction mixture was washed with brine (aq. sat., 50 mL), the aqueous layer was extracted with DCM (2 x 20 mL) and the combined organics were dried (Na2SO4), passed through a phase separator and concentrated in vacuo. The crude product was purified by flash column chromatography eluting with 0 - 5 % ethyl acetate in isohexane to provide (R)-N-benzyl-3-((tert-butyldimethylsilyl)oxy)-N-((R)-1-phenylethyl)-2-((trityloxy)methyl)propan-1 -amine (2.32 g, 90 %) as a colourless oil.

[0839] UPLC_PH9_MECN_50-97_5MIN_V1; Rt 3.52 mins., m / z 656.6 [M+H]+

[0840] UPLC_PH2_MECN_50-97_5MIN_V1; Rt 3.27 mins., m / z 656.6 [M+H]+

[0841] (S)-3-(Benzyl((R)-1-phenylethyl)amino)-2-((trityloxy)methyl)propan-1-ol

[0842] To a solution of (R)-N-benzyl-3-((tert-butyldimethylsilyl)oxy)-N-((R)-1 -phenylethyl)-2- ((trityloxy)methyl)propan-1 -amine (2.32 g, 3.54 mmol) in THF (7.1 mL) was added TBAF (7.1 mL, 7.07 mmol) and the reaction mixture stirred at rt for 6 hrs. The reaction mixture was diluted with EtOAc (10 mL) and water (20 mL). The organics were separated and the aqueous layer extracted with EtOAc (2x 10 mL). The combined organics were dried (Na2SO4), passedthrough a phase separator and concentrated in vacuo. The crude product was purified by flash column chromatography eluting with 0 - 20 % ethyl acetate in isohexane to provide (S)-3-(benzyl((R)-1 -phenylethyl)amino)-2-((trityloxy)methyl)propan-1 -ol (1.73 g, 91 %) as a colourless oil.

[0843] UPLC_PH9_MECN_50-97_5MIN_V1; Rt 2.45 mins., m / z 542.4 [M+H]+

[0844] UPLC_PH2_MECN_50-97_5MIN_V1; Rt 1.52 mins., m / z 542.4 [M+H]+

[0845] (S)-3-Azido-N-benzyl-N-((R)-1-phenylethyl)-2-((trityloxy)methyl)propan-1 -amine

[0846] To a solution of (S)-3-(benzyl((R)-1-phenylethyl)amino)-2-((trityloxy)methyl)propan-1-ol (1.65 g, 3.05 mmol) in THF (15 mL) was added DBU (1.4 mL, 9.14 mmol) followed by 2-azido-1,3-dimethylimidazolinium hexafluorophosphate (1.74 g, 6.09 mmol). The reaction mixture was stirred at rtfor 10 mins then DBU (2.8 mL, 18.28 mmol) added, followed by 2-azido-1,3-dimethylimidazolinium hexafluorophosphate (3.48 g, 12.18 mmol). The reaction mixture was stirred at rtfor 10 mins, diluted with water (100 mL) and DCM (30 mL). The organics were separated and the aqueous layer extracted with DCM (3x10 mL). The combined organics were washed with brine (aq. sat.,100 mL), passed through a phase separator and concentrated in vacuo to provide the crude product. The crude product was purified by flash column chromatography eluting with 0 - 10 % ethyl acetate in isohexane to provide (S)-3-azido-N-benzyl-N-((R)-1 -phenylethyl)-2-((trityloxy)methyl)propan-1 -amine (1.17 g, 68 %) as a white solid.

[0847] UPLC_PH9_MECN_50-97_5MIN_V1; Rt 2.85 mins., m / z 567.4 [M+H]+

[0848] UPLC_PH2_MECN_50-97_5MIN_V1; Rt 2.56 mins., m / z 567.4 [M+H]+

[0849] (S)-3-Azido-N-((R)-1 -phenylethyl)-2-((trityloxy)methyl)propan-1 -amine

[0850] To a stirred solution of (S)-3-azido-N-benzyl-N-((R)-1 -phenylethyl)-2- ((trityloxy)methyl)propan-1 -amine (1.10 g, 1.94 mmol) in acetonitrile (33 mL) and water (6.5mL) was added CAN (1.76 g, 3.88 mmol) and the reaction mixture stirred at rtfor 15 mins. CAN (1.76 g, 3.88 mmol) was added and the reaction mixture stirred fora further 15 mins. To the reaction mixture was added NaHCO3(aq. sat., 80 mL) and the reaction mixture stirred for 10 mins at rt. The resultant mixture was extracted with DCM (3 x 30 mL) and the combined organics were passed through a phase separator and concentrated in vacuo to provide the crude product. The crude product was purified by flash column chromatography eluting with 0 - 5 % methanol in dichloromethane to provide (S)-3-azido-N-((R)-1 -phenylethyl)-2-((trityloxy)methyl)propan-1 -amine (687 mg, 74 %) as a white solid.

[0851] UPLC_PH9_MECN_50-97_5MIN_V1; Rt 2.42 mins., m / z 477.3 [M+H]+

[0852] UPLC_PH2_MECN_50-97_5MIN_V1; Rt0.71 mins., m / z 477.3 [M+H]+

[0853] (R)-N1-((R)-1-Phenylethyl)-2-((trityloxy)methyl)propane-1,3-diamine

[0854] To a solution of (S)-3-azido-N-((R)-1-phenylethyl)-2-((trityloxy)methyl)propan-1-amine (686 mg, 1.44 mmol) in DCM (2.5 mL) was added trimethylphosphine (0.16 mL, 1.58 mmol) and the reaction mixture stirred at rt for 5 mins then water (0.50 mL) was added and the reaction mixture was stirred at rt for 10 mins. The reaction mixture was concentrated in vacuo, resuspended in MeOH and purified by catch-release cartridge (Biotage SCX-2) washing with methanoland elutingwith 0.7M ammonia in methanol to provide (R)-N1-((R)-1- phenylethyl)-2-((trityloxy)methyl)propane-1,3-diamine (642 mg, 99 %) as a yellow oil.

[0855] 1H-NMR (400 MHz, Chloroform-D) 57.40-7.19 (m, 20H), 3.69 (q, J = 6.7 Hz, 1 H), 3.08 (dd, J = 9.4, 5.3 Hz, 1 H), 3.03 (dd, J = 9.2, 5.0 Hz, 1 H), 2.79 (dd, J = 12.4, 6.0 Hz, 1 H), 2.73 (dd, J = 12.6, 6.2 Hz, 1H), 2.61 (dd, J = 11.7, 6.2 Hz, 1 H), 2.41 (dd, 7= 11.4, 6.9 Hz, 1 H), 1.87-1.78 (m, 1H), 1.31 (d, 7 = 6.4 Hz, 3H).

[0856] UPLC_PH2_MECN_2.6MIN_V1; Rt 1.34 mins., m / z 451.5 [M+H]+

[0857] (R)-1-((R)-1-Phenylethyl)-5-((trityloxy)methyl)tetrahydropyrimidin-2(1 H)-one

[0858] To a solution of (R)-N1-((R)-1 -phenylethyl)-2-((trityloxy)methyl)propane-1,3-diamine (575 mg, 1.28 mmol) in DCM (10 mL) at 0 °C was added pyridine (0.36 mL, 4.47 mmol) and the reaction mixture stirred for 5 mins. A solution of triphosgene (170 mg, 0.574 mmol) in DCM (3.0 mL) was added dropwise over 5 mins, and the reaction mixture stirred at 0 °C for 15 mins. The reaction mixture was quenched with NaHCO3(aq. sat., 20 mL) and the aqueous layer extracted with DCM (2x10 mL). The combined organics were washed with brine (aq. sat., 20 mL) passed through a phase separator and concentrated in vacuo. The crude product was purified by flash column chromatography eluting with 0 - 5 % methanol in ethyl acetate to provide (R)-1-((R)-1-phenylethyl)-5-((trityloxy)methyl)tetrahydropyrimidin-2(1 H)-one (296 mg, 49 %) as a yellow foam.

[0859] UPLC_PH2_MECN_2.6MIN_V1; Rt 2.09 mins., m / z 477.4 [M+H]+

[0860] UPLC_PH9_MECN_2.6MIN_V1; Rt 2.13 mins., m / z 477.4 [M+H]+

[0861] (R)-1-Methyl-3-((R)-1-phenylethyl)-5-((trityloxy)methyl)tetrahydropyrimidin-2(1 H)-one

[0862] To a solution of (R)-1-((R)-1-phenylethyl)-5-((trityloxy)methyl)tetrahydropyrimidin-2(1 H)-one (296 mg, 0.621 mmol) in DMF (3.1 mL) at 0 °C was added sodium hydride (60 % dispersion in oil) (124 mg, 3.11 mmol) and the reaction mixture stirred at 0 °C for 10 mins, Iodomethane (0.19 mL, 3.11 mmol) was added dropwise, and the reaction mixture was stirred at 0 °C for 10 mins and then allowed to warm to room temperature and stirred at rt for 2h. The reaction mixture was cooled to 0 °C and quenched with the dropwise addition of cold NH4Cl (aq. sat., 30 mL). The aqueous layer was extracted with EtOAc (3x10 mL). The combined organics were washed with brine (aq. sat., 20 mL), passed through a phase separator and concentrated in vacuo. The crude product was purified by flash column chromatography eluting with 0 - 100 % ethyl acetate in isohexane to provide (R)-1-methyl-3-((R)-1 -phenylethyl)-5-((trityloxy)methyl)tetrahydropyrimidin-2(1 H)-one (310 mg, quant.) as a yellow oil.

[0863] 1H-NMR (400 MHz, DMSO-D6) 57.39-7.23 (m, 20H), 5.61 (q, J = 7.0 Hz, 1 H), 3.18 (dd, J = 11.4, 4.6 Hz, 1 H), 3.01-2.95 (m, 2H), 2.87-2.77 (m, 3H), 2.79 (s, 3H), 2.11 -2.01 (m, 1 H), 1.30 (d, 7 = 7.3 Hz, 3H).

[0864] UPLC_PH2_MECN_2.6MIN_V1; Rt 2.15 mins., m / z 491.5 [M+H]+

[0865] UPLC_PH9_MECN_2.6MIN_V1; Rt2.21 mins., m / z 491.4 [M+H]+

[0866] (R)-5-(Hydroxymethyl)-1-methyl-3-((R)-1-phenylethyl)tetrahydropyrimidin-2(1 H)-one

[0867] To a solution of (R)-1 -methyl-3-((R)-1 -phenylethyl)-5- ((trityloxy)methyl)tetrahydropyrimidin-2(1 H)-one (307 mg, 0.626 mmol) in DCM (10 mL) was added triethylsilane (0.50 mL, 3.13 mmol) followed by trifluoroacetic acid (0.50 mL) dropwise. The reaction mixture was stirred at rtfor 10 mins. The reaction mixture was diluted with DCM (10 mL), carefully basified with NaHCO3(aq. sat.) and the organics were separated. The aqueous layer was back extracted with DCM (2x5 mL). The combined organics were washed with brine (aq. sat., 10 mL), passed through a phase separator and concentrated in vacuo to provide the crude product. The crude product was purified by flash column chromatography eluting with 0 - 5 % methanol in ethyl acetate to provide (R)-5-(hydroxymethyl)-1-methyl-3- ((R)-1-phenylethyl)tetrahydropyrimidin-2(1 H)-one (113 mg, 73 %) as a colourless oil.

[0868] 1H-NMR (400 MHz, DMSO-D6) 57.36-7.31 (m, 2H), 7.26-7.22 (m, 3H), 5.67 (q, J = 7.2 Hz, 1 H), 4.66 (t, J = 5.0 Hz, 1 H), 3.32-3.24 (m, 2H), 3.18 (ddd, J = 11.4, 5.0, 1.4 Hz, 1 H), 2.99 (dd, J = 11.4, 9.2 Hz, 1 H), 2.87 (dd, J = 11.4, 9.2 Hz, 1 H), 2.83 (s, 3H), 2.83-2.78 (m, 1 H), 1.97- 1.86 (m, 1 H), 1.39 (d, J = 7.3 Hz, 3H).

[0869] UPLC_PH2_MECN_2.6MIN_V1; Rt 1.34 mins., m / z 249.4 [M+H]+

[0870] UPLC_PH9_MECN_2.6MIN_V1; Rt 1.33 mins., m / z 249.4 [M+H]+

[0871] ((R)-1-Methyl-2-oxo-3-((R)-1-phenylethyl)hexahydropyrimidin-5-yl)methyl4- methylbenzenesulfonate

[0872] Using (R)-5-(Hydroxymethyl)-1-methyl-3-((R)-1-phenylethyl)tetrahydropyrimidin- 2(1 H)-one (110 mg, 0.441 mmol) in GM5 with 2.0 eq. p-toluene sulfonyl chloride andpurification by flash column chromatography eluting with 0 - 100 % ethyl acetate in isohexane provided ((R)-1-methyl-2-oxo-3-((R)-1-phenylethyl)hexahydropyrimidin-5-yl)methyl4-methylbenzenesulfonate (165 mg, 93 %) as a colourless oil.7.47 (m, 2H), 7.35-7.31 (m, 2H), 7.26-7.19 (m, 3H), 5.61 (q,7 = 7.2 Hz, 1H), 3.98 (d,7 = 6.9 Hz, 2H), 3.19 (dd, J = 11.9, 5.0 Hz, 1 H), 2.96 (dd, 7= 11.7, 7.6 Hz, 1 H), 2.84 (dd, 7= 11.9, 7.8 Hz, 1 H), 2.76 (s, 3H), 2.69 (dd, 7 = 11.7, 3.9 Hz, 1 H), 2.43 (s, 3H), 2.23-2.13 (m, 1 H), 1.29 (d, 7 = 7.3 Hz, 3H).

[0874] UPLC_PH2_MECN_2.6MIN_V1; Rt 1.80 mins., m / z 403.6 [M+H]+

[0875] UPLC_PH9_MECN_2.6MIN_V1; Rt 1.82 mins., m / z 403.8 [M+H]+

[0876] Synthesis of (R)-(3-methyl-2-oxo-1,3-oxazinan-5-yl)methyl 4-methylbenzenesulfonate

[0877] (R)-3-Amino-2-(((tert-butyldimethylsilyl)oxy)methyl)propan-1-ol

[0878] To a solution of (R)-3-(benzyl((R)-1 -phenylethyl)amino)-2-(((tert-butyldimethylsilyl)oxy)methyl)propan-1 -ol (1.62 g, 3.92 mmol) in ethanol (39 mL) was added 10 % palladium on carbon (208 mg, 0.196 mmol), 20 % palladium hydroxide on carbon (137 mg, 0.196 mmol), and ammonium formate (2.48 g, 39.3 mmol). The reaction mixture was evacuated and backfilled with N2three times and then stirred at 60 °C for 1 hour under N2. The reaction mixture was allowed to cool to rt, filtered through celite, the celite was washed with methanol and the filtrate concentrated in vacuo to provide (R)-3-amino-2-(((tert-butyldimethylsilyl)oxy)methyl)propan-1 -ol (804 mg, 94 %) as a yellow oil.

[0879] 1H-NMR (400 MHz, Chloroform-D) 53.83 (dd, 7= 11.0, 4.6 Hz, 1 H), 3.77 (dd, J = 10.8, 6.2 Hz, 1H), 3.69 (dd, J = 10.1, 6.0 Hz, 1H), 3.61 (dd,7= 10.1, 6.0 Hz, 1H), 2.97 (dd, J= 12.4, 4.6 Hz, 1 H), 2.86 (dd, J = 12.4, 8.2 Hz, 1 H), 2.15 (s, 3H), 1.84-1.75 (m, 1 H), 0.89 (s, 9H), 0.05 (s, 6H).

[0880] (R)-5-(((tert-Butyldimethylsilyl)oxy)methyl)-1,3-oxazinan-2-one

[0881] To a solution of (R)-3-amino-2-(((tert-butyldimethylsilyl)oxy)methyl)propan-1-ol (802 mg, 3.66 mmol) in DCM (28 mL) at 0 °C was added pyridine (1.0 mL, 12.8 mmol) and the reaction mixture stirred for 5 mins. A solution of triphosgene, (488 mg, 1.64 mmol) in DCM (17 mL) was added dropwise over 5 mins and the reaction mixture stirred at 0 °C for 30 mins then allowed to warm to rt and stirred for 16 hr at rt. The reaction mixture was quenched with water (30 mL) and the aqueous layer extracted with DCM (2x 10 mL). The combined organic extracts were dried (Na2SO4) passed through a phase separator and concentrated in vacuo. The crude product was purified by flash column chromatography eluting with 0 - 100 % ethyl acetate in isohexane to provide (R)-5-(((tert-butyldimethylsilyl)oxy)methyl)-1,3-oxazinan-2-one (580 mg, 65 %) as a tan solid.

[0882] 1H-NMR (400 MHz, Chloroform-D) 55.13 (s, 1 H), 4.33 (ddd, 7= 11.2, 3.9, 1.4 Hz, 1 H), 4.17 (dd, 7= 11.0, 7.8 Hz, 1 H), 3.66 (d, 7 = 6.4 Hz, 2H), 3.44-3.38 (m, 1 H), 3.25 (ddd, 7= 11.0, 7.7, 1.3 Hz, 1 H), 2.30-2.21 (m, 1 H), 0.89 (s, 9H), 0.05 (s, 6H).

[0883] (R)-5-(((tert-Butyldimethylsilyl)oxy)methyl)-3-methyl-1,3-oxazinan-2-one

[0884] To a solution of (R)-5-(((tert-butyldimethylsilyl)oxy)methyl)-1,3-oxazinan-2-one (578 mg, 2.36 mmol) in DMF (7.9 mL) at 0 °C was added sodium hydride (60 % dispersion in oil, 471 mg, 11.8 mmol) and the reaction mixture was stirred at 0 °C for 10 mins, Iodomethane (0.73 mL, 11.8 mmol) was added dropwise over 1 minute, and the reaction mixture was allowed to rt and stirred at rt for 3 hours. The reaction mixture was quenched by dropwise addition tocold NH4Cl (aq. sat., 30 mL) and the reaction mixture was extracted with EtOAc (3x 10 mL). The combined organic extracts were washed with brine (aq. sat., 30 mL), passed through a phase separator and concentrated in vacuo. The crude product was purified by flash column chromatography eluting with 0 - 80 % ethyl acetate in isohexane to provide (R)-5-(((tert-butyldimethylsilyl)oxy)methyl)-3-methyl-1,3-oxazinan-2-one (577 mg, 94 %) as a yellow oil.

[0885] 1H-NMR (400 MHz, Chloroform-D) 54.27 (ddd, 7= 10.8, 3.7, 1.1 Hz, 1H), 4.11 (dd,7 = 11.0, 7.8 Hz, 1 H), 3.64 (d, J = 6.4 Hz, 2H), 3.30 (ddd, J = 11.4, 6.0, 1.4 Hz, 1 H), 3.20 (dd, J = 11.6, 7.7 Hz, 1 H), 2.98 (s, 3H), 2.35-2.26 (m, 1 H), 0.89 (s, 9H), 0.05 (s, 6H).

[0886] (S)-5-(Hydroxymethyl)-3-methyl-1,3-oxazinan-2-one

[0887] To a solution of (R)-5-(((tert-butyldimethylsilyl)oxy)methyl)-3-methyl-1,3-oxazinan-2-one (575 mg, 2.22 mmol) in THF (5.0 mL) was added TBAF (4.4 mL, 4.43 mmol) and the reaction mixture stirred at rt for 6 hrs. The reaction mixture was concentrated in vacuo, resuspended in EtOAc (10 mL) and filtered. The filtrate was dried (Na2SO4), passed through a phase separator and concentrated in vacuo. The crude product was purified by flash column chromatography eluting with 0-25 % methanol in ethyl acetate to provide (S)-5-(hydroxymethyl)-3- methyl- 1,3-oxazinan-2-one (327 mg, quant.) as a yellow oil that solidified upon standing to give an off-white solid.

[0888] 1 H-NMR (400 MHz, Chloroform-D) 54.30 (dq, J = 11.0, 1.5 Hz, 1 H), 4.14 (dd, J = 11.2, 8.0 Hz, 1 H), 3.74-3.67 (m, 2H), 3.37 (qd, J = 5.9, 1.2 Hz, 1 H), 3.20 (dd, 7= 11.7, 7.1 Hz, 1 H), 2.97 (s, 3H), 2.34 (qt, J = 10.2, 3.4 Hz, 1 H).

[0889] (R)-(3-Methyl-2-oxo-1,3-oxazinan-5-yl)methyl 4-methylbenzenesulfonate

[0890] Using (S)-5-(hydroxymethyl)-3-methyl-1,3-oxazinan-2-one (325 mg, 2.24 mmol) in GM5 with p-toluene sulfonyl chloride (2.0 eq.) and purification by flash column chromatography eluting with 0 - 100 % ethyl acetate in isohexane provided (R)-(3-methyl-2-oxo-1,3-oxazinan-5-yl)methyl 4-methylbenzenesulfonate (561 mg, 84 %) as a colourless oil that solidified upon standing to provide a white solid.

[0891] 1H-NMR (400 MHz, Chloroform-D) 57.80-7.77 (m, 2H), 7.39-7.37 (m, 2H), 4.24 (ddd, J = 11.2, 3.4, 0.9 Hz, 1 H), 4.09-4.03 (m, 3H), 3.40 (ddd, J = 12.0, 5.6, 1.0 Hz, 1 H), 3.18 (ddd, J = 11.9, 6.2, 1.1 Hz, 1 H), 2.94 (s, 3H), 2.56-2.49 (m, 1 H), 2.47 (s, 3H)

[0892] UPLC_PH2_MECN_2.6MIN_V1; Rt 1.47 mins., m / z 300.3 [M+H]+

[0893] UPLC_PH9_MECN_2.6MIN_V1; Rt 1.48 mins., m / z 300.2 [M+H]+

[0894] Synthesis of benzyl (R)-2-oxo-5-((tosyloxy)methyl)piperidine-1 -carboxylate

[0895] (R)-1-((Benzyloxy)carbonyl)-6-oxopiperidine-3-carboxylic acid

[0896] To a solution of (R)-1 -((benzyloxy)carbonyl)piperidine-3-carboxylic acid (1.00 g, 3.80 mmol) in EtOAc (24 mL) was added water (24 mL) followed by sodium periodate (3.25 g, 15.2 mmol) and ruthenium (III) chloride monohydrate (86 mg, 0.380 mmol). The reaction mixture was stirred at rt for 2 hours. To the reaction mixture was added water (20 mL) and the reaction mixture filtered through celite. The organics were then separated from the filtrate and the aqueous layer back extracted with EtOAc (2 x 20 mL). The combined organic extracts were washed with brine (aq. sat., 50 mL), passed through a phase separator and concentrated in vacuo. The crude product was purified by flash column chromatography eluting with 0- 100 % ethyl acetate in isohexane to provide (R)-1-((benzyloxy)carbonyl)-6-oxopiperidine-3- carboxylic acid (430 mg, 41 %) as a brown oil.

[0897] 1H-NMR (400 MHz, Chloroform-D) 57.44-7.30 (m, 5H), 5.29 (s, 2H), 4.05 (dd,7 = 13.5, 5.3 Hz, 1 H), 3.97 (dd, J = 13.3, 7.8 Hz, 1 H), 2.98-2.91 (m, 1 H), 2.68 (dt, J = 17.2, 6.5 Hz, 1 H), 2.56 (ddd, J= 17.2, 8.2, 6.6 Hz, 1H), 2.23-2.08 (m, 2H), 2.03-1.54 (m, 1H).

[0898] UPLC_PH2_MECN_2.6MIN_V1; Rt 1.37 mins., m / z 276.3 [M-H]-

[0899] UPLC_PH9_MECN_2.6MIN_V1; Rt 1.03 mins., m / z 276.3 [M-H]-

[0900] Benzyl (R)-5-(hydroxymethyl)-2-oxopiperidine-1 -carboxylate

[0901] To a solution of (R)-1-((benzyloxy)carbonyl)-6-oxopiperidine-3-carboxylic acid (150 mg, 0.541 mmol) in THF (1.8 mL) was added NEt3(0.30 mL, 2.16 mmol) and the reaction mixture cooled to -40 °C. Isobutyl Chloroformate (0.14 mL, 1.08 mmol) was added dropwise over 5 mins and the reaction mixture stirred at -40 °C for 20 mins then isobutyl chloroformate (0.07 mL, 0.54 mmol) was added and reaction stirred for a further 10 mins. Then the reaction mixture was diluted with methanol (1.8 mL), sodium borohydride (82 mg, 2.16 mmol) was added and the reaction mixture stirred at -40 °C for 1 hour. The reaction mixture was quenched with NH4Cl (aq. sat., 10 mL) and extracted with EtOAc (3x5 mL). The combined organics were washed with brine (aq. sat., 10 mL), passed through a phase separator and concentrated in vacuo. The crude product was purified by flash column chromatography elutingwith 0 - 100 % ethyl acetate in isohexane to provide benzyl (R)-5-(hydroxymethyl)-2-oxopiperidine-1 -carboxylate (34.8 mg, 24 %) as a colourless oil.

[0902] UPLC_PH2_MECN_2.6MIN_V1; Rt 1.37 mins., m / z 264.1 [M+H]+

[0903] UPLC_PH9_MECN_2.6MIN_V1; Rt 1.36 mins., m / z 264.1 [M+H]+

[0904] Benzyl (R)-2-oxo-5-((tosyloxy)methyl)piperidine-1 -carboxylate

[0905] Using benzyl (R)-5-(hydroxymethyl)-2-oxopiperidine-1-carboxylate (33 mg, 0.127 mmol) in GM5 with p-toluene sulfonyl chloride (2.0 eq.) and purification by flash column chromatography elutingwith 0 - 70 % ethyl acetate in isohexane provided benzyl (R)-2-oxo-5-((tosyloxy)methyl)piperidine-1 -carboxylate (31.9 mg, 60 %) as a colourless oil.

[0906] 1H-NMR (400 MHz, Chloroform-D) 57.78-7.75 (m, 2H), 7.44-7.31 (m, 7H), 5.27 (s, 2H), 3.99 (dd, J = 9.8, 5.7 Hz, 1 H), 3.94-3.89 (m, 2H), 3.42 (dd, J = 13.3, 9.2 Hz, 1 H), 2.57 (ddd, J = 17.3, 6.3, 5.2 Hz, 1 H), 2.48 (ddd, 1 H), 2.45 (s, 3H), 2.35-2.24 (m, 1 H), 2.00-1.88 (m, 1 H), 1.57-1.48 (m, 1H)

[0907] UPLC_PH2_MECN_2.6MIN_V1; Rt 1.82 mins., m / z 418.2 [M+H]+

[0908] UPLC_PH9_MECN_2.6MIN_V1; Rt 1.84 mins., m / z 418.3 [M+H]+

[0909] Synthesis of benzyl (R)-3-methyl-2-oxo-5-((tosyloxy)methyl)imidazolidine-1-carboxylate

[0910] 1 -Benzyl 5-methyl (R)-3-methyl-2-oxoimidazolidine-1,5-dicarboxylate

[0911] 1 -Benzyl 5-methyl (R)-2-oxoimidazolidine-1,5-dicarboxylate (100 mg, 0.359 mmol) and potassium carbonate (99 mg, 0.719 mmol) were combined in dimethoxyethane (2.0 mL) and stirred at RT for 10 min. To this mixture was added iodomethane (0.027 mL, 0.431 mmol) and the reaction mixture was stirred at 50 °C for 18 hours. The reaction mixture was allowed to cool to room temperature, then water (2 mL) was added, followed by EtOAc (5 mL). The layers were separated and the aqueous phase extracted with EtOAc (3x5 mL). The combined organic fractions were washed with brine (aq. sat., 5 mL), passed through a phase separator and concentrated under reduced pressure to give 1 -benzyl 5-methyl (R)-3-methyl-2-oxoimidazolidine-1,5-dicarboxylate (100 mg, 95 %) as a yellow solid.

[0912] UPLC_PH2_MECN_2.6MIN_V1, RT 1.48 min., m / z 293.3 [M+H]+

[0913] Benzyl (R)-5-(hydroxymethyl)-3-methyl-2-oxoimidazolidine-1 -carboxylate

[0914] To a solution of 1 -benzyl 5-methyl (R)-3-methyl-2-oxoimidazolidine-1,5-dicarboxylate (100 mg, 0.342 mmol) in ethanol (2.0 mL) was slowly added sodium borohydride (39 mg, 1.03 mmol) and the resulting mixture was stirred at room temperature under nitrogen atmosphere for 3 h. Sodium borohydride (13 mg, 0.342 mmol) was added and the reaction stirred at room temperature for a further 18 h. The reaction was quenched with water (2 mL) and the product extracted with EtOAc (3x10 mL). The organic fractions were combined, washed with brine (aq. sat., 5 mL) and passed through a phase separator. The resulting solution was concentrated under reduced pressure to give benzyl (R)-5-(hydroxymethyl)-3-methyl-2-oxoimidazolidine-1 -carboxylate (92 mg, 92 %) as a yellow oil.

[0915] UPLC_PH2_MECN_2.6MIN_V1, RT1.31 min., m / z 265.3 [M+H]+

[0916] Benzyl (R)-3-methyl-2-oxo-5-((tosyloxy)methyl)imidazolidine-1 -carboxylate

[0917] To a microwave vial was added benzyl (R)-5-(hydroxymethyl)-3-methyl-2-oxoimidazolidine-1 -carboxylate (90 mg, 0.341 mmol), p-toluene sulfonyl chloride (58 mg, 0.306 mmol) and triethylamine (0.71 mL, 5.11 mmol) in dry dichloromethane (5.0 mL) and the reaction mixture stirred at rt for 18 h. The reaction mixture was concentrated under reduced pressure and the crude product purified by flash column chromatography, elutingwith 0 - 100 % ethyl acetate in isohexane to give benzyl (R)-3-methyl-2-oxo-5-((tosyloxy)methyl)imidazolidine-1 -carboxylate (40 mg, 28 %) as a colourless residue.

[0918] UPLC_PH2_MECN_2.6MIN_V1, RT 1.72 min., m / z 419.3 [M+H]+

[0919] Synthesis of (R) and (S)-(2-methyl-1,1 -dioxidoisothiazolidin-4-yl)methyl 4-methylbenzenesulfonates

[0920] (R)-1-(Benzyloxy)-3-(methylamino)propan-2-ol

[0921] (R)-2-((Benzyloxy)methyl)oxirane (0.93 mL, 6.09 mmol) was added dropwise to a solution of methylamine (567 mg, 18.3 mmol) in dichloromethane (10 mL) at 0 °C and the reaction mixture stirred at room temperature for 20 minutes. The reaction mixture was concentrated under reduced pressure and the crude product purified by reversed-phase flash column chromatography (Teledyne RediSep Gold C18100g) elutingwith 0 - 70 % acetonitrile in aqueous ammonium carbonate (pH9) to give (2R)-1 -benzyloxy-3-(methylamino)propan-2-ol (740 mg, 3.79 mmol, 62.23 %) as a colourless oil.

[0922] UPLC_pH9_MECN_2.6min_V1, Rt 1.29 min., m / z 196.3 [M+H]+

[0923] (S)-4-((Benzyloxy)methyl)-2-methylisothiazolidine 1,1 -dioxide

[0924] (2R)-1 -Benzyloxy-3-(methylamino)propan-2-ol (740 mg, 3.79 mmol) was dissolved in dichloromethane (20 mL). Triethylamine (2.5 mL, 18.0 mmol) was added, methanesulfonyl chloride (1.4 mL, 18.0 mmol) was then added dropwise and the mixture stirred at room temperature for 30 minutes. The reaction mixture was quenched with sodium bicarbonate solution (aq. sat.), diluted with water (20 mL) and the layers separated. The aqueous layer was extracted with dichloromethane (2 x 20 mL) and the combined organic extracts dried, filtered and concentrated in vacuo. The residue was dissolved in tetrahydrofuran (10 mL) under nitrogen and cooled to -78 °C before n-butyllithium (9.4 mL, 15.0 mmol) was added dropwise and the reaction stirred at -78 °C for 30 minutes. The reaction mixture was allowed to warm to room temperature and stirred at rt for 2 hours before being quenched with ammonium carbonate (aq. sat., 10 mL) and diluted with dichloromethane (20 mL). The layers were separated and the aqueous layer further extracted with dichloromethane (2 x 20 mL).The combined organic extracts were dried, filtered and concentrated in vacuo. The crude product was purified by flash column chromatography, elutingwith 0 - 50 % ethyl acetate in isohexane to give (S)-4-((benzyloxy)methyl)-2-methylisothiazolidine 1,1 -dioxide (145 mg, 9.46 %) as a colourless oil.

[0925] UPLC_pH9_MECN_2.6min_V1, Rt 1.55 min., m / z 256.2 [M+H]+

[0926] (S)-(2-Methyl-1,1-dioxidoisothiazolidin-4-yl)methyl4-methylbenzenesulfonate

[0927] (S)-4-((Benzyloxy)methyl)-2-methylisothiazolidine 1,1 -dioxide (145 mg, 0.57 mmol) was dissolved in ethanol (30 mL) and hydrogenated using an H-cube, with a 10 % palladium on carbon catalyst cartridge, flow rate 1 mL / min, pressure 10 bar, residence time 6 hours (recirculating flow). The solution was then concentrated in vacuo and the residue used in the next step without further purification. The crude alcohol was then used in GM5to give (S)-(2- methyl-1,1-dioxidoisothiazolidin-4-yl)methyl 4-methylbenzenesulfonate (80 mg, 0.25 mmol, 41 % over 2 steps) as a colourless oil.

[0928] UPLC_pH9_MECN_2.6min_V1, Rt 1.54 min., m / z 320.1 [M+H]+

[0929] (S)-1-(benzyloxy)-3-(N-methylmethylsulfonamido)propan-2-yl methanesulfonate

[0930] Methylamine hydrochloride (2.47 g, 36.5 mmol) and potassium carbonate (8.42 g, 60.9 mmol) were dissolved in methanol (10 mL) and the mixture stirred for 10 minutes at rt. The reaction was cooled to 0 °C before (S)-2-((benzyloxy)methyl)oxirane (1.9 mL, 12.2 mmol) was added dropwise and the reaction stirred at room temperature for 16 hours. The reaction mixture was concentrated in vacuo and redissolved in dichloromethane (20 mL). Triethylamine (5.0 mL, 36.0 mmol) was added, followed by methanesulfonyl chloride (2.8 mL, 36.0 mmol) dropwise and the reaction stirred for 30 minutes at room temperature. The reaction was quenched with sodium bicarbonate solution (aq. sat.), separated and the aqueous layer extracted with dichloromethane. The combined organic extracts were dried, filtered, concentrated in vacuo and the crude product purified by flash column chromatography eluting with 20-70 % ethyl acetate in isohexane to give (S)-l-(benzyloxy)-3-(N-methylmethylsulfonamido)propan-2-yl methanesulfonate (2080 mg, 49 %) as a colourless oil.

[0931] UPLC_pH9_MECN_2.6min_V1, Rt 1.59 min., m / z 352.2 [M+H]+

[0932] (R)-4-((Benzyloxy)methyl)-2-methylisothiazolidine 1,1 -dioxide

[0933] (S)-l-(Benzyloxy)-3-(N-methylmethylsulfonamido)propan-2-yl methanesulfonate (2080 mg, 5.92 mmol) was dissolved in tetrahydrofuran (20 mL) under nitrogen and cooled to -78 °C before n-butyllithium (9.2 mL, 14.8 mmol) was added dropwise and the mixture allowed to warm to room temperature and stirred at rt for 16 hours. The reaction mixture was quenched with ammonium chloride (aq. sat., 20 mL), diluted with dichloromethane (50 mL), and separated. The aqueous layer was extracted with dichloromethane (2 x 50 mL) and the combined organic layers dried, filtered and concentrated in vacuo. The residue was purified by flash column chromatography, eluting with 20-70 % ethyl acetate-ethanol (3:1) in isohexane to give (R)-4-((benzyloxy)methyl)-2-methylisothiazolidine 1,1-dioxide (500 mg, 33 %) as a yellow oil.

[0934] UPLC_pH9_MECN_2.6min_V1, Rt 1.58 min., m / z 256.3 [M+H]+

[0935] (R)-(2-Methyl-1,1 -dioxidoisothiazolidin-4-yl)methyl 4-methylbenzenesulfonate

[0936] (R)-4-((Benzyloxy)methyl)-2-methylisothiazolidine 1,1 -dioxide (500 mg, 1.96 mmol) was dissolved in ethanol (70 mL) and hydrogenated using a H-cube, with a 10 % palladium on carbon catalyst cartridge, flow rate 1 mL / min, pressure 20 bar, residence time 20 hours (recirculating flow). The solution was then concentrated in vacuo and used in the next step without further purification. The crude alcohol was then used in GM5 to give (R)-(2-methyl-1,1 -dioxidoisothiazolidin-4-yl)methyl 4-methylbenzenesulfonate (60 mg, 10 % over 2 steps) as a colourless oil.

[0937] UPLC_pH9_MECN_2.6min_V1, Rt 1.56 min., m / z 320.1 [M+H]+

[0938] Synthesis of (4S)-3-methyl-l-(2-nitrophenyl)sulfonyl-2-oxo-imidazolidin-4-yl]methyl 4-methylbenzenesulfonate

[0939] O1 -Benzyl O5-methyl (5S)-3-(2-nitrophenyl)sulfonyl-2-oxo-imidazolidine-1,5-dicarboxylate

[0940] Methyl (S)-3-Cbz-2-oxoimidazolidine-4-carboxylate (400 mg, 1.44mmol) and potassium carbonate (238 mg, 1.73 mmol) were combined in 1,4-dioxane (2.0 mL) and stirred at RT for 10 min. To this mixture was added 2-nitrobenzenesulfonyl chloride (637 mg, 2.88 mmol) and the reaction mixture was stirred at 50 °C for 18 hours. The reaction mixture was cooled to RT, then diluted with EtOAc (10 mL) and water (5 mL) and the layers separated. The aqueous layer was extracted with EtOAc (3x 10 mL), and the organic layers combined, washed with brine (aq. sat., 2x 10 mL), dried, filtered, concentrated in vacuo, and the crude product purified by flash column chromatography, elutingwith 0 - 100 % ethyl acetate in isohexane to give O1 -benzyl O5-methyl (5S)-3-(2-nitrophenyl)sulfonyl-2-oxo-imidazolidine-1,5-dicarboxylate (370 mg, 56 %) as a yellow solid.

[0941] UPLC_pH2_MECN_2.6min_V1, Rt 1.88 min., m / z 464.2 [M+H]+

[0942] Methyl (4S)-1-((2-nitrophenyl)sulfonyl)-2-oxoimidazolidine-4-carboxylate

[0943] O1 -Benzyl O5-methyl (5S)-3-(2-nitrophenyl)sulfonyl-2-oxo-imidazolidine-1,5- dicarboxylate (370 mg, 0.798 mmol) was dissolved in dichloromethane (2.0 mL)and trifluoroacetic acid (3.0 mL) and the reaction mixture stirred for 18 h at 50 °C. The mixture was diluted with DCM (20 mL), basified to pH9 with NaHCO3 (aq. sat., 30 mL). The aqueous phase was extracted with EtOAc (3 x 20 mL), then the organic fractions were combined, washed with brine (aq. sat., 2x10 mL), passed through a phase separator and concentrated in vacuo to give methyl (4S)-1-(2-nitrophenyl)sulfonyl-2-oxo-imidazolidine-4-carboxylate (250 mg, 95 %) as a brown residue.

[0944] UPLC_pH2_MECN_2.6min_V1, Rt 1.50 min., m / z 330.1 [M+H]+

[0945] Methyl (4S)-3-methyl-1 -((2-nitrophenyl)sulfonyl)-2-oxoimidazolidine-4-carboxylate

[0946] Methyl (4S)-1-(2-nitrophenyl)sulfonyl-2-oxo-imidazolidine-4-carboxylate (250 mg, 0.607 mmol) and potassium carbonate (168 mg, 1.21 mmol) were combined in 1,4-dioxane (2.0 mL) and stirred at RT for 10 min. To this mixture was added iodomethane (0.045 mL, 0.729 mmol) and the reaction mixture stirred at 50 °C for 18 hours. The reaction mixture was cooled to RT, then diluted with EtOAc (10 mL) and water (5 mL) and the layers separated. The aqueous layer was extracted with EtOAc (3x10 mL), then the organic layers were combined, washed with brine (aq. sat., 2x10 mL), passed through a phase separator and concentrated under reduced pressure. The crude product was purified by flash column chromatography eluting with 0 - 100 % ethyl acetate in isohexane to yield methyl (4S)-3-methyl-1-(2- nitrophenyl)sulfonyl-2-oxo-imidazolidine-4-carboxylate (110 mg, 53 %) as a yellow solid.

[0947] UPLC_pH2_MECN_2.6min_V1, Rt 1.62 min., m / z 344.2 [M+H]+

[0948] (4S)-(Hydroxymethyl)-3-methyl-1-((2-nitrophenyl)sulfonyl)imidazolidin-2-one

[0949] To a solution of methyl (4S)-3-methyl-1 -(2-nitrophenyl)sulfonyl-2-oxo-imidazolidine-4-carboxylate (110 mg, 0.320 mmol) in ethanol (2.0 mL) was slowly added sodium borohydride (36 mg, 0.961 mmol) and the resulting mixture was stirred at RT under N2atmosphere for 3 h. Sodium borohydride (12 mg, 0.320 mmol) was added and the reaction mixture stirred at RT for a further 18h. The reaction mixture was quenched with water (2 mL) and the solution extracted with EtOAc (3x10 mL). The organic fractions were combined, washed with brine (aq. sat., 5 mL) and passed through a phase separator. The resulting solution was concentrated under reduced pressure. The crude product was purified by flash column chromatography eluting with 0 - 100 % ethyl acetate in isohexane to give (4S)- (hydroxymethyl)-3-methyl-1-(2-nitrophenyl)sulfonyl-imidazolidin-2-one (70 mg, 69 %) as a yellow solid.

[0950] UPLC_pH2_MECN_2.6min_V1, Rt 1.32 min., m / z 316.2 [M+H]+

[0951] (4S)-3-Methyl-1-(2-nitrophenyl)sulfonyl)-2-oxoimidazolidin-4-yl]methyl4- methylbenzenesulfonate

[0952] To a microwave vial was added (4S)-4-(hydroxymethyl)-3-methyl-1-(2- nitrophenyl)sulfonyl-imidazolidin-2-one (70 mg, 0.222 mmol), p-toluene sulfonyl chloride (38 mg, 0.200 mmol) and pyridine (0.27 mL, 3.33 mmol) in dry dichloromethane (5.0 mL) and the reaction mixture stirred at rtfor 18 h. The reaction mixture was concentrated under reduced pressure to give the crude product which was purified by flash column chromatography eluting with 0 - 100 % ethyl acetate in isohexane to give (4S)-3-methyl-1-(2- nitrophenyl)sulfonyl-2-oxo-imidazolidin-4-yl]methyl4-methylbenzenesulfonate (80 mg, 77 %) as a colourless residue.

[0953] UPLC_pH2_MECN_2.6min_V1, Rt 1.81 min., m / z 470.2 [M+H]+

[0954] Synthesis of (R)-(4-Methyl-5-oxomorpholin-2-yl)methyl 4-methylbenzenesulfonate

[0955] (2R)-3-(Benzyl(methyl)amino)propane-1,2-diol

[0956] A / -Benzylmethylamine (2.0 mL, 15.5 mmol) and (S)-(-)-glycidol (1.1 mL, 16.3 mmol) were dissolved in methanol (100 mL) and the reaction mixture stirred at reflux for 24 hours. The reaction mixture was cooled to room temperature and concentrated in vacuo to give (2R)- 3-[benzyl(methyl)amino]propane-1,2-diol (3201 mg, 91 %) as a yellow oil.

[0957] UPLC_PH9_MECN_2.6MIN_V1; Rt 1.29 mins., m / z 196.3 [M+H]+

[0958] (2R)-3-(Methylamino)propane-1,2-diol

[0959] (2R)-3-[Benzyl(methyl)amino]propane-1,2-diol (2828 mg, 12.5 mmol) was dissolved in ethanol (30 mL) under nitrogen then palladium on carbon (663 mg, 0.623 mmol) was added. The reaction was evacuated, refilled with hydrogen to 35 psi, and stirred at room temperature for 46 hours. The reaction mixture was filtered through celite and concentrated under reduced pressure to give (2R)-3-(methylamino)propane-1,2-diol (1.66g, 100 %) as a yellow oil.

[0960] 1H-NMR (400 MHz, Chloroform-D) 53.80-3.75 (m, 1 H), 3.74-3.68 (m, 1 H), 3.61-3.56 (m, 1 H), 2.79 (br. s, 3H), 2.75-2.72 (m, 1 H), 2.69-2.64 (m, 1 H), 2.44 (s, 3H).

[0961] (R)-6-(Hydroxymethyl)-4-methylmorpholin-3-one

[0962] (2R)-3-(Methylamino)propane-1,2-diol (1.66 g, 12.6 mmol) wasdissolved in acetonitrile (50 mL) and methanol (10 mL). Triethylamine (2.1 mL, 15.2 mmol) was added and the mixture cooled to -10 °C before a solution of chloroacetyl chloride(1.1 mL, 13.9 mmol) in acetonitrile (10 mL) was added dropwise. The reaction mixture was stirred at room temperature for 18 hours, concentrated in vacuo and resuspended in tertbutanol (40 mL). The solution was added to a solution of potassium tert-butoxide (2828 mg, 25.2 mmol) in tert-butanol (40 mL, 370 mmol) dropwise over 4 hours and stirred at room temperature for 21 hours. The reaction mixture was concentrated in vacuo and the crude product purified by flash column chromatography, elutingwith 0 - 30 % ethanol in ethyl acetate to give (R)-6-(hydroxymethyl)-4-methylmorpholin-3-one (814 mg, 45 %) as a colourless oil.

[0963] UPLC_PH9_MECN_2.6MIN_V1; Rt0.28 mins., m / z 146.2 [M+H]+

[0964] (R)-(4-Methyl-5-oxomorpholin-2-yl)methyl4-methylbenzenesulfonate

[0965] (6R)-6-(Hydroxymethyl)-4-methyl-morpholin-3-one (150 mg, 1.03 mmol) was dissolved in dichloromethane (10 mL) and pyridine (1.7 mL, 20.7 mmol) before p-toluene sulfonyl chloride (394 mg, 2.07 mmol) was added portion-wise over 5 minutes and the mixture stirred at room temperature for 24 hours. The reaction mixture was diluted with ethyl acetate (20 mL) and washed successively with water (30 mL), hydrochloric acid (aq., 2M, 30 mL), sodium bicarbonate (aq. sat., 30 mL) and brine (aq. Sat., 10 mL) and the organic layer dried, filtered and concentrated in vacuo. The residue was purified by flash column chromatography, elutingwith 20-100 % ethyl acetate in isohexane to give (R)-(4-methyl-5-oxomorpholin-2-yl)methyl4-methylbenzenesulfonate (189.9 mg, 61 %) as a brown oil.

[0966] UPLC_PH9_MECN_2.6MIN_V1; Rt 1.47 mins., m / z 300.2 [M+H]+

[0967] Synthesis of (R)-(5,7-dimethyl-4-oxo-5-azaspiro[2.4]heptan-7-yl)methyl 4-methylbenzenesulfonate

[0968] To a solution of tert-butyl (3R)-1 -[(1 R)-1 -(4-methoxyphenyl)ethyl]-3-methyl-5-oxo-pyrrolidine-3-carboxylate (374 mg, 1.12 mmol) in methanol (9.7 mL) was added 4M HCl-1,4-dioxane 4.3 mL, 17.2 mmol). The reaction mixture was stirred at 60 °C for 5h. The reaction mixture was concentrated in vacuo to provide the crude methyl ester as a yellow oil. The residue was dissolved in methanol (1.1 mL) and tetrahydrofuran (1.1 mL) and cooled to 0 °C. Sodium borohydride (93 mg, 2.47 mmol) was added and the reaction mixture stirred at 0 °Cfor 20 mins. The reaction mixture was quenched at 0 °C slowly over 5 mins with NH4Cl (aq. sat., 5 mL), then the organic solvents were removed under reduced pressure. H2O (10 mL) and EtOAc (10 mL) were added and the layers separated. The aqueous phase was extracted with EtOAc (2x5 mL) and the combined organics were washed with brine (aq. sat., 10 mL), dried (Na2SO4), passed through a phase separator, and concentrated under reduced pressure to give the second intermediate alcohol as a pale-yellow oil. The crude alcohol was dissolved in dichloromethane (2.2 mL), pyridine (1.8 mL) and p-toluene sulfonyl chloride (427 mg, 2.24 mmol) were added. The reaction mixture was stirred at RT for 3 days. The mixture was diluted with EtOAc (10 mL) then washed with H2O (10 mL). The organic phase was washed successively with 2M HCl (2 x 10 mL), sat. aq. NaHCO3(10 mL), and brine (aq. sat., 10 mL). The organics phase was dried (Na2SO4), passed through a phase separator and the solvents evaporated under reduced pressure. The crude product was purified by flash column chromatography eluting with 10 - 100 % EtOAc-isohexane to give [(3R)-1-[(1 R)-1-(4-methoxyphenyl)ethyl]-3-methyl-5-oxo-pyrrolidin-3-yl]methyl 4-methylbenzenesulfonate (399 mg, 85 %) as a yellow solid.

[0969] UPLC_pH2_MECN_2.6min_V1, Rt1.78 min., m / z 418.5 [M+H]+

[0970] Synthesis of (R)-(1 -methyl-5-oxopyrrolidin-2-yl)methyl 4-methylbenzenesulfonate

[0971] (R)-Methyl 1-methyl-5-oxopyrrolidine-2-carboxylate (250 mg, 1.59 mmol) was dissolved in tetrahydrofuran (5.0 mL) and methanol (5.0 mL) and cooled to 0°C before sodium borohydride (120 mg, 3.18 mmol) was added portion-wise. The reaction mixture was stirred at RT for 2 hours. The reaction mixture was concentrated in vacuo, resuspended in dichloromethane and water and the layers separated. The aqueous layer was extracted with ethyl acetate thrice and the combined organic layers dried, filtered, and concentrated in vacuo. The residue was resuspended in dichloromethane (10mL) and pyridine (2.0 mL), then p-toluene sulfonyl chloride (606 mg, 3.18 mmol) added and the reaction mixture stirred at RT for 16 hours. The reaction mixture was quenched with ammonium chloride, separated and the aqueous layer extracted with dichloromethane. The combined organic layers were dried, filtered, concentrated in vacuo, and the crude product purified by flash column chromatography, elutingwith 0 - 25 % ethanol-EtOAc to give [(2R)-1 -methyl-5-oxo-pyrrolidin-2-yl]methyl 4-methylbenzenesulfonate (100 mg, 22 %) as a colourless oil.

[0972] UPLC_pH2_MECN_2.6min_V1, Rt 1.44 min., m / z 284.1 [M+H]+

[0973] Synthesis of Mesylates

[0974] Pyrazin-2-ylmethyl methanesulfonate used in Example 121

[0975] To a solution of pyrazin-2-ylmethanol (171 mg, 1.55 mmol) in dichloromethane (6 mL) were added methanesulfonyl chloride (0.14 mL, 1.9 mmol) and triethylamine (0.65 mL, 4.7 mmol) and the mixture stirred at room temperature for 3 hours. The reaction mixture was concentrated under reduced pressure to give crude pyrazin-2-ylmethyl methanesulfonate (506 mg, assumed quantitative) as a brown solid (main impurity is triethylammonium chloride, purity not assessed). The crude product was used directly in subsequent reactions without further purification.

[0976] UPLC_pH2_MECN_2.6min_V1, Rt 0.93 min., m / z 189.0 [M+H]+

[0977] Pyridazin-3-ylmethyl methanesulfonate used in Example 120

[0978] To a solution of pyridazin-3-ylmethanol (171 mg, 1.55 mmol) in dichloromethane (6 mL) were added methanesulfonyl chloride (0.14 mL, 1.9 mmol) and triethylamine (0.65 mL, 4.7 mmol) and the mixture was stirred at room temperature for 3 hours. The reaction mixture was concentrated under reduced pressure to give crude pyridazine-3-ylmethyl methanesulfonate (435 mg, assumed quantitative) as a brown solid (main impurity is triethylammonium chloride, purity not assessed). The crude product was used directly in subsequent reactions without further purification.

[0979] UPLC_pH9_MECN_2.6min_V1, Rt0.71 min., m / z 189.0 [M+H]+

[0980] (6-Methoxypyridazin-3-yl)methyl methanesulfonate used in example 141

[0981] (6-methoxypyridazin-3-yl)methanol (217 mg, 1.55 mmol) was dissolvedin triethylamine (0.65 mL, 4.65 mmol) and dichloromethane (3.0 mL) and the mixture wascooled to 0 °C. Methanesulfonyl chloride (0.14 mL, 1.86 mmol) was added drop-wise and the reaction was stirred at 0 °C for 10 minutes. The reaction was concentrated and the resulting brown residue was used in the next step with no further purification.

[0982] UPLC_pH2_MECN_2.6min_V1, Rt 1.17 min., m / z 219.0 [M+H]+

[0983] (R)-(1-(Methylsulfonyl)pyrrolidin-3-yl)methyl methanesulfonate

[0984] (R)-Pyrrolidin-3-ylmethanol (250 mg, 2.47 mmol) was dissolved in triethylamine (0.83 mL, 5.93 mmol) and dichloromethane (10 mL) and the mixture cooled in ice. Methanesulfonyl chloride (0.46 mL, 5.93 mmol) was added dropwise and the reaction mixture stirred at room temperature for 4 hours. The reaction mixture was quenched with sodium bicarbonate (aq. sat., 10 mL), extracted with dichloromethane (3 x 20 mL), the combined organic layers were dried, filtered and concentrated in vacuo to give (R)-(1-(methylsulfonyl)pyrrolidin-3-yl)methyl methanesulfonate (704 mg) as an orange solid which was used without further purification.

[0985] UPLC_pH9_MECN_2.6min_V1, Rt 1.11 min., m / z 258.0 [M+H]+

[0986] General Scheme 3: Syntheses of benzyl-aryl ether boronates (by alkylation) followed by Suzuki coupling

[0987] Synthesis of (3-(pyridin-2-ylmethoxy)phenyl)boronic acid

[0988] 3-Hydroxyphenylboronic acid (100 mg, 0.725 mmol), 2-picolyl chloride hydrochloride (178 mg, 1.09 mmol), and potassium carbonate (301 mg, 2.18 mmol) were dissolved in acetonitrile (5.0 mL) and the mixture stirred at 60 °C for 16 hours. The reaction mixture was concentrated under reduced pressure and the crude product purified by flash column chromatography, eluting with 20-80 % ethyl acetate in isohexane to give [3-(2-pyridylmethoxy)phenyl]boronic acid (110 mg, 66 %) as white solid.

[0989] UPLC_PH9_MECN_2.6MIN_V1; Rt 1.33 mins., m / z 230.2 [M+H]+

[0990] The following intermediates were made by analogous methods:

[0991] Suzuki couplings

[0992] Synthesis of 3-[3-(2-pyridylmethoxy)phenyl]cinnoline - Example 145

[0993] [3-(2-Pyridylmethoxy)phenyl]boronic acid (110 mg, 0.478 mmol), 1,1'-bis(diphenylphosphino)ferrocenepalladium (II) dichloride (14 mg, 0.0191 mmol), 3-bromocinnoline (20 mg, 0.0957 mmol), and potassium carbonate (66 mg, 0.478 mmol) were dissolved in 1,4-dioxane (2.0 mL) and water (0.20 mL) under nitrogen and the reaction mixture stirred at 80 °C for 16 hours. The reaction mixture was cooled, diluted with dichloromethane (20 mL) and water (20 mL) and separated. The aqueous layer was extracted with dichloromethane (2 x 20 mL) and the combined organic layers dried, filtered and concentrated in vacuo. The residue was purified by prep. HPLC, Waters XBridge C18 (5 pmOBD 19x 250 mm) eluting with 30-70 % acetonitrile in aqueous ammonium carbonate (pH9). The eluted fractions were concentrated and lyophilised to give 3-[3-(2-pyridylmethoxy)phenyl]cinnoline (15 mg, 51 %) as an off-white solid.

[0994] 1H-NMR (400 MHz, Chloroform-D) 58.62 (d, J = 5.0 Hz, 1 H), 8.56 (d, J = 8.2 Hz, 1 H), 8.16 (s, 1 H), 7.97 (t, J = 2.1 Hz, 1 H), 7.88 (d, J = 8.2 Hz, 1 H), 7.85-7.81(m, 2H), 7.61 (d, J = 7.8 Hz, 1H), 7.48 (t, J = 8.0 Hz, 1H), 7.28-7.27 (m, 1 H), 7.13 (ddd, J = 8.2, 2.7, 0.9 Hz, 1H), 5.36 (s, 2H)

[0995] UPLC_PH2_MECN_QC_V1, Rt 4.27 min., m / z 314.2 [M+H]+

[0996] UPLC_PH7_4_MECN_QC_V1, Rt 5.19 min., m / z 314.3 [M+H]+

[0997] UPLC_PH9_MECN_QC_V1, Rt 4.68 min., m / z 314.2 [M+H]+

[0998] The following compounds were made using General Method 3:

[0999] A / -Alkylation[001000] (R)-1-Methyl-4-((3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)phenoxy)methyl)pyrrolidin-2-one[001001] To a solution of (R)-4-((3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)phenoxy)methyl)pyrrolidin-2-one (920 mg, 2.90 mmol) in dry tetrahydrofuran (12 mL) at 0 °Cwas added sodium hydride (60 % dispersion in oil, 580 mg, 14.5 mmol) and the reaction mixture stirred at 0 °C for 15 mins then iodomethane (0.720 mL, 11.6 mmol) was added and the reaction mixture stirred at RT for 16 hours. The reaction mixture was cooled to 0 °C and quenched with half sat. NH4Cl(aq) (25 mL) and stirred until effervescence stopped. The reaction mixture was then diluted with EtOAc (20 mL), the organic layer separated, and the aqueous layer extracted with EtOAc (2 x 10 mL). The combined organic layers were washed with brine (aq. sat., 25 mL), passed through a phase separator, concentrated under reduced pressure and purified by flash column chromatography, eluting with 0 - 3 % MeOH in DCM to afford (R)-1 -methyl-4-((3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)methyl)pyrrolidin-2-one (752 mg, 78 %) as a colourless oil.[001002]1H-NMR (400 MHz, DMSO-D6) 57.32-7.24 (m, 2H), 7.16 (d, J = 2.7 Hz, 1 H), 7.06 (ddd, J = 7.8, 2.7, 1.4 Hz, 1 H), 4.00-3.92 (m, 2H), 3.51 (dd, J = 9.8, 8.0 Hz, 1 H), 3.20 (dd, J = 10.1, 5.5 Hz, 1H), 2.80-2.73 (m, 1H), 2.71 (s, 3H), 2.42 (dd, J = 16.9, 9.2 Hz, 1 H), 2.14 (dd, J = 16.9, 6.4 Hz, 1H), 1.29(s, 12H)[001003] UPLC_PH2_MECN_2.6MIN_V1; Rt 1.82 mins., m / z 332.2 [M+H]+[001004] UPLC_PH9_MECN_2.6MIN_V1; Rt 1.82 mins., m / z 332.2 [M+H]+[001005] General Scheme 4: Syntheses of N-arylbicyclic imidazoles by Ullman Coupling[001006] Example: (S)-4-((3-(1 H-imidazo[4,5-b]pyridin-1-yl)phenoxy)methyl)-1-((R)-1-(4-methoxyphenyl)ethyl)pyrrolidin-2-one and (S)-4-((3-(3H-imidazo[4,5-b]pyridin-3-yl)phenoxy)methyl)-1-((R)-1-(4-methoxyphenyl)ethyl)pyrrolidin-2-one[001007] To a solution of 1 H-imidazo[4,5-b]pyridine (132 mg, 1.11 mmol) in dry 1,4-dioxane (10 mL) was added copper (I) iodide (106 mg, 0.554 mmol), (S)-4-((3-iodophenoxy)methyl)-1-((R)-1-(4-methoxyphenyl)ethyl)pyrrolidin-2-one (250 mg, 0.554 mmol) and potassium phosphate tribasic (235 mg, 1.11 mmol) followed by picolinic acid (80mg, 0.65 mmol). The reaction mixture was evacuated and backfilled with nitrogen three times, thensparged with nitrogen for 10 mins. The reaction mixture was stirred at 110°C for 16 h. The reaction mixture was diluted with EtOAc, filtered and 1 M NaOH(aq) (10 mL) added. The aqueous layer was extracted with EtOAc (3x 10 mL). The organic layers were combined, washed with brine (aq. sat.) and the solvent removed under reduced pressure. The crude product was purified by flash column chromatography eluting with 0 - 100 % ethyl acetate in isohexane to give the two regioisomers:[001008] Regioisomer a: (S)-4-((3-(3H-imidazo[4,5-b]pyridin-3-yl)phenoxy)methyl)-1-((R)-1 -(4-methoxyphenyl)ethyl)pyrrolidin-2-one (100 mg, 41 %) as a yellow oil.[001009]1H-NMR (400 MHz, Chloroform-D) 68.64 (dd, J = 4.8, 1.6 Hz, 1 H), 8.34 (s, 1 H), 7.87 (dd, J = 8.1, 1.5 Hz, 1 H), 7.47-7.43 (m, 1 H), 7.31 (dd, J = 8.2, 5.0 Hz, 1 H), 7.23-7.19 (m, 2H), 7.08-7.05 (m, 1 H), 6.89-6.85 (m, 2H), 6.77 (dt, J = 9.3, 2.5 Hz, 2H), 5.47 (q, J = 7.2 Hz, 1 H), 3.87 (dd, J = 8.9, 5.7 Hz, 1 H), 3.77 (dd, J = 8.7, 7.3 Hz, 1 H), 3.69 (s, 3H), 3.53 (dd, J = 9.8, 7.6 Hz, 1 H), 2.89 (dd, J = 10.1, 4.6 Hz, 1 H), 2.85-2.77 (m, 1 H), 2.68 (dd, J = 16.7, 8.9 Hz, 1 H), 2.32 (dd, J = 16.9, 5.5 Hz, 1H), 1.51 (d, J = 6.9 Hz, 3H).[001010] UPLC_PH2_MECN_2.6MIN_V1, Rt 1.67 min., m / z 443.3 [M+H]+[001011] Regioisomer b: (S)-4-((3-(1 H-imidazo[4,5-b]pyridin-1-yl)phenoxy)methyl)-1-((R)-1 -(4-methoxyphenyl)ethyl)pyrrolidin-2-one (100 mg, 41 %) as a yellow oil.[001012]1H-NMR (400 MHz, Chloroform-D) 58.46 (dd, J = 5.0, 1.4 Hz, 1 H), 8.35 (s, 1 H), 8.15 (dd, J = 8.0, 1.6 Hz, 1 H), 7.42 (t, J = 8.2 Hz, 1 H), 7.34-7.28 (m, 2H), 7.25 (d, J = 3.7 Hz, 1 H), 7.21 (dt, J = 9.3, 2.3 Hz, 2H), 6.83 (dq, J = 8.2, 1.1 Hz, 1 H), 6.81 -6.77 (m, 2H), 5.47 (q, J = 7.2 Hz, 1 H), 3.89 (dd, J = 9.2, 5.5 Hz, 1 H), 3.81 -3.73 (m, 1 H), 3.69 (s, 3H), 3.52 (dd, 7= 10.1, 7.8 Hz, 1 H), 2.90 (dd, 7= 10.1, 5.0 Hz, 1 H), 2.84-2.75 (m, 1 H), 2.67 (dd, 7 = 16.9, 9.2 Hz, 1 H), 2.32 (dd, 7 = 16.9, 6.0 Hz, 1 H), 1.50 (d, 7 = 7.3 Hz, 3H).[001013] UPLC_PH2_MECN_2.6MIN_V1, Rt 1.74 min., m / z 443.3 [M+H]+[001014] The following analogous compounds and intermediates were made using General Method 8:[001015] (S)-4-((3-(3H-lmidazo[4,5-b]pyridin-3-yl)phenoxy)methyl)pyrrolidin-2-one- Example 160[001016] A solution of (S)-4-((3-(3H-imidazo[4,5-b]pyridin-3-yl)phenoxy)methyl)-1-((R)- 1 -(4-methoxyphenyl)ethyl)pyrrolidin-2-one (100 mg, 0.226 mmol) in TFA (1 mL) was stirred at 50 °C for 2 hours. The reaction mixture was concentrated under reduced pressure and the residuere dissolved in DCM (5 mL). Residual TFA was neutralised with NaHCO3(aq. sat., 5 mL), the solution extracted with DCM (5 mL), the organic fractions were combined, washed with brine (aq. sat.), passed through a phase separator and concentrated in vacuo to give the crude product as a brown residue which was purified by prep HPLC followed by lyophilization from water-acetonitrile to afford (S)-4-((3-(3H-imidazo[4,5-b]pyridin-3-yl)phenoxy)methyl)pyrrolidin-2-one (31 mg, 44 %) as a white solid.[001017]1H-NMR (400 MHz, Chloroform-D) 58.45 (dd, J = 4.6, 1.4 Hz, 1 H), 8.33 (s, 1 H), 8.14 (dd, 7 = 8.2, 1.4 Hz, 1H), 7.46 (t, 7 = 8.2 Hz, 1 H), 7.37 (t, 7 = 2.1 Hz, 1H), 7.31 (td, J = 5.2, 2.7 Hz, 2H), 6.97-6.94 (m, 1 H), 6.07 (s, 1 H), 4.08-4.00 (m, 2H), 3.62 (dd, J = 9.6, 8.2 Hz, 1 H), 3.37(dd, 7 = 9.8, 5.3 Hz, 1H), 3.06-2.96 (m, 1H), 2.55 (dd,7= 17.4, 9.2 Hz, 1H), 2.28 (dd,7 = 16.9, 6.4 Hz, 1H).[001018] UPLC_PH2_MECN_QC_V1: Rt 3.26 min., m / z 309.2 [M+H]+[001019] UPLC_PH7_4_MECN_QC_V1: Rt 3.60 min., m / z 309.2 [M+H]+[001020] UPLC_PH9_MECN_QC_V1: Rt 3.33 min., m / z 309.2 [M+H]+[001021] (S)-4-((3-(1 H-lmidazo[4,5-b]pyridin-1-yl)phenoxy)methyl)pyrrolidin-2-one- Example 161[001022] A solution of (S)-4-((3-(1 H-imidazo[4,5-b]pyridin-1-yl)phenoxy)methyl)-1-((R)-1 -(4-methoxyphenyl)ethyl)pyrrolidin-2-one (100 mg, 0.226 mmol) in TFA (1 mL) was stirred at 70 °C for 2 hours. The reaction mixture was concentrated under reduced pressure and the residue dissolved in DCM (5 mL). Residual TFA was neutralised with NaHCO3(aq. sat., 5 mL), then the product was extracted with DCM (5 mL). The combined organic fractions were washed with brine (aq. sat.), passed through a phase separator and concentrated in vacuo to give the crude product as a brown residue which was purified by prep HPLC followed by lyophilization from water-acetonitrile to afford (S)-4-((3-(1 H-imidazo[4,5-b]pyridin-1-yl)phenoxy)methyl)pyrrolidin-2-one (24 mg, 34 %) as a white solid.[001023]1H-NMR (400 MHz, Chloroform-D) 58.61 (dd, J = 4.6, 1.4 Hz, 1 H), 8.34 (s, 1 H), 7.87 (dd, J = 8.2, 1.4 Hz, 1 H), 7.51 -7.47 (m, 1 H), 7.27 (dd, J = 8.0, 4.8 Hz, 1 H), 7.10-7.08 (m, 1 H), 7.00 (dt, J = 6.9, 1.3 Hz, 2H), 6.22 (s, 1 H), 4.07-4.00 (m, 2H), 3.64 (dd, J = 9.6, 8.2 Hz, 1 H), 3.37 (dd, J = 9.6, 5.0 Hz, 1 H), 3.06-2.96 (m, 1 H), 2.57 (dd, J = 17.4, 9.2 Hz, 1 H), 2.28 (dd, J = 17.2, 6.2 Hz, 1H).[001024] UPLC_PH2_MECN_QC_V1, Rt 3.00 min., m / z 309.2 [M+H]+[001025] UPLC_PH7_4_MECN_QC_V1, Rt 3.39 min., m / z 309.2 [M+H]+[001026] UPLC_PH9_MECN_QC_V1, Rt 3.14 min., m / z 309.2 [M+H]+[001027] The following analogous compounds and intermediates were made using General Method 4:[001028] Synthesis of (S)-4-((3-iodophenoxy)methyl)-1 -methylpyrrolidin-2-one[001029] (S)-4-((3-lodophenoxy)methyl)-1-((R)-1-(4-methoxyphenyl)ethyl)pyrrolidin-2-one[001030] (S)-4-((3-lodophenoxy)methyl)-1-((R)-1-(4-methoxyphenyl)ethyl)pyrrolidin-2-one was obtained using ((S)-1 -((R)-1 -(4-methoxyphenyl)ethyl)-5-oxopyrrolidin-3-yl)methyl 4-methylbenzenesulfonate and 3-iodophenol following General Method 1 to afford (S)-4-((3-iodophenoxy)methyl)-1-((R)-1-(4-methoxyphenyl)ethyl)pyrrolidin-2-one (160 mg, 93 %) as a yellow oil.[001031] UPLC_PH2_MECN_2.6MIN_V1; Rt 1.98 mins., m / z 452.2 [M+H]+[001032] (S)-4-((3-iodophenoxy)methyl)pyrrolidin-2-one[001033] (4S)-4-[(3-lodophenoxy)methyl]pyrrolidin-2-one was obtained from (S)-4-((3-iodophenoxy)methyl)-1-((R)-1-(4-methoxyphenyl)ethyl)pyrrolidin-2-one following General Method 4 in neatTFA (5 mL) at 70 °C to afford (4S)-4-[(3-iodophenoxy)methyl]pyrrolidin-2-one (170 mg, 98 %) as a pale-yellow solid.[001034] UPLC_PH2_MECN_2.6MIN_V1; Rt 1.71 mins., m / z 359.2 [M+MeCN]+[001035] (S)-4-((3-lodophenoxy)methyl)-1-methylpyrrolidin-2-one[001036] (4S)-4-[(3-lodophenoxy)methyl]-1-methyl-pyrrolidin-2-one was obtained from (4S)-4-[(3-iodophenoxy)methyl]pyrrolidin-2-one following General Method 7 to afford (4S)-4-[(3-iodophenoxy)methyl]-1-methyl-pyrrolidin-2-one (250 mg, 92 %) as a colourless oil.[001037] UPLC_PH2_MECN_2.6MIN_V1; Rt 1.80 mins., m / z 332.1 [M+H]+[001038] Synthesis of (R)-4-((3-iodophenoxy)methyl)-1 -methylpyrrolidin-2-one[001039] (R)-4-((3-lodophenoxy)methyl)-1-((R)-1-(4-methoxyphenyl)ethyl)pyrrolidin-2-one[001040] (R)-4-((3-lodophenoxy)methyl)-1-((R)-1-(4-methoxyphenyl)ethyl)pyrrolidin-2-one was obtained using [(3R)-1-[(1 R)-1-(4-methoxyphenyl)ethyl]-5-oxo-pyrrolidin-3-yl]methyl 4-methylbenzenesulfonate and 3-iodophenol following General Method 1 to afford (R)-4-((3-iodophenoxy)methyl)-1-((R)-1-(4-methoxyphenyl)ethyl)pyrrolidin-2-one (380 mg, 85 %) as a colourless oil.[001041] UPLC_PH2_MECN_2.6MIN_V1; Rt 2.02 mins., m / z 452.2 [M+H]+[001042] (R)-4-((3-lodophenoxy)methyl)pyrrolidin-2-one[001043] (4R)-4-[(3-lodophenoxy)methyl]pyrrolidin-2-one was obtained from (R)-4-((3-iodophenoxy)methyl)-1-((R)-1-(4-methoxyphenyl)ethyl)pyrrolidin-2-one following General Method 4 in neatTFA (5 mL) at 70 °C to afford (4R)-4-[(3-iodophenoxy)methyl]pyrrolidin-2-one (140 mg, 99 %) as a pale-yellow solid.[001044] UPLC_PH2_MECN_2.6MIN_V1; Rt 1.70 mins., m / z 359.2 [M+MeCN]+[001045] (S)-4-((3-lodophenoxy)methyl)-1-methylpyrrolidin-2-one[001046] (4R)-4-[(3-lodophenoxy)methyl]-1-methyl-pyrrolidin-2-one was obtained from (4R)-4-[(3-iodophenoxy)methyl]pyrrolidin-2-one following General Method 7 to afford (4R)-4-[(3-iodophenoxy)methyl]-1-methyl-pyrrolidin-2-one (140 mg, 67 %) as a pale-yellow residue.[001047] UPLC_PH2_MECN_2.6MIN_V1; Rt 1.78 mins., m / z 332.1 [M+H]+[001048] Single routes[001049] 2-(3-((4-Methyl-4H-1,2,4-triazol-3-yl)methoxy)phenyl)quinoxaline - Example 165[001050] 3-Quinoxalin-2-ylphenol (118 mg, 0.530 mmol), (4-methyl-4H-1,2,4-triazol-3-yl)methanol (50.0 mg, 0.442 mmol), 1,1 '-(azodicarbonyl)dipiperidine (223 mg, 0.884 mmol) and tri-n-butylphosphine (0.220 mL, 0.884 mmol) were dissolved in toluene (2 mL) and stirred at room temperature for 5 hours. The reaction mixture was diluted with ethyl acetate (5 mL) and water (5 mL). The aqueous layer was extracted with ethyl acetate (2x5 mL) and the combined organic extracts washed with brine (aq. sat.), dried and concentrated under reduced pressure. The residue was partially purified by column chromatography, eluting with 0 - 10 % methanol in isohexane, prior to purification by prep HPLC. The product-containing fractions were concentrated in vacuo and the product lyophilised to give 2-(3-((4-methyl-4H-1,2,4-triazol-3-yl)methoxy)phenyl)quinoxaline (21.7 mg, 16 %) as a white solid.[001051]1H-NMR (400 MHz, Chloroform-D) δ 9.30 (s, 1 H), 8.14 (ddd, J = 13.2, 7.7, 1.7 Hz, 3H), 7.90 (t, J = 2.1 Hz, 1 H), 7.81-7.74 (m, 3H), 7.50 (t, J = 8.0 Hz, 1 H), 7.21 (dd, J = 8.5, 2.5 Hz, 1 H), 5.44 (s, 2H), 3.83 (s, 3H).[001052] UPLC_PH2_MECN_QC_V1: Rt 3.89 min., m / z 318.2 [M+H]+[001053] UPLC_PH9_MECN_QC_V1: Rt 3.93 min., m / z 318.2 [M+H]+[001054] (4R)-4-[[3-(3-Deuteroquinoxalin-2-yl)phenoxy]methyl]-1-methyl-pyrrolidin-2- one - Example 166[001055] (4R)-4-[[3-(3-Chloroquinoxalin-2-yl)phenoxy]methyl]-1-methyl-pyrrolidin-2- one (47 mg, 0.128 mmol) and tetrakis(triphenylphosphine)palladium(O) (7.4 mg, 0.00639 mmol) were dissolved in A / , A / -dimethylformamide (2.0 mL). Triethylamine (0.27 mL, 1.92 mmol) was added under nitrogen then formic acid D2 (0.048 mL, 1.28 mmol) added dropwise, and the reaction mixture was stirred at to 110 °C for one hour. The reaction was cooled, diluted with ethyl acetate (10 mL) and water (10 mL) and separated. The aqueous layerwas extracted with ethyl acetate (3x 10 mL) and the combined organic layers dried, filtered, and concentrated in vacuo. The crude product was purified by flash column chromatography, elutingwith 20-80 % isohexane in ethyl acetate, followed by prep HPLC, Waters XBridge C18 (5 pm OBD 19 x 250 mm) elutingwith 20 - 60 % acetonitrile in aqueous ammonium carbonate (pH9), followed by flash column chromatography, elutingwith 0 - 20 % methanol in ethyl acetate. The eluted fractions were concentrated in vacuo and the product lyophilised to give (4R)-4-[[3-(3-deuterioquinoxalin-2-yl)phenoxy]methyl]-1-methyl-pyrrolidin-2-one (22 mg, 51 %) as a white solid.[001056]1H-NMR (400 MHz, Chloroform-D) δ 8.37 (s, 1 H), 8.20 (dd, J = 8.0, 1.6 Hz, 1 H), 7.86-7.78 (m, 3H), 7.73 (s, 1 H), 7.48 (t, J = 8.0 Hz, 1 H), 7.04 (dd, J = 8.2, 2.7 Hz, 1 H), 4.12 (dd, J = 9.2, 5.5 Hz, 1 H), 4.06 (dd, J = 9.2, 7.3 Hz, 1 H), 3.68 (dd, J = 10.1, 8.2 Hz, 1 H), 3.47 (dd, J = 10.5, 5.0 Hz, 1 H), 2.96-2.94 (m, 1 H), 2.92 (s, 3H), 2.89-2.82 (m, 1 H), 2.60 (d, J = 14.7 Hz, 1 H).[001057] UPLC_PH9_MECN_QC_V1: Rt 4.50 min., m / z 335.3 [M+H]+[001058] UPLC_PH7_4_MECN_QC_V1: Rt 4.99 min., m / z 335.3 [M+H]+[001059] UPLC_PH2_MECN_QC_V1: Rt 4.50 min., m / z 335.3 [M+H]+[001060] (4R)-4-[[3-(3-Fluoroquinoxalin-2-yl)phenoxy]methyl]-1-methyl-pyrrolidin-2- one (Example 167) and (4R)-4-[[3-(3-Hydroxyquinoxalin-2-yl)phenoxy]methyl]-1-methyl- pyrrolidin-2-one (Example 168)[001061] (4R)-4-[[3-(3-Chloroquinoxalin-2-yl)phenoxy]methyl]-1-methyl-pyrrolidin-2- one (36 mg, 0.0979 mmol) and potassium fluoride (28 mg, 0.489 mmol) were dissolved in dimethyl sulfoxide (1.0 mL) and the mixture stirred at 80 °C for 16 hours. The crude product was purified by prep HPLC (Waters XBridge C185 pm OBD 19 x 250 mm), eluting with 40 - 75 % acetonitrile in pH9 ammonium bicarbonate. The eluted fractions were concentrated in vacuo and the product lyophilised to give two samples:[001062] (4R)-4-[[3-(3-Fluoroquinoxalin-2-yl)phenoxy]methyl]-1-methyl-pyrrolidin-2- one (5.5 mg, 16 %) as a pale-yellow solid.[001063]1H-NMR (400 MHz, Chloroform-D) δ 8.22-8.17 (m, 1 H), 8.00-7.96 (m, 1 H), 7.82- 7.77 (m, 3H), 7.71 (t, J = 1.1 Hz, 1 H), 7.47 (t, J = 8.0 Hz, 1 H), 7.07 (dd, J = 8.2, 1.8 Hz, 1 H), 4.12-4.01 (m, 2H), 3.65-3.59 (m, 1 H), 3.40 (q, J = 5.0 Hz, 1 H), 2.97-2.89 (m, 4H), 2.71 -2.62 (m, 1 H), 2.40-2.32 (m, 1H).[001064] UPLC_PH9_MECN_QC_V1: Rt 4.87 min., m / z 352.2 [M+H]+[001065] UPLC_PH7_4_MECN_QC_V1: Rt 5.44 min., m / z 352.2 [M+H]+[001066] UPLC_PH2_MECN_QC_V1: Rt 4.88 min., m / z 352.2 [M+H]+[001067] (4R)-4-[[3-(3-Hydroxyquinoxalin-2-yl)phenoxy]methyl]-1-methyl-pyrrolidin-2- one (2 mg, 5 %) as a brown solid.[001068]1H-NMR (400 MHz, Chloroform-D) δ 10.77 (s, 1 H), 8.06 (d, J = 8.2 Hz, 1 H), 7.98- 7.94 (m, 2H), 7.55-7.51 (m, 1 H), 7.45-7.36 (m, 2H), 7.29 (s, 1 H), 7.05 (dd, J = 7.6, 2.5 Hz, 1 H), 4.12-4.00 (m, 2H), 3.64-3.60 (m, 1 H), 3.40 (q, J = 5.0 Hz, 1 H), 2.97-2.86 (m, 4H), 2.66 (dd, J = 16.9, 9.6 Hz, 1H), 2.38 (dd, J = 17.2, 6.2 Hz, 1 H).[001069] UPLC_PH9_MECN_QC_V1: Rt 3.98 min., m / z 350.2 [M+H]+[001070] UPLC_PH7_4_MECN_QC_V1: Rt 4.39 min., m / z 350.2 [M+H]+[001071] UPLC_PH2_MECN_QC_V1: Rt 3.98 min., m / z 350.2 [M+H]+[001072] (R)-4-((3-(7-Hydroxybenzo[e][1,2,4]triazin-3-yl)phenoxy)methyl)-1 - methylpyrrolidin-2-one (Example 169)[001073] (4R)-4-[[3-(7-Bromo-1,2,4-benzotriazin-3-yl)phenoxy]methyl]-1-methyl- pyrrolidin-2-one (35 mg, 0.0847 mmol) and sodium hydroxide (0.24 mL, 1.69 mmol) were dissolved in dimethyl sulfoxide (2.0 mL) and the mixture stirred at room temperature for 4hours. The reaction was neutralised with hydrochloric acid (aq., 2M, 1 mL) and concentrated in vacuo. The crude product was purified by prep HPLC, Waters XBridge C18 (5 pm OBD 19 x 250 mm) elutingwith 20 - 60 % acetonitrile in aqueous ammonium carbonate (pH9). The eluted fractions were concentrated in vacuo and the product lyophilised to give (4R)-4-[[3-(7-hydroxy-1,2,4-benzotriazin-3-yl)phenoxy]methyl]-1-methyl-pyrrolidin-2-one (2.1 mg, 7 %) as a yellow solid.[001074]1H-NMR (400 MHz, Chloroform-D) δ 8.27 (d, J = 7.8 Hz, 0.7H), 8.19 (s, 0.7H), 8.01-7.98 (m, 1.2H), 7.75 (s, 0.7H), 7.65 (d,7 = 8.7 Hz, 0.7H), 7.46 (t,7 = 7.8 Hz, 0.7H), 7.12 (t, J = 8.2 Hz, 0.3H), 7.05 (dd, J = 8.2, 1.8 Hz, 0.7H), 6.53 (t, J = 2.3 Hz, 0.3H), 6.45 (dd, J = 8.2, 2.3 Hz, 0.7H), 5.45 (s, 0.3H), 4.16-3.87 (m, 2H), 3.68-3.57 (m, 1 H), 3.43 (dd, 7= 10.1, 5.0 Hz, 0.7H), 3.36 (dd,7= 10.3, 4.8 Hz, 0.3H), 2.96-2.82 (m, 4H), 2.73-2.61 (m, 1H), 2.42 (dd,7= 17.2, 5.7 Hz, 0.7H), 2.32 (dd,7= 17.4, 5.5 Hz, 0.3H)[001075] UPLC_PH9_MECN_QC_V1: Rt 3.30 min., m / z 351.2 [M+H]+[001076] UPLC_PH7_4_MECN_QC_V1: Rt 3.94 min., m / z 351.2 [M+H]+[001077] UPLC_PH2_MECN_QC_V1: Rt 4.06 min., m / z 351.2 [M+H]+[001078] (5S)-1-Methyl-5-[(3-quinoxalin-2-ylphenoxy)methyl]imidazolidin-2-one (Example 170)[001079] To a solution of 3-quinoxalin-2-ylphenol (40 mg, 0.179 mmol) in dry DMF (1.5 mL) was added potassium carbonate (47 mg, 0.341 mmol) and the reaction mixture stirred under N2for 10 mins. A solution of [(4S)-3-methyl-1-(2-nitrophenyl)sulfonyl-2-oxo-imidazolidin-4-yl]methyl 4-methylbenzenesulfonate (80 mg, 0.170 mmol) in dry DMF (1.2 mL) was added and the reaction mixture stirred at 80 °C for 18h. The reaction mixture was cooled to RT, then thiophenol (19 mg, 0.170 mmol) was added and the resulting mixture stirred at rt for 30 mins. The reaction mixture was diluted with EtOAc (10 mL) and water (5 mL) and the layers separated. The aqueous layer was extracted with EtOAc (3x10 mL) and the combined organic layers were washed with brine (aq. sat., 10 mL), passed through a phase separator and concentrated under reduced pressure. The crude product was purified by flash column chromatography eluting with 0 - 100 % ethyl acetate in isohexane followed by prep HPLC to afford (5S)-1-methyl-5-[(3-quinoxalin-2-ylphenoxy)methyl]imidazolidin-2-one (21 mg, 37 %) as a yellow solid.[001080]1H-NMR (400 MHz, Chloroform-D) δ 9.31 (s, 1 H), 8.17-8.11 (m, 2H), 7.81-7.73 (m, 4H), 7.49 (t, J = 8.0 Hz, 1 H), 7.06 (dq, J = 8.2, 1.1 Hz, 1 H), 4.45 (s, 1 H), 4.24 (dd, J = 9.4, 5.3 Hz, 1 H), 4.18 (dd, J = 9.4, 5.3 Hz, 1 H), 4.07-4.00 (m, 1 H), 3.65 (t, J = 8.9 Hz, 1 H), 3.37 (dd, J = 8.7, 6.9 Hz, 1H), 2.92 (s, 3H).[001081] UPLC_PH2_MECN_QC_V1, RT4.6 min., m / z 335.3 [M+H]+[001082] UPLC_PH7_4_MECN_QC_V1, RT 4.8 min., m / z 335.3 [M+H]+[001083] UPLC_PH9_MECN_QC_V1, RT 4.38 min., m / z 335.3 [M+H]+[001084] Synthesis of (R)-1,3-Dimethyl-4-((3-(quinoxalin-2-yl)phenoxy)methyl)imidazolidin-2-one (Example 171)[001085] Using benzyl (R)-3-methyl-2-oxo-5-((3-(quinoxalin-2-yl)phenoxy)methyl)imidazolidine-1 -carboxylate in GM4 gave a crude sample of (R)-l-methyl-4-((3-(quinoxalin-2-yl)phenoxy)methyl)imidazolidin-2-one as a brown residue.[001086] Using the crude sample of (R)-1-methyl-4-((3-(quinoxalin-2-yl)phenoxy)methyl)imidazolidin-2-one in GM7 gave (R)-1,3-dimethyl-4-((3-(quinoxalin-2-yl)phenoxy)methyl)imidazolidin-2-one (4.0 mg, 43 %) as a colourless gum.[001087]1H-NMR (400 MHz, Chloroform-D) δ 9.31 (s, 1 H), 8.17-8.11 (m, 2H), 7.82-7.74 (m, 4H), 7.49 (t, J = 8.0 Hz, 1 H), 7.06 (dt, J = 8.2, 1.4 Hz, 1 H), 4.23 (dd, J = 9.4, 5.3 Hz, 1 H), 4.13 (dd, J = 9.2, 5.5 Hz, 1 H), 3.91 -3.85 (m, 1 H), 3.55 (t, J = 8.9 Hz, 1 H), 3.22 (dd, J = 8.9, 6.6 Hz, 1 H), 2.92 (s, 3H), 2.83 (s, 3H).[001088] UPLC_PH2_MECN_QC_V1, RT 4.60 min., m / z 349.4 [M+H]+[001089] UPLC_PH7_4_MECN_QC_V1, RT5.11 min., m / z 349.5 [M+H]+[001090] UPLC_PH9_MECN_QC_V1, RT 4.62 min., m / z 349.5 [M+H]+[001091] Synthesis of (R)-4-(((5-(benzo[e][1,2,4]triazin-3-yl)pyridin-3-yl)oxy)methyl)-1- ((R)-1-(4-methoxyphenyl)ethyl)pyrrolidin-2-one[001092] 5-(((R)-1-((R)-1-(4-Methoxyphenyl)ethyl)-5-oxopyrrolidin-3-yl)methoxy)nicotinohydrazide[001093] To a solution of ethyl 5-(((R)-1-((R)-1-(4-methoxyphenyl)ethyl)-5-oxopyrrolidin-3-yl)methoxy)nicotinate (104 mg, 0.261 mmol) in ethanol (0.40 mL) was added hydrazine hydrate (0.21 mL, 4.25 mmol) and...

Claims

1. CLAIMS1. A compound of formula (I), or a pharmaceutically acceptable salt and / or solvate thereof:wherein:R1is selected from:-membered heteroaryl, and -C(O)NR1aR1b;whereinR1aand R1bare each independently selected from: H, Ci-6alkyl, and Ci-6haloalkyl; Z1and Z4are each nitrogen, andZ2, Z3, Z5, and Z6are independently selected from: a bond, carbon, nitrogen, and oxygen;and wherein said-membered heteroaryl are optionally substituted by one or more R2;R2is selected from: deuterium, halo, -CN, -NO2, -NR2aR2b, -OR2a, =O, Ci_6alkyl, Ci_6haloalkyl, C2-6 alkenyl, C2.6alkynyl, C3-6 cycloalkyl, 4- to 6-membered heterocycloalkyl, -S(O)xR2a, -C(O)R2a, -OC(O)R2a, and -C(O)OR2a;L is selected from: Ci_3alkylene and -C(O)-;wherein said Ci.3alkylene is optionally substituted by one or more R3;R3is selected from: deuterium, halo, -CN, -NO2, -NR3aR3b, -OR3a, =O, Ci_6alkyl, Ci_6haloalkyl, C2-6alkenyl, C2.6alkynyl, C3.6cycloalkyl, 4- to 6-membered heterocycloalkyl, -S(O)xR3a, -C(O)R3a, -OC(O)R3a, -C(O)OR3a;X1is selected from: -O-, and -S(O)X-;Ring A is selected from:, wherein A1, A2, and A3are each independently selected from the group consisting of: carbon, nitrogen, oxygen, and sulphur, optionally wherein Ring A is substituted by one or more R4;are each independently selected from the group consisting of: carbon and nitrogen, optionally wherein Ring A is substituted by one or more R5; provided that Ring A is not a substituted or unsubstitutedare each independently selected from the group consisting of: carbon, nitrogen, oxygen, and sulphur, optionally wherein Ring A is substituted by one or more R4;R4is selected from: deuterium, halo, -CN, -NO2, -NR4aR4b, -OR4a, =O, Ci_6alkyl, Ci_6haloalkyl, C2-6 alkenyl, C2.6alkynyl, C3-6 cycloalkyl, 4- to 6-membered heterocycloalkyl, -S(O)xR4a, -C(O)R4a, -OC(O)R4a, and -C(O)OR4a;R5is selected from: deuterium, halo, -CN, -NO2, -NR5aR5b, -OR5a, Ci_6alkyl, Ci_6haloalkyl, C2.6alkenyl, C2.6alkynyl, C3.6cycloalkyl, -S(O)xR5a, -C(O)R5a, -OC(O)R5a, and -C(O)OR5a;Ring B is 5- or 6-membered heteroaryl, wherein:one of B1and B3is selected from: a bond, -CH=, -CR61=, -N=, and -NR62-, and the other of B1and B3is selected from: -CH=, -CR61=, -N=, and -NR62-,B2is selected from: -C= and -N-, andB4is selected from: -N= and -NR62-,provided that B3is -CH= or -CR61= when B1is a bond and B2is -C=, and that B2is -C= when B1is -CH= or-CR61= and B3is a bond;R61is selected from: deuterium, halo, -CN, -NO2, -NR6aR6b, -OR6a, Ci_6alkyl, Ci_6haloalkyl, C2.6alkenyl, C2.6alkynyl, C3.6cycloalkyl, 4- to 6-membered heterocycloalkyl, -S(O)xR6a, -C(O)R6a, -OC(O)R6a, and -C(O)OR6a;R62is selected from: Ci_6alkyl, Ci_6haloalkyl, C2.6alkenyl, C2.6alkynyl, C3-6 cycloalkyl, 4- to 6-membered heterocycloalkyl, -S(O)xR6a, -C(O)R6a, and -C(O)OR6a;Ring C is selected from: 4- to 7-membered cycloalkyl, 5- to 7-membered cycloalkenyl, 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, phenyl, and 5- or 6-membered heteroaryl,wherein said 4- to 7-membered heterocycloalkyl, 4- to 7-membered cycloalkyl, 5- to 7-membered cycloalkenyl, and 5- to 7-membered heterocycloalkenyl are optionally substituted by one or more R7, and said phenyl and 5- or 6-membered heteroaryl are optionally substituted by one or more R8;R7is selected from: deuterium, halo, -CN, -NO2, -NR7aR7b, -OR7a, =O, Ci_6alkyl, Ci_6haloalkyl, C2-6alkenyl, C2.6alkynyl, C3-6 cycloalkyl, 4- to 6-membered heterocycloalkyl, -S(O)xR7a, -C(O)R7a, -OC(O)R7a, and -C(O)OR7a;R8is selected from: deuterium, halo, -CN, -NO2, -NR8aR8b, -OR8a, Ci_6alkyl, Ci_6haloalkyl, C2.6alkenyl, C2.6alkynyl, C3.6cycloalkyl, 4- to 6-membered heterocycloalkyl, -C(O)R8a, -OC(O)R8a, and -C(O)OR8a;R2a, R3a, R4a, R5a, R6a, R7a, and R8aare each independently selected from: H, deuterium, C1-6alkyl, C1-6haloalkyl, C3-6cycloalkyl, and 4- to 6-membered heterocycloalkyl;R2b, R3b, R4b, R5b, R6b, R7b, and R8bare each independently selected from: H, deuterium, C1-6alkyl, C1-6haloalkyl, C3-6cycloalkyl, 4- to 6-membered heterocycloalkyl, and -C(O)-Ci-6alkyl;or wherein, at each occurrence, R2aand R2b, R3aand R3b, R4aand R4b, R5aand R5b, R6aand R6b, R7aand R7b, or R8aand R8b, together with the nitrogen atom to which they are attached, may form a 4-6-membered heterocycloalkyl ring;each x is independently 0, 1, or 2;wherein any of the aforementioned alkyl, alkylene, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, phenyl, or heteroaryl groups is optionally substituted, where chemically possible, by one or more substituents independently at each occurrence selected from the group consisting of: Ci-6alkyl, Ci_6alkyl-ORa, deuterium, oxo, halo, nitro, cyano, NRaRb, ORa, SRa, CO2Ra, C(O)Ra, CONRaRa, S(O)Ra, and S(O)2Ra; wherein Rais independently at each occurrence selected from H, and Ci-4alkyl; and Rbis independently at each occurrence selected from H, Ci-4alkyl, C(O)-Ci-4alkyl and S(O)2-Ci-4alkyl; andwherein the compound of formula (I) is not:ii) a compound selected from List A:List A:

2. The compound accordingto claim 1, or a pharmaceutically acceptable salt and / orsolvate thereof, wherein, optionally substituted by one or more R2., optionally wherein R1is substituted with one or more R2.

4. The compound accordingto claim 1, wherein R1is a 5- to 6and 5- to 6-membered heteroaryl, optionally substituted by one or more R2.

5. The compound accordingto anyone of claims 1 to 4, wherein R2is selected from: deuterium, halo, -CN, -NO2, -NR2aR2b, -OR2a, =O, C1-6alkyl, C1-6haloalkyl.

6. The compound accordingto anyone of claims 1 to 5, wherein L is Ci_3alkylene, optionally substituted by one or more independently selected R3.

7. The compound according to any one of claims 1 to 6, wherein X1is: -O-.

8. The compound accordingto anyone of claims 1 to 7, wherein -L-X1- is -CH2-O-.

9. The compound accordingto any one of claims 1 to 8, wherein Ring A is, optionally wherein Ring A is substituted by one or more R5.

10. The compound accordingto anyone of claims 1 to 9, wherein Ring A is selected from:, wherein Ring A is optionally substituted by one or more R5.

11. The compound according to any one of claims 1 to 10, wherein the group12. The compound according to any one of claims 1 to 10, wherein the group13. The compound according to anyone of claims 1 to 12, wherein the groupoptionally substituted by one or more R7or R8.

14. The compound according to any one of claims 1 to 10, wherein the groupis selected from:C is substituted by one or more R7or R8.

15. The compound according to claim 1, wherein the compound is a compound of formula (II), or a pharmaceutically acceptable salt and / or solvate thereof:whereinR1is selected from:and 5- to 6-membered heteroaryl, optionally substituted by one or more R2.

16. The compound according to claim 1, wherein the compound is a compound of formula (III), or a pharmaceutically acceptable salt and / or solvate thereof:whereinthegroup is optionally substituted by one or more R2.

17. The compound according to claim 1, wherein the compound is a compound of formula (IV), or a pharmaceutically acceptable salt and / or solvate thereof:whereinthegroup is optionally substituted by one or more R2.

18. A compound according to claim 1, wherein the compound is selected from Compound List 1 in the description, or a pharmaceutically acceptable salt and / or solvate thereof.

19. A pharmaceutical composition comprising a compound according to any one of claims 1 to 18, except that the compounds of List A in claim 1 are not excluded, or a pharmaceutically acceptable salt and / or solvate thereof, and a pharmaceutically acceptable excipient.

20. A compound according to any one of claims 1 to 18, except that the compounds of List A in claim 1 are not excluded, or a pharmaceutically acceptable salt and / or solvate thereof, for use as a medicament.

21. A compound according to any one of claims 1 to 18, except that the compounds of disclaimer i) and ii) in claim 1 are not excluded, or a pharmaceutically acceptable salt and / or solvate thereof, for use in the treatment of a disease or medical disorder associated with dysregulation of tropomyosin receptor kinase B (TrkB or NTRK2).

22. A compound according to any one of claims 1 to 18, except that the compounds of disclaimer i) and ii) in claim 1 are not excluded, or a pharmaceutically acceptable salt and / or solvate thereof, for use in the treatment of a disease or medical disorder selected from: autism spectrum disorder (ASD), intellectual disability, Rett Syndrome, Down’s Syndrome (DS), Major Depressive Disorder (MDD), Bipolar Disorder (BD), Post-Traumatic Stress Disorder (PTSD), Generalized Anxiety Disorder (GAD), NeuroAIDS (HIV-associated neurocognitive disorder), Fetal Alcohol Spectrum Disorder (FASD), Hypoxia-Ischemic Encephalopathy (HIE), and Traumatic Brain Injury (TBI);optionally wherein the disease or medical disorder is selected from: Major Depressive Disorder (MDD), Post-Traumatic Stress Disorder (PTSD), Generalized Anxiety Disorder (GAD), Bipolar Disorder (BD) and Traumatic Brain Injury (TBI).